Scentific Report 2015/2016

Scientific Report

1996 2016

Scientific Report 2015• 2016 RESULTS AND PERSPECTIVES

2015•2016

Scientific Report 2015• 2016 Results and Perspectives

contents

6 Humanitas

6 Who we are

Research & University Hospital

8 Humanitas at a glance 10 Our history 11 Our philosophy 12 Scientific research 19 Humanitas University 20 International collaborations and recognitions 21 Humanitas Group in Italy 22 Translational

research

24 I mmunity and inflammation

Interview with Alberto Mantovani

The interface between immunology and oncology anticipates new advances in research

28 o ncology Interview with Armando Santoro

H umanitas at the forefront of innovation in specialist therapies 32 cardiovascular Interview with Gianluigi Condorelli

A comprehensive approach to research in cardiology: from nanomedicine to standards of care

36 n euroscience Interview with Alberto Albanese

High-tech and early diagnosis against degenerative and chronic neurological conditions

40 hepatology Interview with Savino Bruno

Hepatitis C: a revolution which will ultimately defeat the virus in the future

44 Humanitas

Clinical & Research Departments

45 Departments and teams - Clinical area 52 Scientific Research and Laboratories

54 Paper

published

2015

The yearly Scientific Report 2015 appears at a particularly significant phase of transition, both from the point of view of Humanitas as an institution, and from a broader perspective concerning evolution in medicine.

As far as Humanitas is concerned from an institutional point of view, suffice it to mention three moments in the past, the present and the future: 2016 marks the twentieth anniversary of Humanitas Hospital, it is characterized by the full maturity of the academic experience of Humanitas University, and witnesses the laying of the foundation stone of the new campus, as apparent from the excavations and the cranes on site.

These crucial institutional hallmarks coincide with a revolution in medicine. I am referring to the development of Precision Medicine, an increasingly personalized approach geared towards genetic features where lab bench and bedside are getting closer and are likely to become increasingly inseparable.

Precision Medicine implies the creation of a patient-centered ecological niche that integrates several different areas of knowledge, skills and competences ranging from genomics and bioinformatics to traditional clinical disciplines.

This perspective calls for a strong commitment in the education of a generation of future physicians and researchers able to face the fascinating, yet demanding challenges of precision medicine. Our Country boasts a great tradition in nurturing these new talents, which – unfortunately – is seriously undermined at present.

Physicians actively engaged in independent research (physician scientists) are an endangered species and this represents a global problem, as can be easily seen considering how this topic is widely covered by mainstream scientific literature.

Nevertheless, Italy – somehow denying its tradition – does not address the problem at a systemic level with a comprehensive and long-term strategy.

Humanitas is firmly committed to nurturing future generations of physicians and scientists.

In this context, translation from bench to bedside is an example of how research can be transferred to society, and can be considered the third mission of a University, alongside its two more traditional ones: education and scientific research in its strictest sense.

Translation to society includes a variety of facets: from communication to education, to transferring results to industry and technology. We are aware of our Country’s current constraints: we have committed ourselves to deal with those issues and are going to continue to do so, maintaining our focus on patients as human individuals.

Alberto Mantovani Scientific Director of Humanitas; Professor of General Pathology, Humanitas University

5

Humanitas Research & University Hospital

6

Who we are

Humanitas is a highly specialised hospital, research and teaching center and hosts Humanitas University. Built around centers for the prevention and treatment of cancer, cardiovascular, neurological and orthopedic disease – together with an Ophthalmic Center and a Fertility Center – Humanitas also operates a highly specialised Emergency Department.

As the first Italian hospital to have been qualitycertified by Joint Commission International, Humanitas is accredited by the National Health System.

Humanitas Research & University Hospital promotes health, prevention and early diagnosis by means of innovative and advanced outpatient healthcare facilities.

Appointed as IRCCS by the Ministry of Health (an accreditation in the Italian system that acknowledges institutions focused on excellence in clinical care and research), Humanitas is a world-famous center of excellence for immune system-related diseases, from cancer to rheumatoid arthritis.

Humanitas Research Hospital is the flagship of a hospital group also present in Milan, Bergamo, Turin, Catania, and Castellanza (Varese).

7

Humanitas at a glance

Our people 2,500 in total, of whom: more than 700 physicians more than 200 researchers more than 1,000 nurses, technicians, biologists and others more than 450 client service and staff

Clinical activity (yearly) 40,000 inpatients from Italy and abroad more than 2.3 million outpatients 50,000 Emergency Room (ER) patients more than 3.1 million lab tests 40,000 NMR examinations and CT scans more than 28,000 surgical procedures

Our facilities 90,000 sqm, of which: 75,000 are devoted to clinical activity 6,000 to scientific activity 4,000 to training and teaching

3,000 to facilities for patients and relatives 783 operative beds: 580 ordinary acute 73 day hospital 28 intensive care unit 102 rehabilitation 41 operating rooms 200 examination rooms 8

Our cutting-edge technologies Radiotherapy&Radiosurgery: 5 accelerators including 1 EDGE, 2 TRUEBEAM + GAMMA KNIFE 2 CT-PET with cyclotron (radio pharmaceutical production) da VINCI Robot and TELELAP ALF-X 2 O-arm for spine 6 MRI including 3T 6 CT, including one 128 slices Excimer and femtosecond laser

9

our history

1989 Design and construction of Humanitas are assigned to Techint based on James Gowan’s project.

1996

The hospital construction terminates and – on March 4, 1996 – Humanitas opens its doors and welcomes its first patient.

1997 Humanitas is subsidized by the National Health System for inpatient services.

1999 Humanitas Foundation is established for psychological and practical support to patients and caregivers.

2000 Humanitas becomes a teaching center of the Università degli Studi di Milano for the Nursing Degree, followed by Medicine and Biotechnology.

2002 Humanitas becomes a case-study for the Master in Business Administration at Harvard University and also receives excellence accreditation by the Joint Commission international, becoming the first Italian hospital to be acknowledged by one of the most important bodies for hospital quality certification worldwide.

2003 Humanitas opens the ER and the Radiotherapy Unit.

2005 The Ministry of Health accredits Humanitas as IRCCS. Fondazione Humanitas per la Ricerca is launched.

2007 Inauguration of the Research and Teaching Center.

2010 Humanitas launches the International Medical School in collaboration with the Università degli Studi di Milano.

years 10

1996 2016

2013 Scientific output from Humanitas reaches a total Impact Factor of 2,627, an outstanding result that positions the IRCCS among the first Italian Institutions for quality of research.

Diagnostic services enlargement with new available facilities.

2014 Humanitas University, a new international institution dedicated to the medical sciences, is established.

2015 Groundbreaking for the new Humanitas University Campus

Our philosophy

Our mission is to: • improve our patients’ lives by offering increasingly effective treatments based on an innovative and sustainable organization • invest in research that ultimately improves clinical management and outcomes • train a new generation of professionals for clinical skills, research and academia.

On the patients’ side Humanitas cooperates with Fondazione Humanitas to provide support to patients and their families.

In particular, Fondazione Humanitas supports patients with chronic diseases and their families by means of dedicated programs and properly trained nursing volunteers.

Humanitas and prevention Being proactive is the winning strategy to maintain good health. Even the most serious diseases can be prevented (primary prevention) or improved (secondary prevention) with physical activity and correct lifestyle.

Humanitas is actively involved in campaigns to promote healthy lifestyles and focuses on prevention and early diagnosis thanks to daily investments in expertise and technologies.

11

scientific research

Certified excellence Progress and growth during the last 3 years have been outstanding. (…)

The recruitment of translational researchers and physician scientists has been particularly successful and is going to be further expanded. (…)

Research at Humanitas In recent years, Humanitas’ scientific productivity has been constantly increasing in quality, achieving very high levels, as indicated by bibliometric indexes: over 3,000 Impact Factor points in 2015 (ranking among the first IRCCS Institutions in scientific output), with particular focus on the immune system. The latter is crucial for contemporary research in medicine because of its strong impact on different clinical areas, from cancer to cardiovascular diseases, inflammatory and autoimmune diseases.

The overall increase in scientific productivity is particularly impressive. (…)

Progress in education has been outstanding. (…)

The establishment of the International Medical School and the M.D.-Ph.D. program is viewed as a major strength of the HRI, which positions the Institute as a leader in the training of the next generation of physician scientists in Europe. (…)

The ranking of Humanitas is also very impressive (…): it is now top 10% in Italy and Western Europe worldwide (SCImago ranking).

From labs to patients, rapidly More than 200 researchers work at the University Research and Teaching Center – which is fully integrated with the hospital – utilizing cutting edge technologies, such as the recently acquired two-photon microscope. The group operates in close collaboration with the 700 physicians from the hospital, in order to facilitate translation, i.e. the direct application of the most recent advances in healthcare through a systematic and ongoing process of innovation. Scientists and researchers from 16 countries spanning over four continents carry out innovative research in immunology, and are involved in studies on high impact noncommunicable diseases, e.g. cancer, myocardial infarction, stroke, and autoimmune diseases.

12

In Italy among the Top

5%

In Western Europe and in the World among the Top

10%

Evaluation of Humanitas’ scientific output Every year Scimago Research Group analyzes yearly publications of approximately 5,000 research centers. According to the “Excellence Rank” (the percentage of articles published in the first decile), Humanitas ranks among the top 10% worldwide (315th out of 4,849 institutions) and in Western Europe (141st out of 1,535 institutions), and among the top 5% in Italy (8th out of 163).

Excellence

Scimago Excellence Rank 2015 100 90

Cold Spring

80 Inst. for System Biology

70

Dana Farber

60 IIT

40

Italian Universities

30

Foreingn Universities

20

Other Italian institutes Italian Hospitals

Excellence

Foreign Hospitals

IEO H. San Raffaele

Policlinico MI

10 0

0

10

20

30

90

40

Cold Spring

80

60

Cambridge S. Matteo Mayo Clinic Unimi

Politecnico MI

100

70

Sloan Kettering CC

HUMANITAS

50

Inst. for System Biology Dana Farber

50

60

70

80

90

Q1 100

13

scientific research

Publications 563 421

416 289

600

363

349

197

2015

2014

2013

2012

2011

2010

2009

2008

2007

160

2006

2005

110

172

Number of Humanitas’ publications Years 2005-2015

Impact factor 3,076

3,218

2,627

scientific activities

2,253 1,587

752

724

1,727

3,076 = Impact Factor in 2015 more than 300 professionals involved into research,

1,878

of whom:

896

200 researchers (PIs, Junior PIs/Staff scientists, Postdocs and PhD students, technologists/ technicians) 2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

387

Total Impact Factor of Humanitas’ publications Years 2005-2015

14

more than 100 clinicians involved into research

20 labs 20,000 sqm dedicated to research and education

Geographical distribution of foreign researchers at Humanitas

From EU Countries (Total 13)

Rest of the World (Total 9)

Poland

3

Canada

1

France

2

Colombia

1

Spain

2

Ecuador

1

Belgium

1

India

2

Croatia

1

Israel

1

Denmark

1

Japan

1

Greece

1

Macau

1

Serbia and Montenegro

1

Western Sahara

1

UK

1

Italian researchers who returned after an experience abroad

total

23

15

scientific research

Humanitas Research Day The relevance of the 2016 Humanitas Research Day is mirrored by the large number of posters presented – in total 150 – and the great participation of physicians, reasearchers, and lab personnel. The Research Day is an yearly opportunity for everybody involved in the preclinical and clinical research at Humanitas to be presented.

The program included thematic workshops, selected lectures by young physicians and promising researchers, a poster session – where the best posters on preclinical, translational, and clinical topics were awarded – and the presentation of the young researchers awarded national or international prizes during the previous year.

Fondazione Humanitas per la Ricerca is involved in supporting clinical and basic studies on pathophysiology of immunological defense mechanisms and of risk factors for several diseases, among which chronic inflammatory, cancer, cardiovascular, and neurological diseases.

The research activity of Fondazione Humanitas is monitored by an Advisory Board whose chairman is the Nobel Prize awardee Rolf Zinkernagel.

The Advisory Board of Fondazione Humanitas per la Ricerca: Rolf Zinkernagel, MD/PhD (President) University of Zurich and University Hospital of Zurich Institute of Experimental Immunology Zurich, Switzerland Fabio Cominelli, MD/PhD University Hospital Dept. of Medicine-Gastroenterology Cleveland, Ohio, USA Charles Dinarello, MD Professor of Medicine Division of Infectious Diseases University of Colorado Health Sciences Center Denver, Colorado, USA Pietro De Camilli, MD Eugene Higgins Professor of Cell Biology and of Neurobiology Director, Yale Program in Cellular Neuroscience and Neurodegeneration and Repair New Haven, Connecticut, USA

International Advisory Boards

16

Humanitas firmly believes in the evaluation process. For this reason, an Advisory Board for preclinic research headed by the Nobel Prize awardee Rolf Zinkernagel has been appointed.

Another International Advisory Board assesses and evaluates Humanitas Cancer Center research and clinical activities on a continuous base.

Napoleone Ferrara, MD/PhD Genentech Inc. South San Francisco, USA Lorenzo Moretta, MD Research Director Giannina Gaslini Pediatric Institute Professor of General Pathology University of Genova Genova, Italy Göran K. Hansson, MD/PhD Karolinska University Hospital Stockholm, Sweden

switzerland UK

italy

brazil

GREECE

TIMER

italy

switzerland

ireland spain france

italy

Ireland

austria

czech rep.

sweden germany

NORway

denmark

UK belgium netherlands

usa

austria

sweden germany

norway

denmark

UK belgium netherlands

switzerland

The network of the EU-sponsored research projects

BeTheCure (IMI)

france

ireland

germany

usa

ADITEC

italy

EUROSTARS

Grants to Humanitas’ researchers AICR 2014

Sequential combination of chemo-immunotherapy with trabectedin and functionalized immunomodulatory nanostructures to optimally target Tumor-Associated Macrophages in vivo

ERACOSYSMED 2015

Systems medicine approach to minimize macrophage-associated interstitial fibrosis and tubular atrophy in renal allograft rejection

ERANET NEURON 2014

Role of microglial metabolism in perinatal neuroinflammation

ERC advanced grant

Epigenetics and microRNAs in myocardial function and disease PTX3 in humoral innate immunity (PHII)

ERC starting grant

Generation and maintenance of long-lived memory T cells in humans

FP7 ICT UK, France, Germany, Italy, Norway, Spain, Switzerland

ICT-enabled, cellular artificial liver system incorporating personalized patient management and support

H2020-PHC-RIA

Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)

Marie Curie CIG

Characterization of NK cell distributions and functions in human tissues in HIV-1 pathogenesis Global microRNA profiling of normal and Pbx1-null hematopoietic stem cells and progenitors for the identification of new regulators of the balance between self-renewal and differentiation Improving adoptive T cell transfer immunotherapy for cancer with T memory stem cells

Marie Curie IIF

mRNA translational regulation in heart failure

Marie Curie Individual Fellowship EF ST

Development and evaluation of nanomedicines for cancer treatment through immunomodulation: targeting Tumor-Associated Macrophages (NANOTAM) In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer (MONONANOCHEM)

Marie Curie IRG

Role of microRNAs 143 and 145 in cardiovascular physiology and disease: from bench to bedside

Marie Curie ITN ETN

European Sepsis Academy: towards new biomarkers to improve sepsis management

17

scientific research

The Ethical Committee Since 2005, an Ethical Committee has been active at Humanitas. This is an independent body which protects the rights, security and well being of the parties involved, within the realm of clinical research. Any experimentation process, be it carried out industrially or within the Institute, depends on the Committee’s decision, which takes into account the correctness and the compliance to ethical standards of new therapeutic methods, or diagnoses, that involve human beings directly.

Key priorities for the Ethical Committee are independence (granted by the fact that its personnel does not work for the same hospital as the one where the Committee operates), and a

multifaceted approach, where different professional competencies and skills are indispensable for ensuring critical evaluation of different aspects of experimentation.

According to current regulations, the Ethical Committee must be composed by: two clinicians, a biostatistician, a pharmacologist, a chemist, the Medical Director, the Scientific Director and an expert in law.

In addition, the hospital where the Committee is based may appoint other members among general practitioners and local doctors, nurses and people committed to voluntary work, provided that the independence – and multifaceted-approach criteria above are met.

Humanitas’ biobank Advanced research increasingly needs to be supplied with biological samples (small amounts of blood and other biological fluids, or small sections of tissue removed during surgery) to be analyzed. These samples come from donors who suffer from different diseases, and are helpful to understand how patients differ from one another and – in perspective – to develop personalized treatment. In order to cater for this need, Humanitas has established a biobank.

A biobank can be compared to a “current account” where donors “deposit” their own biological material, and obtain “interest” in return, in the form of knowledge of their disease.

By signing an Informed Consent form, and under absolute confidentiality, donors authorize Humanitas to take samples to be used for biomedical research programs which would otherwise be impossible to carry out.

18

Humanitas University is a private non profit institution dedicated to medical sciences, founded in 2014. It is strictly interconnected with Humanitas hospital, where clerkship activities take place.

Courses are based on over 10-years’ experience in academic teaching, as well as on an active learning approach.

A wide range of degrees and postgraduate courses such as PhDs programs, Master courses, Residency programs are available, but training activities will keep growing, since they are going to be addressed not only at students but also at professionals.

In 2015 the works for the new campus began with the goal – once fully operating – to host over 800 students (initially starting from 120 a year for a MD course in English and 50 a year for a Nursing BD).

19

japan

china

sweden

germany denmark austria

ireland

Collaboration at international level is fundamental for clinical practice. In the last years, collaborations with national and international top-ranking hospitals and the constant effort in implementing the most advanced technologies have led to outstanding results in the treatment of neoplastic, gastrointestinal, cardiovascular, neurological and immunological diseases.

UK

International collaborations and recognitions

usa

Brazil

singapore

israel

poland

spain france switzerland croatia

HARVARD BUSINESS SCHOOL

20

portugal

belgium

argentina

Harvard University

Joint Commission

Workers’ safety

Responsible Payments

Considered by Harvard University one of the four most innovative hospitals worldwide, Humanitas is a case study for its organization model, which combines quality of care with economic sustainability, development and social responsibility.

Humanitas was the first polyclinic in Italy, and among the very few in Europe, to have been certified by the Joint Commission International.

This acknowledgement of excellence has been confirmed and renewed since 2002 and has required compliance with over 1,300 standards.

Humanitas is OHSAS 18001 (Occupational Health and Safety Assessment Specification) certified, an international recognition that highlights the hospital attention to its own workers’ safety and health.

Humanitas has joined the Codice Italiano Pagamenti Responsabili (The Italian Code of Responsible Payments), an initiative which has been launched

by Assolombarda to promote prompt and timely payments to suppliers and aimed at improving national and international reputation of Italian companies, thus strengthening their competitiveness.

Humanitas Group in Italy

1 Milan-Rozzano Istituto Clinico Humanitas

www.humanitas.it

1,861 beds 200,000 square meters 1,670 physicians 107,000 annual inpatient admissions 6,000,000 annual outpatients

Milan Humanitas San Pio X 2

www.sanpiox.net

Turin Clinica Cellini 3

www.clinicacellini.it

4

Turin

Humanitas Gradenigo www.gradenigo.it

3

4

5 6 7 1 2

5

Castellanza

Humanitas Mater Domini www.materdomini.it

6

Arese

Humanitas Medical Care www.humanitas-care.it

7

Bergamo

Humanitas Gavazzeni

www.humanitasgavazzeni.it

Catania Humanitas Centro Catanese di Oncologia 8

8

www.humanitascatania.it

21

Translational research

Specific instruments of Humanitas Laboratories IMMUNOLOGY, ONCOLOGY, NEUROSCIENCE, CARDIOVASCULAR Confocal microscopes equipped for FRET analysis, TIRF and fast FRAP Confocal microscopes Leica SP8 HyVolution STED SMD CellR for high-quality time-lapse imaging Two-photon microscope Olympus VS120 Virtual Microscopy Slide Scanning System LSR Fortessa cell Analyzer Bio-Plex multiplex system for the detection and quantification of multiple analytes BD FacsAria Automacs Cell Isolation ION TORRENT sequencer Next Seq 500 Sequencing System AB 3500 genetic analyzer IScan System NGS Express

NEUROSCIENCE 2 operating theatres equipped with O-Arm (three-dimensional imaging device) coupled to a neuronavigation system Cavitron Ultrasonic Surgical Aspirator (CUSA) for parenchymal tumor tissues or bone tissues BoneScalpel Ultrasonic Osteotome Neuromonitoring and neuronavigation combined with intraoperative 3D ultrasound for stereotactic excision of deep brain lesions 3D endoscopy tools for skull-base surgery 5 NMR (among which 3-Tesla, 1 open with ambient light) NMR equipment for functional imaging studies Acquisition and processing workstation for diffusion MRI tractography 4 TC (among which 1 64-slice) Inverted microscopes IX71 Perfusion system Electron-multiplying CCD (EMCCD) camera Quantem 512 Patch-clamp amplificatory Multiclamp Analog/ digital converter Digidata 1440A Light-Emission-Diod as source light PatchStar Micromanipulator

22

Metamorph software

Immunity and inflammation Oncology Cardiovascular Neuroscience Hepatology

CARDIOVASCULAR High-frequency, high-resolution VeVo 2100 digital imaging platform with linear array technology and Color Doppler Mode Mikro-Tip Pressure Volume System (MPVS)-Ultra Foundation System Telemetry for blood pressure and ECG assessment Scanning Ion Conductance Microscopy Optical Mapping for electrical Impulse Propagation IonOptix for Ca2+ transient and contractile assessment Patch-Clamp instruments for studies on action potential

23

IMMUNITY AND INFLAMMATION

The interface between immunology and oncology anticipates new advances in research

Interview with Alberto Mantovani Scientific Director of Humanitas; Professor of General Pathology, Humanitas University 24

Which have been the most significant developments the past year?

Well, they are developments which occurred as a follow-up on previous work done by our different research groups. Specifically, these advances are focused on regulatory mechanisms of immune and inflammatory response in various models of cancer and inflammatory conditions.

It should first be pointed out that the new forefront in the fight against cancer is represented by immunotherapy in all its different aspects, and multifaceted applications.

In view of this, an outstanding result was obtained here at Humanitas, when an oncosoppressor gene associated to tumor-promoting inflammation was identified.

I am particularly keen on emphasising the whole series of studies we conducted on the pentraxin PTX3, an essential component of the humoral arm of innate immunity.

We found that PTX3 acts as an oncosuppressor in various experimental models, as well as in humans. Differently from the other suppressor oncogenes which have been identified and described so far, and which act directly on tumor cells, PTX3 gene encodes for an effector molecule of the humoral innate immune system.

In other terms, before the results of our studies, there was no known precedent for a humoral innate immunity effector molecule acting as a cancer gene.

This observation represents a missing link in the connection between inflammation and cancer by providing evidence that tumor-promoting inflammation is an essential component of the microenvironment in which cancer cells grow and replicate.

More specifically, PTX3 regulates complement-dependent tumor-promoting inflammation. In addition, PTX3 gene activation inhibits tumor-promoting inflammation and cancer genetic instability and progression. On the other hand, PTX3 inactivation or deficiency unleashes an unrestrained complement cascade favoring an exacerbated inflammatory response and enhanced carcinogenesis.

We have described PTX3 early deactivation at the initial – still benign – stages of some tumoral types, e.g. in colonic polyps, then favoring the progressing to malignancy.

This research, conducted thanks to the fundings by AIRC (Associazione Italiana per la Ricerca sul Cancro), has involved clinicians and reaserchers at Humanitas and a network of national and international top-ranking centers, and has been published in 2015 on Cell, a prime authoritative scientific journal. Due to the high quality of

reasearch, the PhD student who is the first author of the paper was awarded several prizes.

We may say PTX3 is an old pal of yours, but its study keeps revealing enlightening data.

Actually PTX3 was discovered, characterized, and developed in the early 90s. This acute phase protein, a member of the long pentraxin subfamily, has been highly conserved during the evolution, which suggests an ancestral survival advantage. We have already shown that PTX3 is able to protect from infections, for instance Aspergillus fumigatus – a critical challenge for immunodeficient neutropenic patients such as transplant recipients – or Pseudomonas aeruginosa – the major cause of symptomatic lung disease and progressive lung dysfunction in patients affected by cystic fibrosis – and we are testing it as a candidate therapeutic agent against these infectious diseases. As outlined above, we are currently exploring its potential application as an antitumoral agent as well.

It has been demonstrated that the defective variants of PTX3 gene can be associated with susceptibility to urinary tract infections or invasive aspergillosis. Besides, the results of a collaborative Italian study in which Humanitas took part suggested that PTX3 may help identify patients with acute respiratory distress syndrome who developed bacterial infections and thus need antibiotic treatment, and emphasized its potentiality as a novel diagnostic and prognostic biomarker of inflammatory conditions, ranging from severe sepsis to cardiovascular disorders and cancer-associated inflammation.

In this way, our studies have layed the first stone for the transfer of PTX3 to the clinic, both as a potential therapeutic tool in infections, and as a diagnostic marker.

Speaking of biomarkers, PTX3 represents a positive achievement in terms of translation from the lab’s bench to the patient’s bed. But we work with a pipeline of candidate prognostic or severity markers both in oncologic conditions (e.g. pancreatic cancer or colorectal cancer) and nononcologic diseases (e.g. sepsis or urinary tract infections).

In particular, thanks to original tools developed here, we obtained data indicating that macrophage infiltration is related to prognosis and response to chemotherapy in pancreatic cancer. As a matter of fact, in 2015 the trend towards genetic and genomic approaches was considerably reinforced.

25

IMMUNITY AND INFLAMMATION Interview with Alberto Mantovani

The whole picture must be framed within the context of precision medicine, whose actual definition is “treating the right patient with the right treatment at the right time”.

Namely, any intervention – be it diagnostic or therapeutic – must (necessarily) consider the whole picture, the entire biology of the patient and of the disease.

Could you provide some examples of precision medicine with therapeutical outcomes at Humanitas?

top paper

What is particularly worth mentioning is the research carried out into the mechanisms that underlie the development and the maintenance of chronic inflammation in patients with inflammatory bowel disease, which encompasses Crohn’s disease and ulcerative colitis.

Our institution took part in international multicenter clinical trials conducted on subjects with active moderate-to-severe inflammatory bowel disease, which led to the development of vedolizumab, an innovative drug acting via different mechanisms in comparison with the biological agents of current therapeutic use. Vedolizumab is a humanized monoclonal antibody against α4β7 integrin, a cell-surface glycoprotein expressed on circulating B and T lymphocytes whose interaction with the mucosal addressin-cell adhesion molecules (MAdCAM) on intestinal vasculature plays a key role in maintaining active chronic inflammation into the bowel. Vedolizumab specific binding to α4β7 integrin

26

selectively blocks gut lymphocyte trafficking and represents a novel alternative in patients who fail conventional treatment.

Based on the evidence for efficacy both as induction and maintenance therapy and safety profile, vedolizumab has been approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA).

In addition, considerable efforts have been made to investigate the role of microvascular and lymphatic endothelium, until it was possible to outline what we now refer to as “IN” and “ON” mechanisms of chronic inflammation. The first refers to cell entry into the mucosa, migration of leucocytes into the interstitial space, bacterial and foreign antigen invasion, angiogenesis, and is controlled by intestinal microvasculature; the second is related to lymphatics’ activity in tissue edema control, leucocyte exit, bacterial clearance and oedema absorption. The functions of the microvascular and lymphatic endothelium in the gut are therefore complementary, although opposite. In patients with inflammatory bowel disease, a dysfunction in each would work together to amplify disease, with the microvascular endothelium overloading, and the lymphatic endothelium failing to relieve the intestinal mucosa.

Just as one needs the other for proper physiological function, the proverbial “brothers in arms”. Our original investigation on these mechanisms has resulted in promising data in the treatment of experimental inflammation both on immune and non-immune cells, some of which are hopefully to be translated into effective treatments for patients. These results may pave the way to innovative strategies to curb inflammation based on the promotion of the formation of new lymphatic vessels.

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C, Mantovani A.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer Cell. 2015 Feb 12;160(4):700-14. doi: 10.1016/j.cell.2015.01.004.

PTX3 is an essential component of the humoral arm of innate immunity, playing a nonredundant role in resistance against selected microbes and in the regulation of inflammation. PTX3 activates and regulates the Complement cascade by interacting with C1q and with Factor H. PTX3 deficiency was associated with increased susceptibility to mesenchymal and epithelial carcinogenesis. Increased

susceptibility of Ptx3(-/-) mice was associated with enhanced macrophage infiltration, cytokine production, angiogenesis, and Trp53 mutations.

Correlative evidence, gene-targeted mice, and pharmacological blocking experiments indicated that PTX3 deficiency resulted in amplification of Complement activation, CCL2 production, and tumor-promoting macrophage recruitment. PTX3 expression

was epigenetically regulated in selected human tumors (e.g., leiomyosarcomas and colorectal cancer) by methylation of the promoter region and of a putative enhancer.

Thus, PTX3, an effector molecule belonging to the humoral arm of innate immunity, acts as an extrinsic oncosuppressor gene in mouse and man by regulating Complementdependent, macrophage-sustained, tumorpromoting inflammation.

Main reasearch fields Autoimmunity

Autoinflammation

Carlo Selmi

Silvio Danese

Infections

Cecilia Garlanda

Barbara Bottazzi

Memory and Bone Marrow Transplant

Domenico Mavilio

Enrico Lugli

Luca Castagna

Mechanisms of Inflammation and Cancer Mechanisms of Inflammation and Colon Cancer

Antonio Sica

Paola Allavena

Alberto Malesci

Luigi Laghi

27

ONCOLOGY

Humanitas at the forefront of innovation in specialist therapies

Interview with Armando Santoro Director of Humanitas Cancer Center; full professor of Oncology at Humanitas University 28

What is the scenario of clinical research in haematology and oncology at the end of 2015?

Well, in both areas a relevant progress occurred in targeted drugs – also named molecular drugs or biological drugs – leading to more variety in therapeutic options with promising perspectives for a range of conditions.

Worth mentioning are targeted therapies for the treatment of breast cancer, with variable indications for specific subgroups of patients. They have been proved able to maximize the response to both hormone therapy and to HER2-targeted agents.

Another important example of how biological drugs have dramatically changed survival rates is represented by metastatic melanoma. Currently, the greatest hopes are pinned upon combinations of several targeted drugs with different mechanisms of action – e.g. BRAF inhibitors and MEK (MAPK/ERK kinase) inhibitors – whose use in clinical practice has been finally recognized and officially authorized. In fact, in 2015 immunotherapy was definitely established as a major method of treatment. Because of its mechanism of action – triggering an immune cascade to inhibit cancer progression – transversality is surely its most intriguing aspect, as immunotherapy is confirmed by evidence as effective for a large variety of oncologic conditions at different stages. This is obviously referred to the registration of new agents – ipilimumab, nivolumab, pembrolizumab – for the treatment of advanced melanoma, lung cancer – either squamous cells carcinoma or adenocarcinoma – kidney cancer, bladder cancer, and more recently, Hodgkin’s lymphoma.

Humanitas is acting as an influential key player in the area of immunotherapy, through its intense wide-scale participation in a large number of multicentric international clinical trials. Nonetheless, the ever-important role of traditional chemotherapy should not be forgotten.

Humanitas’ researchers have given their contribution also in this field, participating in the fine-tuning of new drug schemes with promising perspectives in haemato-oncology.

Still talking about haemato-oncology, we witnessed similarly lively activity in the development and registration of innovative drugs for both immunotherapy and molecular therapy, which mark the consolidation of a number of research programs that were carried out over the years.

One may ask how Humanitas was able to give a prominent contribution in the development and registration of various

drugs or their combinations, that are meant to become the international standard of care. Such achievement is attributable to the involvement of research groups which have a high expertise and full dedication to phase I studies.

This approach provided an active and intense participation in international clinical trials, which has been acknowledged by the scientific community and has gained excellent ranking in biomedical literature.

Let me refer to three recent papers, that were accepted by major journals in a surprisingly short time after submission.

The first one, which was published on Journal of Clinical Oncology, deals with the management of recurring Hodgkin lymphomas; the second, which appeared on Lancet Oncology, describes the potentiality of nivolumab, the new monoclonal antibody for the treatment of lymphomas; the last one – again published on Lancet Oncology – is the result of our efforts in the development of ceritinib, an anticancer drug that acts as an ALK (Anaplastic Lymphoma Kinase) inhibitor.

Let us outline a few relevant projects in oncology in more detail.

I feel I must point out a couple. As far as solid tumors are concerned, the sequence of cutting-edge worldwide trials on hepatocarcinoma is worth mentioning. This research line takes advantage from two strengths: on one hand, the continuing innovation in hepatobiliary surgery thanks to the enthusiasm and vision of the team led by Guido Torzilli, which has performed cutting-edge surgical techniques that are able to provide unexpected advantages and can be performed also on patients that otherwise were non-treatable (due to the characteristics and size of the tumor). On the other, the active participation of Humanitas Cancer Center’s researchers (worth referencing Lorenza Rimassa, Tiziana Pressiani and Nicola Personeni for their fundamental contribution) in clinical and translational research on novel biologic or immunologic treatment for advanced liver cancer. Still in the field of solid tumors, we played a primary role in international clinical trials on biologic therapies for lung cancer, which include virtually all novel anti EGFR (Epidermal growth factor) and anti ALK agents. Moreover, we are also involved in international clinical trials with state-of-the-art target therapies, alone or combined with immunotherapy.

As already mentioned, the other driving sector of cancer

29

oncology Interview with Armando Santoro

Let us deal with hematology then, where there seem to be equally promising perspectives

30

We have participated – often as coordinators – in many clinical trials which assessed the efficacy of emerging drugs which should be able to change our approach towards a variety of haematologic diseases, namely low-grade malignant lymphoma or chronic lymphocytic leukemia, such as BTK (Bruton’s Tyrosine Kinase) inhibitors and PI3K (Phospho Inositide 3-Kinase) delta inhibitors.

We have been working systematically on a series of innovative agents which are increasingly enriching the range of available drugs for the treatment of multiple myeloma, including monoclonal antibodies (e.g. daratumumab and elotuzumab) and second-generation proteasome inhibitors (e.g. carfilzomib).

Coming back to chemotherapy, over the years we have consolidated new schedules for the treatment of haematologic neoplasms and in particular non-Hodgkin lymphomas, continuing a tradition that sees our institution as an international authority on protocols for cases relapsed after a first line chemotherapy which are candidate to second line chemotherapy, before autologous bone marrow transplants. I wouldn’t be wrong in reiterating that the chemotherapy schemes which have been created and published by Humanitas’ research groups will be adopted as international standards of care.

In terms of forecasting where oncology and haematooncology are heading in perspective, I feel there are two main stimulating fields to look at. Firstly, a precision medicine pattern lies ahead, as the efforts of researchers

are oriented towards precise profiling of cancer patients, in order to target the therapy against a given molecular alteration. Secondly, a common platform for immunology and immunotherapy is, at the moment, the biggest challenge that is absorbing most of the researchers in both these fields worldwide.

Continuous advances in clinical research have to be seen in the context of a high quality integrated assistance, tailored to the patients’ needs and features. Also in this respect, Humanitas is urgently dealing with two projects. The first (of which Laura Velutti is in charge) is aimed at ensuring and improving continuity of care through home-based health care, as well as late-stage and end-of-life caregiving.

The other project consists in the management of longterm cancer survivors, a segment of population which is increasing year by year and requires personalized assistance, especially in the critical phase of transition between hospitalization and reintegration into daily life, which has a strong psychological impact.

To support these demanding needs we devised the Cancerfree Platform (managed by Elena Lorenzi, Isabella Garassino and Raffaele Cavina), a digital tool that has the purpose to facilitate the referral of disease-free patients to their primary care physician, while at the same time maintaining a direct communication with a dedicated oncologist who is fully able to address doubts and questions.

These projects require involvement and interaction of both doctors and patients, and are based on the close cooperation and shared objectives of several professionals that bring different competences. They demand organization, locations and resources, and offer an indisputable advantage in terms of standards of care and best practice.

top paperS

research is a transversal area that concerns Humanitas’ contribution in the development of immunological drugs. A single figure is enough to show the extent of our activity: at the moment, Humanitas is actively engaged in 50 different trials concerning immunotherapy based on a single molecule, the combination of different molecules or on a combination of chemotherapy and immunotherapy, obviously for several different types of tumor. Many of these trials were started in 2015, which is enough to prove their indisputable innovative potential. Preliminary results are really interesting: while monitoring day by day the progression of this researches, we clearly felt we were driving a process intended to define new standards of care for the coming years.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.

Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet. 2016 Mar 5;387(10022):968-77. doi: 10.1016/S01406736(15)00817-X. Epub 2015 Dec 17.

Main reasearch fields

Pancreatic Cancer

Clinical Pharmacology Alessandro Zerbi

Paolo Zucali

Matteo Simonelli

Lymphomas

Prostate Cancer

Carmelo Carlo-Stella

Lung and Chest Cancer

Marco Alloisio

Maria Chiara Tronconi

Luca Toschi

Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Oncologist. 2015 Mar;20(3):323-8. doi: 10.1634/ theoncologist.2014-0420. Epub 2015 Feb 10.

Giorgio Guazzoni

Marta Scorsetti

Breast Cancer

Corrado Tinterri

Rosalba Torrisi

Roberto A, Castagna L, Zanon V, Bramanti S, Crocchiolo R, McLaren JE, Gandolfi S, Tentorio P, Sarina B, Timofeeva I, Santoro A, Carlo-Stella C, Bruno B, Carniti C, Corradini P, Gostick E, Ladell K, Price DA, Roederer M, Mavilio D, Lugli E.

Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Blood. 2015 Apr 30;125(18):2855-64. doi: 10.1182/ blood-2014-11-608406. Epub 2015 Mar 5.

31

cardiovascular

A comprehensive approach to research in cardiology: from nanomedicine to standards of care

Interview with Gianluigi Condorelli Director of the Cardiovascular Department and of Cardiovascular Research at Humanitas; full professor of Cardiology at Humanitas University 32

Could you outline the most recent developments of translational research in cardiology?

Interactive, fruitful collaboration between basic scientists and clinical specialists is having an impact on many aspects of cardiology. An excellent example of the potential of applying basic-science technologies to cardiovascular diseases is the identification of circulating microRNAs and their use as disease-specific biomarkers or new therapeutic tools.

Indeed, a rather prolific research path we have been pursuing now for about three years has led to the discovery of microRNA biomarkers for the diagnosis and prognosis of several cardiovascular pathologies, including heart failure, acute myocardial infarction, cardiomyopathies and atherosclerosis. Moreover, we have discovered rather exciting microRNA-mediated mechanisms. For example, focusing on the complex interplay between endothelial cells, vascular smooth muscle cells and pericytes, Leonardo Elia has determined that direct transfer of specific microRNAs from smooth muscle cells to endothelial cells is involved in modulating the angiogenic potential of the latter. I am referring to microRNA-143 and microRNA-145, also indicated as the microRNA-143/145 cluster since the two are transcribed as a single unit, albeit each having a distinct sequence.

Interestingly, the passage of microRNA-143/145 from one cell type to the other occurs through 50-200nm-diameter structures called membrane (or tunneling) nanotubes.

Transfer of the microRNAs via these nanotubes is controlled by the transforming growth factor β pathway, and once within endothelial cells the cluster blunts angiogenesis. Corroborating this is the finding that experimental overexpression of microRNA-143 or microRNA-145 reduces the ability of endothelial cells grown in culture to form capillary-like structures and to proliferate. Thus, the microRNA-143/145 cluster is fundamental for the modulation of endothelial cell function, vascular homeostasis and angiogenesis.

How might this basic research finding be developed for the clinic? Well, leaving the cardiology field to the side for one moment, angiogenesis is regarded as a critical feature for the growth of tumors. Indeed, inhibitors of angiogenesis have strong antitumor activity and may be used for therapeutic ends. We hypothesize that tumors are associated with downregulation of these microRNAs: a reduction in the expression of this cluster within the endothelial cells of a tumor would cause an increase in angiogenesis and thus enhance tumor survival by augmenting its blood supply.

In support of this notion, some tumors have been found to have lower levels of microRNA-143/145 in comparison to normal specimens of the same tissue. Delivery of synthetic microRNA-143/145 to these tumors may thus be a promising therapeutic strategy to follow.

Modulation of angiogenesis in the development of cardiovascular disease, on the other hand, is currently less well defined, but our line of research is aiming precisely at finding responses to yet unanswered questions.

Do you think we can foresee other applications in these new and unchartered territories?

Indeed. We are making a significant effort to exploit the enormous therapeutic potential that microRNAs have in cardiology. In the heart, misexpression of these nucleotides is known to cause cardiac dysfunction, and intervening to normalize microRNA levels may have tremendous clinical implications. In this context, a crucial step is being able to deliver synthetic microRNAs or their inhibitors specifically to heart cells. Among the delivery systems available, nanoparticles seem particularly promising. However, while they have been largely investigated in the oncological field, their development and use for the treatment of cardiovascular disease is still in its infancy. On this point, Daniele Catalucci has conducted at Humanitas a proof-of-concept study on biocompatible, bioresorbable, negatively charged calciumphosphate nanoparticles. On account of their structural and chemical similarity with the mineral component of bones and teeth, these innovative nanoparticles have the ideal biocompatibilty, bioresorbability and biodegradability needed for the development of a safe and efficient system for the delivery of bioactive molecules to the heart.

Our results on in vitro and in vivo experimental models indicate that these “bioinspired� nanoparticles successfully encapsulate miRNAs and carry them into cardiomyocytes without promoting toxicity or interfering with the functional properties of the cells (most importantly, their excitability and contractility). This research is being funded by the Italian National Research Council and the Ministry of Health.

To our knowledge, it is the first cross-domain study that, ranging from functional chemistry to molecular and cellular cardiac physiology, provides important advances in the field of cardiovascular nanomedicine.

However, before this basic research can be transferred to the 33

cardiovascular Interview with Gianluigi Condorelli

clinic, studies are needed in support of the transferability of the findings to humans. Personalized medicine applications would first require experimentation on human cardiomyocytes derived from Induced Pluripotent Stem Cells, or IPSCs. iPSCs can be obtained easily from any patient and made to differentiate into the desired kind of cell, in our case allowing us to sidestep the difficult process of obtaining suitable numbers of viable human heart cells.

Studies of this type will undoubtedly increase the possibility of developing bioinspired, surface-charged nanoparticles to carry drugs – be they peptides or nucleotides – to diseased organs and even to selected cell populations.

Great attention is paid to research quality. The same is true when it comes to quality of healthcare in cardiology.

top paper

Well, both aspects are equally essential and somewhat depend on each other, in particular when we consider our commitment to translational research. The huge number of patients assisted at Humanitas’ Cardio Center provides us with strong motivation to pursue high-quality healthcare supported by the best specialist expertise. Each year at Humanitas, for instance, more than a thousand stents are implanted following Percutaneous Coronary Interventions (PCIs). Now, it seems fair to ask what the best therapeutic option for these patients might be.

Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia L.

TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization Circ Res. 2015 May 22;116(11):1753-64. doi: 10.1161/CIRCRESAHA.116.305178. Epub 2015 Mar 23.

Rationale. The miR-143/145 cluster is highly expressed in smooth muscle cells (SMCs), where it regulates phenotypic switch and vascular homeostasis. Whether it plays a role in neighboring endothelial cells (ECs) is still unknown.

Objective. To determine whether SMCs control EC functions through passage of miR-143 and miR-145.

34

A more focalized and stringent issue, namely choosing the most appropriate percutaneous treatment strategy that mitigates the risk of in-stent restenosis – that is encountered within 2-3 years in 5-10% of cases with drugeluting stents, and in 20-30% with bare metal stents – was tackled recently by a study, registered on the PROSPERO database, conducted by an international group in which Giulio Stefanini, from Humanitas’ Hemodynamics, Invasive Cardiology and Coronary Care Department, took part.

Applying the statistical approach called network metaanalysis, the researchers combined the outcomes of 27 clinical trials, published between 2001 and 2014, comprising a total of approximately six thousand patients who had undergone percutaneous interventions for in-stent restenosis. The findings suggested that conducting PCI with everolimus-eluting stents was superior to others when taking into account angiographic and clinical outcomes and the risk of restenosis and repeat revascularizations; another option was a drug-coated balloon, because of its ability to provide favorable results without adding a new stent layer. This meta-analysis, published in The Lancet in 2015, is the most comprehensive synthesis of evidence on the effectiveness of a currently available treatments for in-stent coronary restenosis. Its potential contribution to clinical practice is far from negligible, since over 2 million people worldwide receive a stent each year and cardiovascular disease is a growing problem, currently afflicting nearly 1% of the population. Poignantly, the prognosis of cardiovascular disease has been described as more malignant than cancer.

Methods and results. We used cocultures of SMCs and ECs under different conditions, as well as intact vessels to assess the transfer of miR-143 and miR-145 from one cell type to another. Imaging of cocultured cells transduced with fluorescent miRNAs

suggested that miRNA transfer involves membrane protrusions known as tunneling nanotubes. Furthermore, we show that miRNA passage is modulated by the transforming growth factor (TGF) β pathway because both a specific transforming growth factor-β (TGFβ) inhibitor (SB431542) and an shRNA against TGFβRII suppressed the passage of miR-143/145 from SMCs to ECs. Moreover, miR-143 and miR-145 modulated angiogenesis by reducing the proliferation index of ECs and their capacity to form vessel-like structures when cultured on matrigel. We also identified hexokinase II (HKII) and integrin β 8 (ITGβ8)-2 genes

essential for the angiogenic potential of ECs-as targets of miR-143 and miR-145, respectively. The inhibition of these genes modulated EC phenotype, similarly to miR-143 and miR-145 overexpression in ECs. These findings were confirmed by ex vivo and in vivo approaches, in which it was shown that TGFβ and vessel stress, respectively, triggered miR-143/145 transfer from SMCs to ECs. Conclusions. Our results demonstrate that miR-143 and miR-145 act as communication molecules between SMCs and ECs to modulate the angiogenic and vessel stabilization properties of ECs.

Main reasearch fields Molecular Mechanisms of Heart Failure

Cardiac Signaling

Gianluigi Condorelli

Epigenetics and Aterosclerosis

Daniele Catalucci

Epigenetics in Myocardial Diseases

Leonardo Elia

ipscs and Primary Cardiomiopathyes

Roberto Papait

Predictive Factors and Coronary Artery Disease

Elisa Di Pasquale

Sarcomeric Proteins in Myocardial Diseases

Giulio Stefanini

Risk Factors in Cardiovascular Diseases

Marie Louise Bang

Nanomedicine and Molecular Electrophysiology

Giuseppe Ferrante

Acquired Ommunity and Cardiovascular Disease

Michele Miragoli

New Technologies in Cardiovascular Diseases

Marinos Kallikourdis

New Technologies in Arrhythmia Therapeutics

35

Bernhard Reimers

Lucia Torracca

Riccardo Cappato

Maurizio Gasparini

neuroscience

High-tech and early diagnosis against degenerative and chronic neurological conditions

Interview with Alberto Albanese Director of the Neurology Department

36

Where is research in neurology heading?

In 2015 research projects focused on neurodegenerative disorders – Parkinson’s disease and parkinsonism – began at Humanitas, as a new field of clinical research to be explored.

A foreword is needed: The word “Parkinson’s disease” as such does not mean much. Rather, there are a multiplicity of conditions gathered under this ”umbrella term”. We should say instead Parkinson’s diseases.

Moreover, even though it has been considered a condition limited to the motor system for a long time, in the past two decades there have been increasing awareness and attention to the non-motor aspects of the disease, which include cognitive decline, behavioural changes, pain, and autonomic dysfunction. The therapeutic armamentarium is also expanding to help patients who have non-motor symptoms.

At the moment, clinical research at Humanitas is geared to identify predictive or prognostic markers for potential cognitive impairment leading to dementia with disease progression. It has been estimated that cognitive impairment occurs in approximately one out of three patients with Parkinson’s disease, the probability being higher with increasing age or condition duration. This large proportion of patients deserve careful identification, as they may be candidates for a neuroprotective treatment, putatively able to modify the course of their conditions. Of note, in absence of cognitive impairment, nowadays a patient – thanks to the available treatments – can experience acceptable living conditions without severe disability. In particular, the autonomic nervous system has been shown to be highly susceptible to change at early stages. We are assessing whether the presence and the severity of autonomic dysfunction at cardiovascular and gastrointestinal levels is a reliable marker for the occurrence of cognitive deterioration.

Autonomic dysfunction is assessed by means of two approaches: imaging and cardiovascular reflex testing. Cardiac sympathetic denervation can be detected early by imaging studies, such as myocardial 123I-metaiodobenzylguanidine scintigraphy.

Moreover, cardiovascular reflex testing can assess the functional status of autonomic nerves innervating the heart.

This investigation is conducted in collaboration with Raffaello Furlan, director of the Division of Internal Medicine thanks to a considerable investment by CARIPLO Foundation.

We have started the enrollment of patients who have been

diagnosed with Parkinson’s disease in the last 2-3 years. The selected cohort is assessed at baseline and at yearly intervals until cognitive decay occurs. We planned a prospective follow-up of a minimum of three years, lasting up to five years, during which two subgroups of patients – with or without cognitive impairment – are expected to emerge.

The individual overall profile of autonomic function will be retrospectively related to the evolution of the disease, with cognitive impairment as the index event.

Integration here appears to be an interesting and innovative aspect.

Could you mention other examples of this in other research areas you are working on?

At the moment cervical dystonia is being investigated, a condition – more commonly referred to as spasmodic torcicollis – which is a movement disorder characterised by inappropriate contractions of the cervical musculature related to a dysfunction of sensorimotor neural circuits. It causes abnormal posture of the neck and head, involuntary movements which may be accompanied by tremor and result in painful abnormal postures. Cervical dystonia has marked effects on patients’ self-image, and adversely affects their quality of life, social relationships and employment.

This condition is not as rare as one might think. Rather, it is often underdiagnosed or misdiagnosed (e.g. it is usually confused with tic disorders or tremors).

Notably, it has been described with precision even in the distant past. In fact, one of the most renowned quotes can be found in the twentieth canto of the Divine Comedy where Dante Alighieri describes the sinners walking through eternity with their heads forcedly twisted backwards and tears in their eyes: (…) Come ’l viso mi scese in lor più basso, mirabilmente apparve esser travolto ciascun tra ’l mento e ’l principio del casso, ché da le reni era tornato ’l volto, e in dietro venir li convenia, perché ’l veder dinanzi era lor tolto. (…) As lower down my sight descended on them, Wondrously each one seemed to be distorted From chin to the beginning of the chest; For tow'rds the reins the countenance was turned, And backward it behoved them to advance, As to look forward had been taken from them.

37

neuroscience Interview with Alberto Albanese

Different drug classes have traditionally been used for the symptomatic treatment of cervical dystonia, then replaced by the introduction of botulinum neurotoxin which has been the treatment of choice for a long time. Nevertheless, using botulinum neurotoxin requires careful muscle selection and identification before injection. In fact, the disease has varied and complex phenomenology, involving different muscles and combinations of muscles, more superficial or deeper, which may be affected to varying degrees and show different patterns of contraction.

Most recently, deep brain stimulation has opened up new prospects. Thus, at the moment we are involved in a dedicated project funded by the Jacques and Gloria Gossweiler Foundation based in Switzerland whose mission is supporting research focused on haematology and neurology.

Let us clarify these technological details, which are – I imagine – not so simple to convey through words

top paper

Well, our efforts are primarily focussed on two interventions which combine brain stimulation and neurosurgery, and have noteworthy technological outcomes.

The first implies a transcranial magnetic stimulation of the premotor cortex – a noninvasive method used to stimulate small regions of the brain – and is performed in collaboration with the Division of Neurosurgery.

The second option is epidural premotor cortical stimulation, consisting in an epidural brain stimulator controlled by an

implantable pulse generator positioned in the subclavear region under local anesthesia. The cortical target is identified using coordinates according to a computerized neuronavigation system, based on the patient’s neuroimaging (brain computed tomography and magnetic resonance imaging).

The clinical outcomes so far have been positive, as an improvement in signs and symptoms has been observed with a certain delay – few weeks – related to the involvement of multiple cortical areas in the pathophysiology of primary dystonia, which is sustained up to a year. At the same time, results show that both the surgical procedures and the brain stimulation are well tolerated The most innovative aspect of both these interventions is their mechanism of action: the interference with the “brain software”, we may say, allows us to monitor and influence voluntary and involuntary movements. At the moment, research is mostly conducted on hyperkinetic conditions which can be studied more easily than hypokinetic or akinetic conditions. As opposed to cardiac pacemakers, a more complex design is required for this kind of stimulation due to the extraordinary complexity of brain circuits.

Another intriguing point is the use of an intelligent pacemaker device whose sensing circuit may be hosted by technological fabrics capable of detecting the peripheral movements and tracking body motility. In addition, these fabrics can be used to manufact garments. A promising line of applied research in this field is ongoing, thanks to a collaboration with Politecnico di Milano. The fascinating prospect is that, once fully developed, this technology is exportable to other diseases.

Fossati G, Morini R, Corradini I, Antonucci F, Trepte P, Edry E, Sharma V, Papale A, Pozzi D, Defilippi P, Meier JC, Brambilla R, Turco E, Rosenblum K, Wanker EE, Ziv NE, Menna E, Matteoli M.

Reduced SNAP-25 increases PSD-95 mobility and impairs spine morphogenesis Cell Death Differ. 2015 Sep;22(9):1425-36. doi: 10.1038/cdd.2014.227. Epub 2015 Feb 13.

Impairment of synaptic function can lead to neuropsychiatric disorders collectively referred to as synaptopathies. The SNARE protein SNAP-25 is implicated in several brain pathologies and, indeed, brain areas of psychiatric patients often display reduced SNAP-25 expression.

It has been recently found that acute downregulation of SNAP-25 in brain slices impairs long-term potentiation; however,

38

the processes through which this occurs are still poorly defined. We show that in vivo acute downregulation of SNAP-25 in CA1 hippocampal region affects spine number. Consistently, hippocampal neurons from SNAP-25 heterozygous mice show reduced densities of dendritic spines and defective PSD-95 dynamics. Finally, we show that, in brain, SNAP-25 is part of a molecular complex including PSD-95 and

p140Cap, with p140Cap being capable to bind to both SNAP-25 and PSD-95. These data demonstrate an unexpected role of SNAP-25 in controlling PSD-95 clustering and open the possibility that genetic reductions of the protein levels – as occurring in schizophrenia – may contribute to the pathology through an effect on postsynaptic function and plasticity.

Humanitas Neuro Center

Neuroscience Program

Neurology

Michela Matteoli

Alberto Albanese

Neurosurgery

Maurizio Fornari

Giulio Maira

Oncological Neurosurgery

Lorenzo Bello

Vincenzo D’Angelo

Neuroradiology

Nunzio Paolo Nuzzi

Neuromuscolar Diseases and Neuroimmunology

Giuseppe Scotti

Gamma Knife

Piero Picozzi

Edoardo Nobile-Orazio

Neurological Rehabilitation

Bruno Bernardini

Marco Grimaldi

Emergency Neurology and Stroke Unit

Simona Marcheselli 39

hepatology

Hepatitis C: a revolution which will ultimately defeat the virus in the future

Interview with Savino Bruno Director of the Internal Medicine Department Director of the General Medicine and Hepatology Division 40

Hepatitis C: what is the current scenario, and what is changing?

This infectious disease is a major cause of liver disorders worldwide and a potential cause of substantial morbidity and mortality. In fact, cirrhosis and events such as decompensation or hepatocellular carcinoma developing in the long-term after hepatitis C virus infection still represent the main cause of death and liver transplantation in Western countries. In particular, among European countries, Italy accounts for the highest prevalence of infected persons.

To explain this high frequency we must go back to the early postwar period, when the combination of less stringent procedures in the manipulation and disinfection of nondisposable needles and the poorer knowledge of the infectious agent have favored its endemic diffusion.

Continuing our historical reconstruction, another great wave of contagion dates back to the Seventies with the beginning of blood transfusions. The persistence of alarming rates of infection has been guaranteed in the following decades by the exchange of non-sterile needles and/or sexual transmission.

Today, out of a million and a half sick people infected over 50 years, many are no longer with us, and this scenario is even more tragic if we consider that two hundred thousand patients are at risk of liver transplant.

Nevertheless, the data that are emerging encourage optimism. For instance, it is now proved that eradicating the infection in patients with clinically significant cirrhosis leads to dramatic improvement in their survival.

In other words, this result demonstrates that nowadays – among patients with compensated cirrhosis – those untreated or with a persistently detectable hepatitis C virus RNA are three to four times more likely to die than comparable persons from the general population, while those who achieve eradication thanks to treatment have a life expectancy similar to that of the general population age- and gender-matched.

This is excellent news. Shall we discuss this outcome and describe the process that allowed to achieve it?

Yes. What I have mentioned refers to preliminary data of an original investigation carried out cooperatively by our Hepatology Department at Humanitas, with the Biomedical Department of Internal and Specialist Medicine

(DIBIMIS) of Università degli Studi di Palermo, as well as with the Division of Gastroenterology and Hepatology, and with Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Università degli Studi di Milano.

We prospectively studied three cohorts of patients – approximately 1,800 patients in total – with compensated hepatitis C virus cirrhosis, 44% of which were eligible to receive an interferon (IFN)-based antiviral therapy. We compared the 10 and 20-year overall survival rates of patients who achieved a sustained virologic response – defined as undetectable serum hepatitis C virus RNA by polymerase chain reaction at week 24 after the treatment cessation – first to those of patients, untreated and decompensated, with a non-sustained virologic response and then to those of the general population. This latter estimate was allowed by the location of the referral centres both in Northern and Southern Italy, which made the population of patients adequately representative of the Italian general population.

In addition, the long duration of follow-up and the average age of the patients at enrollment (50 to 60 years) provides a plausible estimate of life expectancy.

Patients with compensated hepatitis C virus cirrhosis achieving a sustained virologic response obtained a main benefit, levelling their survival curve to that of the general population. We are quite confident that – thanks to a wider applicability of IFN-free regimens with direct antiviral agents which will increase the possibility to eradicate hepatitis C permanently – this gain in life expectancy will provide an even greater survival benefit.

Humanitas is one of the few Italian centers where experimental studies on these innovative and disease modifying drugs have been and are currently being carried out.

Shall we discuss how these drugs act, and the outcomes you envisage for your patients in a – say – 5 years’ time span?

Well, it all started in 2000, when a virus was created in a laboratory through phenomenal biotechnology, i.e. the replisome-based technology.

This innovative approach consists in the assessment of the efficacy of a given drug. Thus, once the direct antiviral agents have been identified as an effective molecule against hepatitis C virus infection.

Since as early as one year after their introduction, the

41

hepatology Interview with Savino Bruno

top paper

new drugs proved their formidable potentiality from the start, being able to cure the hepatitis C virus in patients after 12 weeks.

Moreover, IFN-free direct antiviral agents regimens will allow for a sustained virologic response to be achieved even in sicker patients and in those ineligible for interferon or previously excluded for comorbidities, a major advancement, given that the mortality rate of these patients is extremely high in comparison to the general population. A crucial fact is the need to administer antiviral treatment as early as possible.

Actually, the scenario is not so simple, as drugs engineered using replisome-based technology are stratospherically expensive, i.e. 50 thousand euros in Europe or 90 thousand Us dollars in the United States for the whole course.

As far as antiviral agents are concerned, the Italian Medicine Agency (AIFA) has knocked down a price that will allow 50 thousand patients to receive free medical care from the National Health System.

However, at the moment, this poses some limitations since the indication is driven by selective criteria, and approximately a quarter of eligible patients have access to the new drugs.

Current international guidelines give the highest priority for treatment with new direct antiviral agents to HCV-infected individuals who have already reached advanced stages of the disease and are at higher risk of death without receiving therapy.

In a hopefully near future, the treatment will be available for all patients with hepatitis C virus infection. Everyone of them must heal or at least live “without the virus in their body”.

My feeling – and my hope – is that in a mid-term future, I will not meet any longer patients with decompensated liver cirrhosis who have been seriously ill for years and still are a terribly serious problem for us. In 2020, hepatitis C will have become a rare disease. In medicine, discoveries of this magnitude typically occur once every 100 years.

Viganò L, Conci S, Cescon M, Fava C, Capelli P, D'Errico A, Torzilli G, Di Tommaso L, Giuliante F, Vecchio FM, Salizzoni M, David E, Pinna AD, Guglielmi A, Capussotti L.

Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC J Hepatol. 2015 Jul;63(1):93-101. doi: 10.1016/j.jhep.2015.01.024. Epub 2015 Jan 31

Background & Aims. The incidence of metabolic syndrome-related hepatocellular carcinoma (MS-HCC) is increasing worldwide. High resection risks are anticipated because of underlying steatohepatitis, but long-term results are unknown. To clarify the outcomes following liver resection in patients with MS-HCC and to compare the outcomes of MS-HCC to HCV-related HCC (HCV-HCC).

Methods. All the consecutive patients undergoing liver resection for HCC in six high-volume HPB units between 2000 and 2012 were retrospectively considered.

The patients with MS-HCC were identified and matched one-to-one with HCV-HCC patients without metabolic syndrome.

Matching was based on age, cirrhosis, Child-Pugh class, portal hypertension, HCC number and diameter and liver resection extension.

42

Results. Among 1563 patients undergoing liver resection for HCC in the study period, 96 (6.1%) had MS-HCC. They were matched with 96 HCV-HCC patients. All patients

were Child-Pugh class A, 22.9% had cirrhosis. Forty-one patients per group (42.7%) required major hepatectomy. The MS-HCC group had a higher prevalence of steatohepatitis (25.0% vs. 9.4%, p=0.004).

Operative mortality was 2.1% (1 MS-HCC, 3 HCV-HCC, p=0.621). Morbidity and liver failure rates were similar between the two groups. In the multivariate analysis, cirrhosis, major hepatectomy, and MELD >8, but not steatohepatitis, impacted severe morbidity and liver failure rates.

The MS-HCC group had better 5-year overall survival (65.6% vs. 61.4%, p=0.031) and recurrence-free survival (37.0% vs.

27.5%, p=0.077). Independent negative prognostic factors were HCV-HCC, multiple HCC, microvascular invasion, and satellite nodules.

Conclusions. Liver resection is safe for MS-HCC, as for HCV-HCC. Cirrhosis, but not steatohepatitis, affects short-term outcomes. MS-HCC is associated with excellent long-term outcomes, better than HCV-HCC.Impairment of synaptic function can lead to neuropsychiatric disorders

collectively referred to as synaptopathies.

The SNARE protein SNAP-25 is implicated in several brain pathologies and, indeed, brain areas of psychiatric patients often display reduced SNAP-25 expression.

It has been recently found that acute downregulation of SNAP-25 in brain slices impairs long-term potentiation; however, the processes through which this occurs are still poorly defined. We show that in vivo acute downregulation of SNAP-25 in CA1 hippocampal region affects spine number. Consistently, hippocampal neurons from SNAP-25 heterozygous mice show reduced densities of dendritic spines and defective PSD-95 dynamics. Finally, we show that, in brain, SNAP-25 is part of a molecular complex including PSD-95 and p140Cap, with p140Cap being capable to bind to both SNAP-25 and PSD-95. These data demonstrate an unexpected role of SNAP-25 in controlling PSD-95 clustering and open the possibility that genetic reductions of the protein levels – as occurring in schizophrenia – may contribute to the pathology through an effect on postsynaptic function and plasticity.

Main reasearch fields

Advanced Virus-Related Diseases

Savino Bruno

Marco Carbone

Ana Lleo De Nalda

Autoimmune liver diseases

Hepatocellular Carcinoma

Lorenza Rimassa (New drugs)

Guido Torzilli (Innovative surgical treatment)

Luigi Solbiati (Interstitial and ablated treatment)

43

Board of Directors President Gianfelice Rocca Vice President Ivan Colombo Chief Executive Officer Luciano Ravera Scientific Director Alberto Mantovani

Clinical & Research Departments

Clinical Research Director Humanitas Cancer Center Director Armando Santoro General Manager Stefano Cazzaniga Medical Director Norberto Silvestri Human Resources Director Paola Boromei Scientific Superintendent Nicola Dioguardi Research Advisory Board Rolf Zinkernagel (President) Fabio Cominelli Pietro De Camilli Charles Dinarello Napoleone Ferrara Gรถran K. Hansson Lorenzo Moretta

44

Departments and teams clinical area Updated as of March 2016

Cancer Center Director: Armando Santoro

BREAST UNIT Division director: Corrado Tinterri Claudio Andreoli (°) Erika Barbieri Elena Bissolotti (**) Giuseppe Canavese Marco Eboli Valentina Errico Wolfgang Gatzemeier (•) Emilia Marrazzo Carlo Marco Rossetti Arianna Rubino Andrea Sagona Alberto Testori (•)

MEDICAL ONCOLOGY AND HAEMATOLOGY Division director: Armando Santoro professor at Humanitas University Concetta Arcanà Margherita Autuori Monica Balzarotti Saro Barbagallo (***) Monica Bertossi (**) Silvia Bozzarelli Stefania Bramanti Carmelo Carlo-Stella (•) (*) Carlo Carnaghi Elisa Carra (**) Luca Castagna Raffaele Cavina (•) Elisa Crotti (**) Lucia Damicis (**) Matteo Giovanni Della Porta professor at Humanitas University Rita De Sanctis Fabio De Vincenzo Barbara Ercoli (**) Giuseppe Fatuzzo (***) Giovanna Finocchiaro Isabella Garassino Laura Giordano (**) Elena Lorenzi Nina Machado Torres (**) Massimo Magagnoli Andrea Marrari Giovanna Masci Rita Mazza

Emanuela Mencaglia Lucio Morabito Lucia Morello Angela Nardozza (***) Andrea Nozza Nicola Personeni Ilaria Peschechera (***) Alice Pezzoni (**) Tiziana Pressiani Francesca Ricci Lorenza Rimassa (•) Marianna Rossi Luca Rubino (**) Simona Sala (**) Annalisa Saetta Barbara Sarina Matteo Simonelli Licia Siracusano Elisabetta Todisco Rosalba Torrisi (•) Luca Toschi Maria Chiara Tronconi Claudia Udine (**) Laura Velutti Paolo Andrea Zucali (•) Monica Zuradelli

PET AND NUCLEAR MEDICINE Division director: Arturo Chiti professor at Humanitas University Lidja Antunovic Stefano Grugni Egesta Lopci Katia Marzo Barbara Nardi Giovanna Pepe Marcello Rodari Martina Sollini PhD at Humanitas University Gianluca Tarullo Giovanni Tosi (medical physicist) Ilaria Vaccaro

RADIOTHERAPY AND RADIOSURGERY Division director: Marta Scorsetti professor at Humanitas University

Anna Maria Ascolese Tiziana Comito Luca Cozzi (medical physicist) (°) Giuseppe Roberto D’Agostino Fiorenza De Rose Antonella Fogliata (medical physicist) (°) Davide Franceschini Ciro Franzese Anna Gaudino (medical physicist) Cristina Iftode Francesca Lobefalo Giulia Maggi (**) Pietro Mancosu Pierina Navarria Valentina Palumbo Giacomo Reggiori (medical physicist) Antonella Stravato (medical physicist) Stefano Tomatis (medical physicist) Angelo Tozzi Fabio Zucconi

THORACIC SURGERY Division director: Marco Alloisio Edoardo Bottoni Umberto Cariboni Valentina Errico Giorgio Maria Ferraroli Simone Grappolini (°) Alberto Testori (•) Roberto Travaglini (°) Giulia Veronesi Emanuele Voulaz

(*) Phisycian dealing with activity in the Research laboratories too (**) Research Staff (***) Research Nurse (•) Head of unit (°) Consultant (§) Vicarious ■ Divisions that join in the Humanitas Cancer Center

45

departments and teams Clinical area

Cardio Center Head of department: Gianluigi Condorelli professor at Humanitas University

CARDIAC SURGERY Division director: Lucia Torracca Alessandro Barbone Alessio Basciu Antioco Cappai Enrico Citterio Andrea Davide Fumero Monica Moz Diego Ornaghi (•) Fabrizio Settepani Giuseppe Tarelli

CARDIOVASCULAR PREVENTION CENTER Division director: Lidia Rota Monica Bacci (**) Loredana Mendolicchio Matteo Roveda (**)

CLINICAL CARDIOLOGY Division director: Bernhard Reimers Tiziana Anita Ammaturo Monica Bocciolone (•) Augusto Foresti (°) Veronica Fusi Daniela Guiducci Manuel Marconi (•) Roberta Paliotti Michele Randazzo Cinzia Santucciu Maria Luisa Stella Luisa Ulian

ECHOCARDIOGRAPHY Division director: Renato Maria Bragato Sara Anna Cioccarelli Mirko Curzi Donatella Raspante

46

ELECTROPHYSIOLOGY AND ELECTROSTIMULATION Division director: Maurizio Gasparini Maria Carla Casale Carlo Ceriotti Paola Galimberti Luca Poggio

HAEMODYNAMICS, INVASIVE CARDIOLOGY AND CORONARY CARE Division director: Bernhard Reimers Cristina Barbaro Guido Belli (°) Daniela Cattani (***) Elena Corrada (•) Giuseppe Ferrante (*) Gabriele Luigi Gasparini Francesco Milone (°) Valentina Pacher Paolo Pagnotta (•) Patrizia Presbitero (°) Marco Luciano Rossi Melania Scatturin (**) Giulio Giuseppe Stefanini Dennis Zavalloni Parenti

THROMBOSIS CENTER Division director: Corrado Lodigiani Elena Banfi (**) Paola Ferrazzi Luca Librè Veronica Pacetti

VASCULAR SURGERY I Division director: Efrem Civilini professor at Humanitas University Elisa Casabianca Pier Luigi Giorgetti (°) Giorgio Luca Poletto Athos Popovich

VASCULAR SURGERY II Division director: Maria Grazia Bordoni Vittorio Danesino Alberto Morandi (°) Antonia Petrella Paolo Spada

HEART FAILURE CARDIOLOGY Division director: Maddalena Lettino Alessio Cappelleri Maurizio Mangiavacchi Daniela Pini

RESEARCH CENTER FOR CLINICAL ARRHYTHMOLOGY AND ELECTROPHYSIOLOGY Division director: Riccardo Cappato

(*) Phisycian dealing with activity in the Research laboratories too (**) Research Staff (***) Research Nurse (•) Head of unit (°) Consultant (§) Vicarious ■ Divisions that join in the Humanitas Cancer Center

Diagnostic Imaging Department

Diagnostic Laboratory Services Department

Director: Alberto Malesci

Director: Luca Balzarini

DIAGNOSTIC RADIOLOGY

LABORATORY TESTS

Division director: Luca Balzarini

Division director: Marta Noemi Monari (§)

Cristiana Bonifacio Alice Carla Castelli Elisabetta Colombo Mariagiorgia Farina Tiziana Carmen Ierace (°) Sara Imparato Ezio Lanza Paolo Malerba (•) Lorenzo Monti Oana Codrina Moscovici (°) Federica Mrakic Sposta Maria Alessandra Pestalozza Dario Poretti Manuel Profili Eva Renifilo Luigi Alessandro Solbiati

ECHOGRAPHY Division director: Paola Magnoni Caterina Comola Manuela Cira De Crescenzo Pasquale De Nittis Jean Claude Foteuh Milena Galardo Margherita Lunelli Natalia Moneta Laura Saltarin Alessandra Sapori Chiara Valsania

NEURORADIOLOGY Division director: Marco Grimaldi Francesco Asteggiano Marcello Cadioli (MR scientist) (°) Nunzio Paolo Nuzzi (•) Felice Rognone (°) Giuseppe Scotti (°)

ONCOLOGY & INTERVENTIONAL RADIOLOGY Division director: Romano Lutman Vittorio Pedicini (•) Marco Tramarin

Gastroenterology Department

Valentina Achille Roberto Assandri Barbara Barbieri Gianluca Basso (*) Daniela Bettio Paolo Bianchi (*) Simona Brambilla Elena Bredi Maria Calabro Erminia Anna Casari Cristina Luigia Daleno Concetta De Luca Antonella Ferrario Rossana Mineri Lucia Maria Motta Raffaella Renzulli Carla Barbara Ripamonti (°) Cristina Scuderi

PATHOLOGY Division director: Massimo Roncalli professor at Humanitas University Silvia Armenia Serena Battista Raimondo Boeri (°) Paola Bossi Tatiana Brambilla Piergiuseppe Colombo (•) Annarita Destro Luca Di Tommaso researcher at Humanitas University

DIGESTIVE ENDOSCOPY SERVICE Division director: Alessandro Repici professor at Humanitas University Andrea Anderloni Silvia Carrara Milena Di Leo Elisa Chiara Ferrara Roberta Maselli

GASTROENTEROLOGY AND DIGESTIVE ENDOSCOPY Division director: Alberto Malesci Gianluca Basso (*) Paolo Bianchi (*) Elisa Carlani Tommaso Cavalleri Luigi Laghi (*) Paolo Dario Omodei (•) Paoletta Preatoni Beatrice Salvioli

INFLAMMATORY BOWEL DISEASE Division director: Silvio Danese professor at Humanitas University Marina Alfieri (**) Mariangela Allocca Patrizia Danieli (**) Mariangela Delliponti (**) Gionata Fiorino Federica Furfaro Daniela Gilardi (**)

Bethania Fernandes Barbara Fiamengo Chiara Lo Russo Sofia Manara Jessica Munné Collado Chiara Novello research fellow at Humanitas University Daoud Rahal (•) Mauro Sollai Paola Spaggiari

47

departments and teams Clinical area

General Anaesthesia and Intensive Care Department

General Surgery Department

Director: Ferdinando Raimondi

Director: Guido Torzilli

ANAESTHESIA I Division director: Franco Cancellieri

ANAESTHESIA II Division director: Valentina Bellato

ANAESTHESIA III Division director: Vittorio Gavazzeni

ANAESTHESIA AND CARDIOSURGERY INTENSIVE CARE Division director: Giuseppe Crescenzi Graziano Cortis Pietro Ferrara Licia Melis Concetta Rosica Maria Cristina Soriano Rodrigo Paolo Francesco Tosi Maria Maddalena Visigalli (°)

GENERAL ANAESTHESIA AND INTENSIVE CARE DEPARTMENT

48

Daniela Albiero Enrico Arosio (•) Jana Balazova Gian Michele Battistini Francesca Belforti Gabriella Brancato Stefania Brusa Stefania Cantoni Cristina Carlino Gianluca Luigi Castellani Francesco Corazzi Elena Costantini Paola Matilde De Pietri Stefania Del Grosso Orazio Difrancesco Cristina Dominoni Nadia Fusilli Vittorio Gavazzeni Donatella Girardello (•)

professor at Humanitas University Enrico Giustiniano Yari Gollo Stefania Grimaldi Valeria Lascari Sabrina Malara Silvia Eleonora Malossini Maria Rosaria Martucci Alessandra Mondovì Francesco Pellegrino Fabio Piccirillo Andrea Pradella Francesco Restuccia Ilaria Rivetti Laura Rocchi Nadia Ruggieri Sabrina Spear Grazia Suriano Guido Paolo Turio Federico Arturo Villa Paola Cosma Zito

BARIATRIC SURGERY Division director: Giuseppe Marinari Gabriele D’Alessandro Giuseppe Sarra Sara Testa

GENERAL AND DIGESTIVE SURGERY Division director: Marco Montorsi Stefano Bona (•) Martina Ceolin Hayato Kurihara (•)

Pancreatic Surgery Division director: Alessandro Zerbi professor at Humanitas University Giovanni Capretti Francesca Gavazzi Marco Platto Cristina Ridolfi

Colon and Rectal Surgery Division director: Antonino Spinelli professor at Humanitas University Paola Campenni Michele Maria Carvello Giulia David Matteo Sacchi

GENERAL AND ONCOLOGIC SURGERY Division director: Vittorio Quagliuolo Antonella Ardito Pietro Francesco Bagnoli (•) Andrea Brocchi Ferdinando Carlo Cananzi Luca Cozzaglio (•) Stefano De Pascale Uberto Fumagalli Romario (•) Chiara Erminia Mussi

HEPATOBILIARY SURGERY Division director: Guido Torzilli professor at Humanitas University Matteo Maria Cimino Daniele Del Fabbro Matteo Donadon Barbara Franceschini (**) Angela Palmisano Fabio Porcopio Cristiana Soldani (**) Luca Viganò

Gynaecology Department Director: Paolo E. Levi Setti

FERTILITY CENTER Division director: Paolo Emanuele Levi Setti Elena Albani Annamaria Baggiani Renzo Benaglia Valentina Caccavari Luca Cafaro Valentina Canevisio Federico Cirillo Raffaella De Cesare Alessia De Mita Alessandra Drovanti Valeria Liprandi Elisa Macalli Luciano Negri Maria Rosaria Parisen Toldin Paola Persico Laura Sacchi Valeria Scolaro Cristina Specchia Elena Zannoni Irene Zerbetto

Internal Medicine Department Director: Savino Bruno

professor at Humanitas University

ACCIDENT & EMERGENCY UNIT

GENERAL MEDICINE AND HEPATOLOGY

Division directors: Salvatore Badalamenti Antonio Voza

Division director: Savino Bruno professor at Humanitas University

Monia Aloise Cristina Badalotti Alessandro Barraco Valentina Bellina Alessandro Bottani Gianluigi Citterio Giuseppe Civitavecchia Denise Provvidenza Comina Carlo Fedeli Giovanni Giorgino Elisabetta Lavezzi Federica Longhi Alfonso Maiorino Silvia Oldani Stefano Ottolini Silvia Paiardi Marta Ripoll Pons Anna Spizzi Sabina Tanzi

GYNAECOLOGY

DERMATOLOGY

Division director: Domenico Vitobello

Division director: Antonio Costanzo professor at Humanitas University

Gianluigi Bresciani Cinzia Bulletti Nicoletta Iedà Lara Paladini Gabriele Siesto

Luca Livio Mancini Marcello Monti (°) Alessandra Narcisi Francesco Sacrini Federica Sanna Francesca Savalli

ENDOCRINOLOGY AND DIABETOLOGY Division director: Andrea Lania professor at Humanitas University Paolo Colombo Alessandro Pizzocaro

Ilaria Bianchi Vincenzo Boccaccio Marco Carbone Roberto Ceriani (•) Ana Lleo De Nalda (*) Maria Gioia Pich Ilaria Sogno (**) Maurizio Alessandro Tommasini (°)

GENERAL MEDICINE AND PNEUMOLOGY Division director: Michele Ciccarelli Massimo Crippa Alessandra Ibba Alessia Marseglia (°) Francesca Puggioni Lucia Testoni

Rosa Pedale Luisa Persichini Claudio Ponticelli (°) Silvia Santostasi Rossella Valentino Simona Verdesca

RHEUMATOLOGY AND CLINCAL IMMUNOLOGY Division director: Carlo Francesco Selmi Angela Ceribelli (**) Maria De Santis (**) Bianca Marasini (°) Marco Sergio Massarotti

OUTPATIENT AREA Barbara Bianchini Lara Castagnetti Giovanni Covini (•) Ombretta Nucca Bruno Pessano Vanessa Ronzoni Vincenzo Tullo

INTERNAL MEDICINE Division director: Raffaello Furlan Maria Italia Sara Achenza Franca Barbic (°) Enrico Brunetta Franca Dipaola Rosalba Lembo Mauro Podda (°) Emanuela Maria Scannella

NEPHROLOGY AND DIALYSIS Division director: Salvatore Badalamenti Claudio Angelini (•) Paola Arosio Cesare Berra (•) Albania Calvetta Giuseppe Favacchio Silvia Finazzi Giorgio Graziani (°) Marco Mirani

(*) Phisycian dealing with activity in the Research laboratories too (**) Research Staff (***) Research Nurse (•) Head of unit (°) Consultant (§) Vicarious ■ Divisions that join in the Humanitas Cancer Center

49

departments and teams Clinical area

Neuro Center

EMERGENCY NEUROLOGY AND STROKE UNIT Division director: Simona Marcheselli Beatrice Albano Elisa Coloberti Manuel Corato Lara Fratticci Maria Luisa Soardi (°) Mariacarmela Spinelli Laura Straffi

NEUROLOGY I Division director: Alberto Albanese Stefania Lalli Rossella Maggio

NEUROLOGY II Division director: Eduardo Nobile Orazio Mariangela Bianco Mohamed Ziad Fayoumi (°) Francesca Gallia Claudia Giannotta (**) Giuseppe Liberatore Fabrizia Terenghi

NEUROSURGERY Division director: Maurizio Fornari

50

Luca Attuati Simonetta Beluffi (°) Delia Cannizzaro Andrea Cardia (•) Paola Carmagnini (°) Francesca Cortese Francesco Costa Vincenzo D’Angelo Giuseppe D’Aviri (°) Antonio De Santis (°) Giovanni Battista Lasio (•) Giulio Maira Guido Menasce (°) Davide Milani Alessandro Ortolina Armando Pellanda (°) Piero Picozzi Alberto Pollini (°)

Ortho Center

Stefania Radice Riccardo Rodriguez y Baena (°) Giorgio Savoia (°) Massimo Tomei

ARTHROSCOPIC SURGERY OF THE KNEE

KNEE ORTHOPAEDICS AND SPORT TRAUMATOLOGY

Division director: Enrico Arnaldi

Division director: Piero Volpi

ONCOLOGIC NEUROSURGERY

Stefano Bertora (°) Andrea Bruno Massimo De Donato Paolo Dupplicato Alexander Kirienko (°) Paolo Pesenti (°)

Corrado Bait Antonio Orgiani Emanuele Prospero Alessandro Quaglia

FOOT SURGERY

Division director: Nicola Portinaro

Division director: Lorenzo Bello Alessandra Casarotti Enrica Maria Fava Antonella Leonetti Federico Pessina Guglielmo Puglisi Marco Riva

Division director: Leonardo Maradei Antonio Giardella Nikolaos Markopoulos

PAEDIATRIC AND NEUROORTHOPAEDICS SURGERY

Alberto Grassi Mantelli Artemisia Panou

HAND SURGERY

SHOULDER AND ELBOW SURGERY

Division director: Alberto Lazzerini

Division director: Alessandro Castagna

Luciana Marzella Ilaria Papini Zorli Pier Luigi Raimondi (°) Angela Trabucco Fabiana Zura Puntaroni

Mario Borroni Giacomo Delle Rose Dario Pitino Paolo Renato Rolla (°)

HIP AND KNEE PROSTHETIC SURGERY

Division director: Marco Berlusconi

Division director: Enirco Arnaldi (§) Franco Astore Andrea Baldini (°) Giovanna Borello (°) Emanuele Caldarella Tiziana D’Amato Antonello Della Rocca Federico Della Rocca Antonino Gurgone Mattia Loppini Federica Martorelli Giuseppe Mazziotta Damiano Ricci Riccardo Ruggeri Giuseppe Santoro Marco Scardino Francesco Traverso

TRAUMATOLOGY

Matteo Cavanna Lorenzo Di Mento Davide Marchettini Mattia Mocchi Valeria Peschiera Jose Antonio Puchol Incertis Ivano Scarabello

Rehabilitation Department

Specialised Divisions of Surgery

Director: Stefano Respizzi

CARDIAC & RESPIRATORY REHABILIATION Division director: Stefano Aglieri Anna Beretta Franco Rusconi (°)

Hospitalist Matteo Ferrari Alessandro Eusebio Francesca Meda

NEUROLOGIC REHABILITATION Division director: Bruno Bernardini Giovanna Cerina Viviana Colantonio Carla Corsini Sara Ghirmai Marco Augusto Pagani

ORTHOPAEDIC REHABILITATION Division director: Stefano Respizzi Barbara Baroni Maria Cristina D’Agostino Gianluca Galimberti (•) Paolo Maria Parenti (°) Giuseppe Strangio Elisabetta Tibalt

SPORTS AND EXERCISE MEDICINE Daniela Lucini (•)

EYE CENTER

SURGICAL DAY HOSPITAL

Division director: Paolo Vinciguerra professor at Humanitas University

Division director: Roberta Monzani

Elena Albè Laura Balia Fabrizio Ivo Camesasca Carlo Castellani Marco Criscito (°) Chiara Cuccaro Alessandra Di Maria Claudia Fabiani Marco Gramigna Emanuela Legrottaglie Raffaele Piscopo Giulia Raimondi Alessandro Randazzo Mary Romano Pietro Rosetta Riccardo Scotti (°) Adriana Sergio Maria Ingrid Torres Munoz Rosario Urso Jose Luis Vallejo Garcia Pietro Paolo Vico

OTORHINOLARYNGOLOGY Giovanni Colombo Giovanni Cugini Susanna Di Pietro Luca Malvezzi Stefano Miceli Vanessa Rossi

PLASTIC SURGERY Division director: Marco Klinger Valeria Bandi Barbara Banzatti Barbara Catania Claudio Cordani Silvia Giannasi Francesco Klinger (°) Luca Maione Alessandra Veronesi

Marco Aldo Babbini Benedetta Basta Francesco Carrera Barbara Crescimbini Laura Crozzoli Chiara Ferrari Tiziana Fusco Stefania Gherardi Fabio Intelligente Annarita Larocca Marco Maiola Oreste Davide Montino Ilaria Pisano Maria Del Carmen Rodriguez Beatrice Rossi Claudio Sacchi Alessandro Scafella

UROLOGY Division director: Giorgio Ferruccio Guazzoni professor at Humanitas University Alessio Benetti Nicolò Maria Buffi Paolo Casale Rodolfo Hurle Massimo Lazzeri (°) Giovanni Lughezzani Luisa Pasini Roberta Peschechera Alberto Saita Silvia Zandegiacomo De Zorzi

(*) Phisycian dealing with activity in the Research laboratories too (**) Research Staff (***) Research Nurse (•) Head of unit (°) Consultant (§) Vicarious ■ Divisions that join in the Humanitas Cancer Center

51

Scientific Research and Laboratories

ADAPTIVE IMMUNITY Scientific Superintendence Director: Nicola Dioguardi

Junior principal investigator: Marinos Kallikourdis researcher at Humanitas University

Director: Alberto Mantovani

Elisa Martini Giuliana Roselli Claudia Sardi Debora Vignali

Clinical trials office

CELL SIGNALLING INNATE IMMUNITY

Scientific Direction and Research Laboratories

Director: Michele Tedeschi Alessandra Giampa Francesco Minuti Emanuela Morenghi (biostatistician) Silvia Spagnoli

Innovation Office Alessandra Orlandi

Grant office

Principal investigator: Francesca Granucci Ilena Boemi Valeria Corlianò Laura Gornati Matias Soncini

CELLULAR AND MOLECULAR ENDOCRINOLOGY Principal investigator: Andrea Lania professor at Humanitas University (1)

Head officer: Danilo Petroni

Eleonora Vitali

Simona Pipolo

CELLULAR IMMUNOLOGY Principal investigator: Paola Allavena

(•) Group leader (1) MD-PhD. In addition to research s/he works as a clinician in Endocrinology (2) MD-PhD. In addition to research s/he works as a clinician in Reumathology (3) MD-PhD. In addition to research s/he works as a clinician in Inflammatory Bowel Disease (4) MD-PhD. In addition to research s/he works as a clinician in Epathology

52

(5) MD-PhD. In addition to research s/he works as a clinician in Medical Oncology and Haematology

Cristina Belgiovine Giovanni Castino Nina Cortese Marco Erreni Mohammad Azhar Kamal Manuela Liguori Akhiro Maeda Federica Marchesi Giulia Marelli Imran Siddiqui Fernando Torres Andon

CLINICAL AND EXPERIMENTAL IMMUNOLOGY Principal investigator: Domenico Mavilio Francesca Calcaterra Silvia Della Bella (•) Joanna Mikulak Ferdinando Oriolo Elena Pontarini Paolo Francesco Tentorio Elisa Zaghi

CLINICAL IMMUNOLOGY AND AUTOIMMUNITY AND METABOLISM Principal investigator: Carlo Francesco Selmi (2) Marta Caprioli Angela Ceribelli (2) Maria De Santis (2) Elena Generali Natasa Isailov

EXPERIMENTAL IMMUNOPATHOLOGY Principal investigator: Cecilia Garlanda Marialuisa Barbagallo Kevin Berthenet Sabrina Di Marco Francesca Gianni Sebastien Jaillon Elena Magrini Martina Molgora Fabio Pasqualini Nadia Polentarutti Andrea Ponzetta Federica Riva Domenico Supino

GASTROINTESTINAL IMMUNOPATHOLOGY Principal investigator: Silvio Danese (3) professor at Humanitas University Stefanos Bonovas Carmen Correale Silvia D’Alessio Philippe Fonteyne Molina Cristina Mascaraque Luciana Petti Andrea Piontini Barbara Romano Carlotta Tacconi Federica Ungaro Stefania Vetrano researcher at Humanitas University

HEPATOBILIARY IMMUNOPATHOLOGY

Elisa Forti Simona Marzorati Benedetta Piombanti Chiara Raggi

IMMUNOPHARMACOLOGY Principal investigator: Barbara Bottazzi Kenji Daigo Tamara Gulic Antonio Inforzato Roberto Leone Raffaella Parente Francesca Petroni Marina Sironi Sonia Valentino

LEUKOCYTE BIOLOGY Principal investigator: Massimo Locati Ornella Bonavita Raffaella Bonecchi professor at Humanitas University (•) Elena Borroni Paolo Buratti Lorenzo Drufuca Floriana Farina Matteo Massara Stefano Marzo Valeria Mollica Poeta Manuela Quintavalle Stefania Recalcati Benedetta Savino Elisa Setten Naths Grazia Sukubo Alessandro Vacchini

LEUKOCYTE MIGRATION Principal investigator: Silvano Sozzani Annalisa Del Prete Tiziana Schioppa Francesca Sozio

MEDICAL GENETICS AND RNA BIOLOGY

Principal investigator: Pietro Invernizzi

Principal investigator: Stefano Duga professor at Humanitas University

Francesca Bernuzzi Margherita Correnti Ana Lleo De Nalda (4)

Rosanna Asselta professor at Humanitas University

MOLECULAR IMMUNOLOGY

Marta Lombardi Marialuisa Malosio Cristina Mantovani Elisabetta Menna Filippo Mirabella Raffaella Morini Marco Pizzocri Davide Pozzi Marco Rasile Chiara Starvaggi Cucuzza Matteo Tamborini Romana Tomasoni Claudia Verderio

Principal investigator: Antonio Sica

PHYSIOLOGY

Giulia Cardamone Chiara Chiereghin Davide De Bortoli Laura Gigante Elvezia Paraboschi Valeria Rimoldi Giulia Rovaris Michela Robusto Giulia Soldà (researcher at Humanitas University) Letizia Straniero

Augusto Bleve Francesca Maria Consonni Chiara Porta Elena Riboldi Mariangela Storto

ONCOLOGY EXPERIMENTAL THERAPEUTICS Principal investigator: Carmelo Carlo-Stella (5) Giuseppa Careddu Armando Chierchia Martina Di Trani Alessandra Inguscio Silvia Laura Locatelli Luca Rubino Alessandra Solferino Junior principal investigator: Libero Santarpia Giulia Bottai Laura Paladini Carlotta Raschioni

PHARMACOLOGY AND BRAIN PATHOLOGY Principal investigator: Michela Matteoli professor at Humanitas University Flavia Antonucci Alice Canzi Irene Corradini Chiara Adriana Elia Genni Desiato Fabia Filipello Elisa Focchi Giuliana Fossati Elsa Ghirardini Pooja Joshi Eliana Lauranzano

Principal investigator: Gabriella Cerri Valentina Ferpozzi Luca Fornia

TRANSLATIONAL IMMUNOLOGY Principal investigator: Enrico Lugli Federica De Paoli Gabriele De Simone Karolina Pilipow Alessandra Roberto Eloise Scamardella Veronica Zanon

BIOBANK Daniela Pistillo Giorgia Ceva Grimaldi Valentina Paleari Andrea Uggetti

COMMON RESEARCH SERVICES Lab Manager: Monica Rimoldi Achille Anselmo Javier Cibella Federico Colombo Andrea Doni Fabio Grizzi Carolina Lage Crespo Gianpaolo Milite Diego Morone

NATIONAL RESEARCH COUNCIL (CNR) HUMAN GENOME AND MEDICAL BIOTECHNOLOGIES HUMAN GENOME Principal investigator: Anna Villa Barbara Cassani Francesca Ficara Stefano Mantero Veronica Marrella Martina Pellicciotta Federica Rapposelli Cristina Sobacchi Dario Strina Valentina Taverniti

INFLAMMATION AND IMMUNOLOGY IN CARDIOVASCULAR PATHOLOGIES Principal investigator: Gianluigi Condorelli professor at Humanitas University Claudia Bearzi Pierluigi Carullo Laura Catarozzo Nadia Corrado Silvia Crasto Elisa Di Pasquale Leonardo Elia Barbara Gargano Carolina Magdalen Greco Ignacio Fernando Hall Balcazar Paolo Kunderfranco Michele Latronico Michele Miragoli Christina Pagiatakis Laura Papa Roberto Papait (•) Roberta Roncarati Pierluigi Rossi

Marcello Rubino Marta Russo Lucia Rutigliano Irene Salamon Nicolo Salvarani Chiara Viviani Anselmi Marco Vacchiano

bioMEDICAL TECHNOLOGIES Principal investigator: Paolo Vezzoni Maria Elena Caldana Alessandra Castelli Isabel Chapa Laura Crisafulli Francesca Faggioli Michela Lizier Ciro Menale Sharon Muggeo Eleonora Palagano Marianna Paulis Rosita Rigoni Lucia Susani

SARCOMERS IN CARDIAC PATHOLOGies Principal investigator: Marie Louise Bang Maria Carmela Filomeno Veronica Larcher

SIGNAL TRANSDUCTION IN CARDIAC PATHOLOGies Principal investigator: Daniele Catalucci Paola Ceriotti Vittoria Di Mauro 53

Papers published 2015 Papers published 2015

As of 31 January 2016

Preclinical Research

Adaptive Immunity Benedusi V, Martini E, Kallikourdis M, Villa A, Meda C, Maggi A.

Ovariectomy shortens the life span of female mice.

Oncotarget 2015;6(13):10801-11.

Raw IF: 6.359 Normalized IF: 6 Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, Norata GD, Invernizzi P, Kallikourdis M°.

Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.

Immunobiology 2015;220(8):1025-29.

Raw IF: 3.044 Normalized IF: 4 Kallikourdis M, Viola A, Benvenuti F.

Human immunodeficiencies related to defective APC/T cell interaction.

Chatterjee S, Clark CE, Lugli E, Roederer M, Nutman TB.

Cell Signalling Innate Immunity

Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells.

Santini B, Zanoni I, Marzi R, Cigni C, Bedoni M, Gramatica F, Palugan L, Corsi F, Granucci F, Colombo M.

Cream formulation impact on topical administration of engineered colloidal nanoparticles.

Journal of Immunology 2015;194(6):2706-14.

Raw IF: 4.922 Normalized IF: 3

PLoS One 2015;10(5):e0126366.

Raw IF: 3.234 Normalized IF: 3

Clinical and Experimental Immunology Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D’Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D°, Mikulak J°.

Frontiers in Immunology 2015;6:433.

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Raw IF: 0 Normalized IF: 0

Scientific Reports 2015;5:13647.

Raw IF: 5.578 Normalized IF: 6 Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, Zanotti L, D’Alessio S, Scaldaferri F, Luca G, Arato I, Calafiore R, Sgambato A, Rutella S, Locati M, Danese S, Vetrano S°.

Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine.

Gastroenterology 2015;149(1):163-176.e20.

Raw IF: 16.716 Normalized IF: 15 Tortarolo M, Vallarola A, Lidonnici D, Battaglia E, Gensano F, Spaltro G, Fiordaliso F, Corbelli A, Garetto S, Martini E, Pasetto L, Kallikourdis M, Bonetto V, Bendotti C.

Lack of TNF-alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression.

Journal of Neurochemistry 2015;135(1):109-24.

Raw IF: 4.281 Normalized IF: 6

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

OncoImmunology 2015;4(4):e998538

Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Transplant Infectious Disease 2015;17(2):242-9.

Raw IF: 2.064 Normalized IF: 4 Haque S, Lan X, Wen H, Lederman R, Chawla A, Attia M, Bongu RP, Husain M, Mikulak J, Saleem MA, Popik W, Malhotra A, Chander PN, Singhal PC.

HIV promotes NLRP3 inflammasome complex activation in murine HIVassociated nephropathy.

American Journal of Pathology 2016;186(2):347-58.

Raw IF: 4.591 Normalized IF: 3 Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin M E, Mavilio D°.

Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.

Journal of Autoimmunity 2016;66:40-50.

Raw IF: 8.41 Normalized IF: 8 .

Raw IF: 6.266 Normalized IF: 3

Lan X, Wen H, Saleem MA, Mikulak J, Malhotra A, Skorecki K, Singhal PC.

Cappelletti M, Della Bella S, Ferrazzi E, Mavilio D, Divanovic S.

Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.

Inflammation and preterm birth.

54

Crocchiolo R°, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L.

Journal of Leukocyte Biology 2016;99(1):67-78.

Experimental and Molecular Pathology 2015;98(3):491-501.

Raw IF: 4.289 Normalized IF: 6

Raw IF: 2.706 Normalized IF: 3

° = Corresponding author * = Authors equally contributing to the study # = Last authors equally contributing to the study

Mattiola I, Pesant M, Tentorio PF, Molgora M, Marcenaro E, Lugli E, Locati M°, Mavilio D°.

Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1β, IFN-β, and IL-15 pathways.

Human Genome; Biomedical Technologies

Raw IF: 4.922 Normalized IF: 6

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C°, Mantovani A°.

Pilipow K, Roberto A, Roederer M, Waldmann TA, Mavilio D, Lugli E°.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Journal of Immunology 2015;195(6):2818-28.

IL15 and T-cell stemness in T-cell-based cancer immunotherapy.

Cell 2015;160(4):700-14.

Raw IF: 32.242 Normalized IF: 15

Cancer Research 2015;75(24):5187-93.

Raw IF: 9.329 Normalized IF: 8 Pontarini E*, Fabris M*, Quartuccio L, Cappelletti M, Calcaterra F, Roberto A, Curcio F, Mavilio D#°, Della Bella S#, De Vita S#.

Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren’s syndrome.

Rheumatology 2015;54(8):1429-34.

Raw IF: 4.475 Normalized IF: 6 Roberto A, Castagna L*, Zanon V*, Bramanti S, Crocchiolo R, McLaren JE, Gandolfi S, Tentorio P, Sarina B, Timofeeva I, Santoro A, Carlo-Stella C, Bruno B, Carniti C, Corradini P, Gostick E, Ladell K, Price DA, Roederer M, Mavilio D#°, Lugli E#°.

Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri SS, Tremoli E, Catapano AL, Norata GD, Bottazzi B, Garlanda C, Mantovani A°.

An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.

Journal of Experimental Medicine 2015;212(6):905-25.

Raw IF: 12.515 Normalized IF: 10 Grosjean F, Nasi S, Schneider P, Chobaz V, Liu A, Mordasini V, Moullec K, Vezzoni P, Lavanchy C, Busso N, Acha-Orbea H, Ehirchiou D.

Dendritic cells cause bone lesions in a new mouse model of histiocytosis.

Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation.

PLoS One 2015;10(8):e0133917.

Blood 2015;125(18):2855-64.

Raw IF: 10.452 Normalized IF: 8

Marrella V, Lo Iacono N, Fontana E, Sobacchi C, Sic H, Schena F, Sereni L, Castiello MC, Poliani PL, Vezzoni P, Cassani B, Traggiai E, Villa A°.

Tomescu C, Mavilio D, Montaner LJ.

IL-10 critically modulates B cell responsiveness in Rankl-/- mice.

Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alphaactivated NK cells requires NKp46 and NKG2D. AIDS 2015;29(14):1767-73.

Raw IF: 5.554 Normalized IF: 6

Raw IF: 3.234 Normalized IF: 3

Journal of Immunology 2015;194(9):4144-53.

Pala F, Morbach H, Castiello MC, Schickel JN, Scaramuzza S, Chamberlain N, Cassani B, Glauzy S, Romberg N, Candotti F, Aiuti A, Bosticardo M, Villa A, Meffre E.

Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients.

Journal of Clinical Investigation 2015;125(10):3941-51.

Raw IF: 13.262 Normalized IF: 5 Palagano E, Blair HC, Pangrazio A, Tourkova I, Strina D, Angius A, Cuccuru G, Oppo M, Uva P, Van Hul W, Boudin E, Superti-Furga A, Faletra F, Nocerino A, Ferrari MC, Grappiolo G, Monari M, Montanelli A, Vezzoni P, Villa A, Sobacchi C°.

Buried in the middle, but guilty: intronic mutations in the TCIRG1 gene cause human autosomal recessive osteopetrosis.

Journal of Bone and Mineral Research 2015;30(10):1814-21.

Raw IF: 6.832 Normalized IF: 6 Paulis M°, Castelli A, Lizier M, Susani L, Lucchini F, Villa A, Vezzoni P.

A pre-screening FISH-based method to detect CRISPR/Cas9 off-targets in mouse embryonic stem cells.

Scientific Reports 2015;5:2327.

Raw IF: 5.578 Normalized IF: 6 Paulis M°, Castelli A, Susani L, Lizier M, Lagutina I, Focarelli ML, Recordati C, Uva P, Faggioli F, Neri T, Scanziani E, Galli C, Lucchini F, Villa A*, Vezzoni P*°.

Chromosome transplantation as a novel approach for correcting complex genomic disorders.

Oncotarget 2015;6(34):35218-30.

Raw IF: 6.359 Normalized IF: 6

Raw IF: 4.922 Normalized IF: 6 Rauner M, Coudert A, Sobacchi C, Del Fattore A. Neri T, Muggeo S, Paulis M, Caldana ME, Crisafulli L, Strina D, Focarelli ML, Faggioli F, Recordati C, Scaramuzza S, Scanziani E, Mantero S, Buracchi C, Sobacchi C, Lombardo A, Naldini L, Vezzoni P, Villa A°, Ficara F.

The endocrine role of the skeleton.

International Journal of Endocrinology 2015 ;2015:265151.

Raw IF: 1.948 Normalized IF: 1

Targeted gene correction in osteopetroticinduced pluripotent stem cells for the generation of functional osteoclasts.

Stem Cell Reports 2015;5(4):558-68.

Raw IF: 5.365 Normalized IF: 6

55

Papers published 2015

Immunology in Cardiovascular Pathologies Baheiraei N, Gharibi R, Yeganeh H, Miragoli M, Salvarani N, Di Pasquale E, Condorelli G.

Electroactive polyurethane/siloxane derived from castor oil as a versatile cardiac patch, Part I: synthesis, characterization and myoblast proliferation and differentiation.

Journal of Biomedical Materials Research. Part A. Epub 2015 Nov 5.

Raw IF: 3.369 Normalized IF: 6 Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C°, Mantovani A°.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Cell 2015;160(4):700-14.

Raw IF: 32.242 Normalized IF: 15 Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Pozzoli S, Troffa C, Glorioso V, Kontula KK, Hiltunen TP, Donner KM, Turner ST, Boerwinkle E, Chapman AB, Padmanabhan S, Dominiczak AF, Melander O, Johnson JA, Cooper-Dehoff RM, Gong Y, Rivera NV, Condorelli G, Trimarco B, Manunta P, Cusi D, Glorioso N, Barlassina C.

Donahue M, Visconti G, Focaccio A, Selvetella L, Baldassarre M, Viviani Anselmi C, Briguori C.

Acute kidney injury in patients with chronic kidney disease undergoing internal carotid artery stent implantation.

JACC. Cardiovascular Interventions 2015;8(11):1506-14.

Raw IF: 7.245 Normalized IF: 4 Elia L, Condorelli G°.

RNA (Epi)genetics in cardiovascular diseases.

Journal of Molecular and Cellular Cardiology 2015;89(ptA):11-6.

Raw IF: 4.655 Normalized IF: 6 Glukhov AV, Rosenshtraukh LV, Bhargava A, Miragoli M, Boukens BJ.

Atrial fibrillation: biophysics, molecular mechanisms, and novel therapies.

BioMed Research International. Epub 2015 Jul 9.

Raw IF: 1.579 Normalized IF: 1 Greco CM, Condorelli G°.

Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure.

Nature Reviews. Cardiology 2015;12(8):488-97.

Atrial fibrillation and fibrosis: beyond the cardiomyocyte centric view.

BioMed Research International 2015; 2015:798768.

Raw IF: 1.579 Normalized IF: 2 Miragoli M°, Sanchez-Alonso JL, Bhargava A, Wright PT, Sikkel M, Schobesberger S, Diakonov I, Novak P, Castaldi A, Cattaneo P, Lyon AR, Lab MJ, Gorelik J.

Microtubule-dependent mitochondria alignment regulates calcium release in response to nanomechanical stimulus in heart myocytes.

Cell Reports 2016;14(1):140-51.

Raw IF: 8.358 Normalized IF: 8 Papait R°, Corrado N, Rusconi F, Serio S, Latronico M.

It’s time for an epigenomics roadmap of heart failure.

Current Genomics 2015;16(4):237-244.

Raw IF: 2.342 Normalized IF: 4 Quintavalle C, Anselmi CV, De Micco F, Roscigno G, Visconti G, Golia B, Focaccio A, Ricciardelli B, Perna E, Papa L, Donnarumma E, Condorelli G, Briguori C.

Raw IF: 9.183 Normalized IF: 8

Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury.

Latronico MV, Condorelli G°.

Circulation-Cardiovascular interventions 2015;8(9):e002673.

Therapeutic applications of noncoding RNAs.

Raw IF: 6.218 Normalized IF: 6

TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in nevertreated essential hypertensives.

Current Opinion in Cardiology 2015;30(3):213-21.

Raw IF: 2.696 Normalized IF: 4

Sala R, Mena P, Savi M, Brighenti S, Crozier A, Miragoli M, Stilli D, Del Rio D.

Journal of Hypertension 2015;33(6):1301-9.

Maciąag A, Villa F, Ferrario A, Spinelli CC, Carrizzo A, Malovini A, Torella A, Montenero C, Parisi A, Condorelli G, Vecchione C, Nigro V, Montenero AS, Puca AA.

Urolithins at physiological concentrations affect the levels of pro-inflammatory cytokines and growth factor in cultured cardiac cells in hyperglucidic conditions.

Raw IF: 4.72 Normalized IF: 6 Climent-Salarich M, Quintavalle M, Miragoli M, Chen J, Condorelli G°, Elia L°.

TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization.

Circulation Research 2015;116(11):1753-64.

Raw IF: 11.019 Normalized IF: 8 Dai Y, Condorelli G, Mehta JL.

Scavenger receptors and non-coding RNAs: relevance in atherogenesis.

Cardiovascular Research 2016;109(1):24-33.

Raw IF: 5.94 Normalized IF: 6

Exome sequencing of a family with lone, autosomal dominant atrial flutter identifies a rare variation in ABCB4 significantly enriched in cases.

BMC Genetics 2015;16:15.

Raw IF: 2.397 Normalized IF: 1 Meraviglia V, Azzimato V, Colussi C, Florio MC, Binda A, Panariti A, Qanud K, Suffredini S, Gennaccaro L, Miragoli M, Barbuti A, Lampe PD, Gaetano C, Pramstaller PP, Capogrossi MC, Recchia FA, Pompilio G, Rivolta I, Rossini A.

Acetylation mediates Cx43 reduction caused by electrical stimulation.

Journal of Molecular and Cellular Cardiology 2015;87:54-64.

56

Miragoli M°, Glukhov A.

Raw IF: 4.655 Normalized IF: 3

Journal of Functional Foods 2015;15:97-105.

Raw IF: 3.574 Normalized IF: 3 Thum, T, Condorelli G°.

Long noncoding RNAs and microRNAs in cardiovascular pathophysiology.

Circulation Research 2015;116(4):751-62.

Raw IF: 11.019 Normalized IF: 8

Preclinical Research

Leukocyte Biology Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, Rot A, Sozzani S, Thelen M.

An atypical addition to the chemokine receptor nomenclature: IUPHAR Review “15”.

British Journal of Pharmacology 2015;172(16):3945-9.

Raw IF: 4.842 Normalized IF: 6

Del Prete A*, Luganini A*, Scutera S, Rossi S, Anselmo A, Greco D, Landolfo S, Badolato R, Gribaudo G, Sozzani S, Musso T.

Interferon-α production by plasmacytoid dendritic cells is dispensable for an effective anti-cytomegalovirus response in adaptor protein-3-deficient mice.

Journal of Interferon & Cytokine Research 2015;35(3):232-8.

Raw IF: 2 Normalized IF: 2

Mattiola I, Pesant M, Tentorio PF, Molgora M, Marcenaro E, Lugli E, Locati M°, Mavilio D°.

Seeger P, Musso T, Sozzani S°.

Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1β, IFN-β, and IL-15 pathways.

The TGF-β superfamily in dendritic cell biology.

Cytokine and Growth Factor Reviews 2015;26(6):647-57.

Journal of Immunology 2015;195(6):2818-28.

Raw IF: 5.357 Normalized IF: 6

Raw IF: 4.922 Normalized IF: 6 Sozzani S°, Del Prete A, Bonecchi R, Locati M. Renzi TA, Rubino M, Gornati L, Garlanda C, Locati M, Curtale G°.

MiR-146b mediates endotoxin tolerance in human phagocytes Mediators of Inflammation 2015;2015:145305.

Chemokines as effector and target molecules in vascular biology.

Cardiovascular Research 2015;107(3):364-72.

Raw IF: 5.94 Normalized IF: 6

Raw IF: 3.236 Normalized IF: 4 Sozzani S°, Del Prete A, Bonecchi R, Locati M.

Chemokines as effector and target molecules in vascular biology.

Cardiovascular Research 2015;107(3):364-72.

Raw IF: 5.94 Normalized IF: 6 Sukubo NG, Tibalt E, Respizzi S, Locati M, d’Agostino MC°.

Effect of shock waves on macrophages: a possible role in tissue regeneration and remodeling.

International Journal of Surgery 2015;24(pt B):124-30.

Raw IF: 1.531 Normalized IF: 4

Leukocyte migration Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, Rot A, Sozzani S, Thelen M.

An atypical addition to the chemokine receptor nomenclature: IUPHAR Review “15”.

British Journal of Pharmacology 2015;172(16):3945-9.

Raw IF: 4.842 Normalized IF: 6

Medical Genetics and RNA Biology Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D’Antiga L, Perisic VN, Maggiore G, Caccia S, Duga S°.

Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on fibrinogen γ-module.

Journal of Thrombosis and Haemostasis 2015;13(8):1459-67.

Raw IF: 5.72 Normalized IF: 6 Asselta R°, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S.

Molecular characterization of 7 patients affected by dys- or hypodysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation.

Thrombosis Research 2015;136(1):168-74.

Raw IF: 2.447 Normalized IF: 2 Callari M, Guffanti A, Soldà G, Merlino G, Fina E, Brini E, Moles A, Cappelletti V, Daidone MG.

Castaman G, Rimoldi V, Giacomelli SH, Duga S.

Congenital hypofibrinogenemia associated with novel homozygous fibrinogen Aα and heterozygous Bβ chain mutations.

Thrombosis Research 2015;136(1):144-7.

Raw IF: 2.447 Normalized IF: 2 Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF, Wang Q, Krueger BJ, Ren Z, Keebler J, Han Y, Levy SE, Boone BE, Wimbish JR, Waite LL, Jones AL, Carulli JP, Day-Williams AG, Staropoli JF, Xin WW, Chesi A, Raphael AR, McKenna-Yasek D, Cady J, Vianney de Jong JM, Kenna KP, Smith BN, Topp S, Miller J, Gkazi A; FALS Sequencing Consortium, Al-Chalabi A, van den Berg LH, Veldink J, Silani V, Ticozzi N, Shaw CE, Baloh RH, Appel S, Simpson E, Lagier-Tourenne C, Pulst SM, Gibson S, Trojanowski JQ, Elman L, McCluskey L, Grossman M, Shneider NA, Chung WK, Ravits JM, Glass JD, Sims KB, Van Deerlin VM, Maniatis T, Hayes SD, Ordureau A, Swarup S, Landers J, Baas F, Allen AS, Bedlack RS, Harper JW, Gitler AD, Rouleau GA, Brown R, Harms MB, Cooper GM, Harris T, Myers RM, Goldstein DB. (Collaborator: Duga S).

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.

Science 2015;347(6229):1436-41.

Raw IF: 33.611 Normalized IF: 3 Paraboschi EM, Cardamone G, Rimoldi V, Gemmati D, Spreafico M, Duga S, Soldà G, Asselta R.

Meta-analysis of multiple sclerosis microarray data reveals dysregulation in RNA splicing regulatory genes.

International Journal of Molecular Sciences 2015;16(10):23463-81.

Raw IF: 2.862 Normalized IF: 6 Pensato V, Tiloca C, Corrado L, Bertolin C, Sardone V, Del Bo R, Calini D, Mandrioli J, Lauria G, Mazzini L, Querin G, Ceroni M, Cantello R, Corti S, Castellotti B, Soldà G, Duga S, Comi GP, Cereda C, Sorarù G, D’Alfonso S, Taroni F, Shaw CE, Landers JE, Ticozzi N, Ratti A, Gellera C, Silani V; SLAGEN Consortium.

TUBA4A gene analysis in sporadic amyotrophic lateral sclerosis: identification of novel mutations.

Journal of Neurology 2015;262(5):1376-8.

Raw IF: 3.377 Normalized IF: 3

In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays.

Oncotarget 2016;7(1):976-94.

Raw IF: 6.359 Normalized IF: 3

57

Papers published 2015

Soldà G°, Caccia S, Robusto M, Chiereghin C, Castorina P, Ambrosetti U, Duga S, Asselta R.

First independent replication of the involvement of LARS2 in Perrault syndrome by whole-exome sequencing of an Italian family.

Journal of Human Genetics. Epub 2015 Dec 10.

Raw IF: 2.462 Normalized IF: 4

Pharmacology and Brain Pathology Bedogni F, Cobolli Gigli C*, Pozzi D*, Rossi RL*, Scaramuzza L, Rossetti G, Pagani M, KilstrupNielsen C, Matteoli M, Landsberger N.

Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms.

Two novel splicing mutations in the SLC45A2 gene cause Oculocutaneous Albinism Type IV by unmasking cryptic splice sites.

Journal of Human Genetics 2015;60(9):467-71.

Raw IF: 2.462 Normalized IF: 2

REST-governed gene expression profiling in a neuronal cell model reveals novel direct and indirect processes of repression and up-regulation.

Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies.

Braida D, Ponzoni L, Matteoli M, Sala MM.

Seminars in Immunology 2015;27(4):237-48.

Different attentional abilities among inbred mice strains using virtual object recognition task (VORT): SNAP25+/- mice as a model of attentional deficit.

Raw IF: 5.17 Normalized IF: 6

Behavioural Brain Research 2016;296:393-400.

Molecular and epigenetic basis of macrophage polarized activation.

Raggi C*°, Mousa HS*, Correnti M, Sica A, Invernizzi P*.

Cancer stem cells and TumorAssociated Macrophages: a roadmap for multitargeting strategies.

Oncogene 2016;35(6):671-82.

Raw IF: 8.459 Normalized IF: 8 Sica A°, Erreni M, Allavena P, Porta C. Cellular and Molecular Life Sciences 2015;72(21):4111-26.

Raw IF: 5.808 Normalized IF: 6 Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, Porta C, Anselmo A, Tartari S, Doni A, Zitelli F, Tripodo C, Colombo MP, Sica A°.

RORC1 regulates tumor-promoting ‶emergency″ granulo-monocytopoiesis.

Cancer Cell 2015;28(2):253-269

.

Raw IF: 23.523 Normalized IF: 15

Raw IF: 4.289 Normalized IF: 3 Garcia-Manteiga JM, Bonfiglio S, Malosio ML, Lazarevic D, Stupka E, Cittaro D, Meldolesi J.

Epigenomics of neural cells: RESTinduced down- and upregulation of gene expression in a two-clone PC12 cell model.

BioMed Research International. Epub 2015 Aug 27.

Raw IF: 1.579 Normalized IF: 1 Joshi P, Benussi L, Furlan R, Ghidoni R, Verderio C°.

Carandini T, Colombo F, Finardi A, Casella G, Garzetti L, Verderio C, Furlan R.

Extracellular vesicles in Alzheimer’s disease: friends or foes? Focus on a β-vesicle interaction.

Microvesicles: what is the role in multiple sclerosis?

International Journal of Molecular Sciences 2015;16(3):4800-13.

Frontiers in Neurology 2015;6:111.

Raw IF: 0 Normalized IF: 0

Co-expression of VGLUT1 and VGAT sustains glutamate and GABA co-release and is regulated by activity in cortical neurons.

Journal of Cell Science 2015;128(9):1669-73 .

Raw IF: 5.432 Normalized IF: 3 Fossati G, Morini R, Corradini I, Antonucci F, Trepte P, Edry E, Sherma V, Papale A, Pozzi D, Defilippi P, Meier JC, Brambilla R, Turco E, Rosenblum K, Wanker EE, Ziv NE, Menna E°, Matteoli M°.

Reduced SNAP-25 increases PSD95 mobility and impairs spine morphogenesis.

Cell Death and Differentiation 2015;22(9):1425-36.

Raw IF: 8.184 Normalized IF: 8

58

Frontiers in Cellular Neuroscience 2015;9:438.

Raw IF: 3.028 Normalized IF: 2

Fattorini G, Antonucci F, Menna E, Matteoli M, Conti F.

Macrophage polarization in pathology.

Raw IF: 9.055 Normalized IF: 8

Braida D, Guerini FR, Ponzoni L, Corradini I, De Astis S, Pattini L, Bolognesi E, Benfante R, Fornasari D, Clerici M, Matteoli M, Sala M.

Raw IF: 5.62 Normalized IF: 3

Porta C, Riboldi E, Ippolito A, Sica A°.

Embo Reports 2015;16(2):213-20.

Raw IF: 8.665 Normalized IF: 8

Translational Psychiatry 2015;5:e500.

Molecular Immunology

Active endocannabinoids are secreted on extracellular membrane vesicles.

Garcia-Manteiga JM, Bonfiglio S, Folladori L, Malosio ML, Lazarevic D, Stupka E, Cittaro D, Meldolesi J.

Cerebral Cortex. Epub 2015 May 15.

Straniero L, Rimoldi V, Soldà G, Mauri L, Manfredini E, Andreucci E, Bargiacchi S, Penco S, Gesu GP, Del Longo A, Piozzi E, Asselta R, Primignani P.

Gabrielli M, Battista N, Riganti L, Prada I, Antonucci F, Cantone L, Matteoli M, Maccarrone M, Verderio C°.

Raw IF: 2.862 Normalized IF: 6 Magni G, Merli D, Verderio C, Abbracchio MP, Ceruti S.

P2Y2 receptor antagonists as antiallodynic agents in acute and sub-chronic trigeminal sensitization: role of satellite glial cells.

Glia 2015;63(7):1256-69.

Raw IF: 6.031 Normalized IF: 3 Morini R, Ghirardini E, Butti E, Verderio C, Martino G, Matteoli M°.

Subventricular zone neural progenitors reverse TNF-alpha effects in cortical neurons.

Stem Cell Research and Therapy 2015;6(1):166.

Raw IF: 3.368 Normalized IF: 6

Preclinical Research

Sarcomeres in Cardiac Pathology Bang ML°, Chen J.

Borghi M, De Luca A, Puccetti M, Jaeger M, Mencacci A, Oikonomou V, Pariano M, Garlanda C, Moretti S, Bartoli A, Sobel J, van de Veerdonk FL, Dinarello CA, Netea MG, Romani L.

Circulation Journal 2015;79(10) :2081-7.

Pathogenic NLRP3 inflammasome activity during Candida infection is negatively regulated by IL-22 via activation of NLRC4 and IL-1Ra.

Raw IF: 3.94 Normalized IF: 6

Cell Host and Microbe 2015;18(2):198-209.

Roles of nebulin family members in the heart.

Raw IF: 12.328 Normalized IF: 5 Mastrototaro G*, Liang X*, Li X, Carullo P, Piroddi N, Tesi C, Gu Y, Dalton ND, Peterson KL, Poggesi C, Sheikh F, Chen J, Bang ML°.

Nebulette knockout mice have normal cardiac function but show Z-line widening and upregulation of cardiac stress markers.

Cardiovascular Research 2015;107(2):216-25.

Raw IF: 5.94 Normalized IF: 6

Scientific Research Laboratories Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, Rot A, Sozzani S, Thelen M.

An atypical addition to the chemokine receptor nomenclature: IUPHAR Review “15”.

British Journal of Pharmacology 2015;172(16):3945-9.

Raw IF: 4.842 Normalized IF: 6 Bonavita E, Galdiero MR, Jaillon S, Mantovani A°.

Bottazzi B°, Santini L, Savino S, Giuliani MM, Dueñas Díez AI, Mancuso G, Beninati C, Sironi M, Valentino S, Deban L, Garlanda C, Teti G, Pizza M, Rappuoli R, Mantovani A.

Recognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant.

PLoS One 2015;10(3):e0120807.

Raw IF: 3.234 Normalized IF: 6 Cappuzzello C, Doni A, Dander E, Pasqualini F, Nebuloni M, Bottazzi B, Mantovani A, Biondi A, Garlanda C, D’Amico G.

Mesenchymal stromal cell-derived PTX3 promotes wound healing via fibrin remodeling.

The Journal of Investigative Dermatology 2016;136(1):293-300.

Raw IF: 7.216 Normalized IF: 8 Cardoso AP, Pinto ML, Pinto AT, Pinto MT, Monteiro C, Oliveira MI, Santos SG, Relvas JB, Seruca R, Mantovani A, Mareel M, Barbosa MA, Oliveira MJ.

Phagocytes as corrupted policemen in cancer-related inflammation.

Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour.

Advances in Cancer Research 2015;128:141-71.

BMC Cancer 2015;15:456.

Raw IF: 5.321 Normalized IF: 6 Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C°, Mantovani A°.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Raw IF: 3.362 Normalized IF: 2 Casimirri E, Stendardo M, Bonci M, Andreoli R, Bottazzi B, Leone R, Schito M, Vaccari A, Papi A, Contoli M, Corradi M, Boschetto P.

Biomarkers of oxidative-stress and inflammation in exhaled breath condensate from hospital cleaners.

Biomarkers. Epub 2015 Dec 9.

Raw IF: 2.26 Normalized IF: 2

Cell 2015;160(4):700-14.

Raw IF: 32.242 Normalized IF: 15 Bonavita E, Mantovani A, Garlanda C°.

Cunha C, Monteiro AA, Oliveira-Coelho A, Kühne J, Rodrigues F, Sasaki SD, Schio SM, Camargo JJ, Mantovani A, Carvalho A, Pasqualotto AC.

De Paoli P, Ciliberto G, Ferrarini M, Pelicci P, Dellabona P, De Lorenzo F, Mantovani A, Musto P, Opocher G, Picci P, Ricciardi W, De Maria R.

Alliance Against Cancer, the network of Italian cancer centers bridging research and care.

Journal of Translational Medicine 2015;13(1):360.

Raw IF: 3.93 Normalized IF: 3 Del Prete A*, Luganini A*, Scutera S, Rossi S, Anselmo A, Greco D, Landolfo S, Badolato R, Gribaudo G, Sozzani S, Musso T.

Interferon-α production by plasmacytoid dendritic cells is dispensable for an effective anti-cytomegalovirus response in adaptor protein-3-deficient mice.

Journal of Interferon & Cytokine Research 2015;35(3):232-8.

Raw IF: 2 Normalized IF: 2 Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Mantovani A, Marchesi F°.

Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.

International Reviews of Immunology 2015;34(2):12333.

Raw IF: 4.103 Normalized IF: 6 Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F°.

Dual prognostic significance of tumourassociated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Gut. Epub 2015 Jul 8.

Raw IF: 14.66 Normalized IF: 10 Doni A, Garlanda C°, Mantovani A.

PTX3 orchestrates tissue repair.

Oncotarget 2015;6(31):30435-6.

Raw IF: 6.359 Normalized IF: 6 Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri SS, Tremoli E, Catapano AL, Norata GD, Bottazzi B, Garlanda C, Mantovani A°.

An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode.

PTX3 acts as an extrinsic oncosuppressor.

PTX3-based genetic testing for risk of aspergillosis after lung transplant.

Oncotarget 2015;6(32):32309-10.

Clinical Infectious Diseases 2015; 61(12):1893-4.

Journal of Experimental Medicine 2015;212(6):90525.

Raw IF: 6.359 Normalized IF: 6

Raw IF: 8.886 Normalized IF: 4

Raw IF: 12.515 Normalized IF: 10

59

Papers published 2015

Foo SS, Chen W, Taylor A, Sheng KC, Yu X, Teng TS, Reading PC, Blanchard H, Garlanda C, Mantovani A, Ng LF, Herrero LJ, Mahalingam S.

Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, Palmer BE, Fujita M, Garlanda C, Mantovani A, Kim S, Dinarello CA.

Paeschke A, Possehl A, Klingel K, Voss M, Voss K, Kesphol M, Sauter M, Overkleeft HS, Althof N, Garlanda C, Voigt A.

Role of pentraxin 3 in shaping arthritogenic alphaviral disease: from enhanced viral replication to immunomodulation.

Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL1R8.

The immunoproteasome controls the availability of the cardio-protective pattern recognition molecule Pentraxin3.

PLoS Pathogens 2015;11(2):e1004649.

Proceedings of the National Academy of Sciences of the United States of America 2015;112(8):2497-502.

Raw IF: 4.034 Normalized IF: 3

Raw IF: 7.562 Normalized IF: 4 Foo SS, Reading PC, Jaillon S, Mantovani A, Mahalingam S.

Pentraxins and collectins: friend or foe during pathogen invasion?

Trends in Microbiology 2015;23(12):799-811.

Raw IF: 9.186 Normalized IF: 4 Garlanda C, Jaillon S, Doni A, Bottazzi B, Mantovani A°.

PTX3, a humoral pattern recognition molecule at the interface between microbe and matrix recognition.

Current Opinion in Immunology 2015;38:39-44.

Raw IF: 7.478 Normalized IF: 8 Grizzi F°, Borroni EM, Vacchini A, Qehajaj D, Liguori M, Stifter S, Chiriva-Internati M, Di Ieva A.

Pituitary adenoma and the chemokine network: a systemic view.

Frontiers in Endocrinology 2015;6:141.

Raw IF: 0 Normalized IF: 0 Infante M°, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M.

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.

International Journal of Cancer 2016;138(4): 983-91.

Lualdi M, Pedrini E, Petroni F, Näsman J, Lindqvist C, Scaldaferri D, Taramelli R, Inforzato A, Acquati F.

Pentón-Rol G, Lagumersindez-Denis N, Muzio L, Bergami A, Furlan R, Fernández-Massó JR, Nazabal-Galvez M, Llópiz-Arzuaga A, HerreraRolo T, Veliz-Rodriguez T, Polentarutti N, MarínPrida J, Raíces-Cruz I, Valenzuela-Silva C, Teixeira MM, Pentón-Arias E.

New strategies for expression and purification of recombinant human RNASET2 protein in Pichia pastoris.

Comparative neuroregenerative effects of C-phycocyanin and IFN-beta in a model of multiple sclerosis in mice.

Molecular Biotechnology. Epub 2015 Feb 8.

Journal of Neuroimmune Pharmacology 2016;11(1):153-67.

Raw IF: 9.674 Normalized IF: 4

Raw IF: 1.876 Normalized IF: 1 Mantovani A, Allavena P.

The interaction of anticancer therapies with tumor-associated macrophages.

Journal of Experimental Medicine 2015;212(4):435445.

Raw IF: 12.515 Normalized IF: 10 Mullen L, Seavill M, Hammouz R, Bottazzi B, Chan P, Vaudry D, Ghezzi P.

Development of 'Redox Arrays’ for identifying novel glutathionylated proteins in the secretome.

Scientific Reports 2015;5:14630. .

Raw IF: 5.578 Normalized IF: 3 Neri T, Muggeo S, Paulis M, Caldana ME, Crisafulli L, Strina D, Focarelli ML, Faggioli F, Recordati C, Scaramuzza S, Scanziani E, Mantero S, Buracchi C, Sobacchi C, Lombardo A, Naldini L, Vezzoni P, Villa A°, Ficara F.

Raw IF: 5.085 Normalized IF: 6

Targeted gene correction in osteopetroticinduced pluripotent stem cells for the generation of functional osteoclasts.

Isailovic N, Daigo K, Mantovani A*°, Selmi C*°.

Stem Cell Reports 2015;5(4):558-68.

Interleukin-17 and innate immunity in infections and chronic inflammation.

Raw IF: 5.365 Normalized IF: 6

Journal of Medicinal Food 2015;60:1-11.

Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, Ellisdon AM, Rotter B, Azam T, Mangan NE, Rossello FJ, Whisstock JC, Bufler P, Garlanda C, Mantovani A, Dinarello CA, Nold MF.

Raw IF: 1.626 Normalized IF: 4

IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction.

60

European Journal of Immunology. Epub 2015 Nov 18.

Raw IF: 4.11 Normalized IF: 3 Renzi TA, Rubino M, Gornati L, Garlanda C, Locati M, Curtale G°.

MiR-146b mediates endotoxin tolerance in human phagocytes.

Mediators of Inflammation 2015;2015:145305.

Raw IF: 3.236 Normalized IF: 4 Ristagno G, Varpula T, Masson S, Greco M, Bottazzi B, Milani V, Aleksova A, Sinagra G, Assandri R, Tiainen M, Vaahersalo J, Kurola J, Barlera S, Montanelli A, Latini R, Pettilä V, Bendel S, Skrifvars MB; FINNRESUSCI Study Group.

Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death.

Clinical Chemistry and Laboratory Medicine 2015;53(11):1847-57.

Raw IF: 2.707 Normalized IF: 6 Rodriguez-Grande B, Varghese L, MolinaHolgado F, Rajkovic O, Garlanda C, Denes A, Pinteaux E.

Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia.

Journal of Neuroinflammation 2015;12(1):15.

Raw IF: 5.408 Normalized IF: 3 Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, Zanotti L, D’Alessio S, Scaldaferri F, Luca G, Arato I, Calafiore R, Sgambato A, Rutella S, Locati M, Danese S, Vetrano S°.

Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine.

Nature Immunology 2015;16(4):354-65.

Gastroenterology 2015;149(1):163-176.e20.

Raw IF: 20.004 Normalized IF: 7,5

Raw IF: 16.716 Normalized IF: 15

Preclinical Research

Sica A°, Erreni M, Allavena P, Porta C.

Macrophage polarization in pathology.

Cellular and Molecular Life Sciences 2015;72(21):4111-26.

Raw IF: 5.808 Normalized IF: 6 Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, Porta C, Anselmo A, Tartari S, Doni A, Zitelli F, Tripodo C, Colombo MP, Sica A°.

RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis.

Cancer Cell 2015;28(2):253-269.

Raw IF: 23.523 Normalized IF: 15 Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F°.

Inflammation and prostate cancer: friends or foes?

Inflammation Research 2015;64(5):275-86.

Raw IF: 2.347 Normalized IF: 2 Ummenthum K, Peferoen LA, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B, Peferoen-Baert R, van der Valk P, Garlanda C, Kipp M, Furlan R, van Noort JM, Amor S.

Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease.

European Journal of Immunology. Epub 2015 Nov 18.

Raw IF: 4.034 Normalized IF: 6

Signal Transduction in Cardiac Pathologies Mastrototaro G*, Liang X*, Li X, Carullo P, Piroddi N, Tesi C, Gu Y, Dalton ND, Peterson KL, Poggesi C, Sheikh F, Chen J, Bang ML°.

Nebulette knockout mice have normal cardiac function but show Z-line widening and upregulation of cardiac stress markers.

Cardiovascular Research 2015;107(2):216-25.

Raw IF: 5.94 Normalized IF: 6 Zenaro E, Pietronigro E, Bianca VD, Piacentino G, Marongiu L, Budui S, Turano E, Rossi B, Angiari S, Dusi S, Montresor A, Carlucci T, Nanì S, Tosadori G, Calciano L, Catalucci D, Berton G, Bonetti B, Constantin G.

Neutrophils promote Alzheimer’s diseaselike pathology and cognitive decline via LFA-1 integrin.

Nature Medicine 2015;21(8):880-6.

Raw IF: 27.363 Normalized IF: 7.5

61

Papers published 2015

Translational Research

Cellular and Molecular Endocrinology

Clinical Immunology and Autoimmunity and Metabolism

Fisher AD, Castellini G, Casale H, Fanni E, Bandini E, Campone B, Ferruccio N, Maseroli E, Boddi V, Dèttore D, Pizzocaro A, Balercia G, Oppo A, Ricca V, Maggi M.

Bascherini V, Granato C, Lopalco G, Emmi G, Vannozzi L, Bacherini D, Franceschini R, Iannone F, Salerni A, Molinaro F, Messina M, Frediani B, Selmi C, Rigante D, Cantarini L.

Hypersexuality, paraphilic behaviors, and gender dysphoria in individuals with Klinefelter’s syndrome.

The protean ocular involvement in monogenic autoinflammatory diseases: state of the art.

Journal of Sexual Medicine 2015;12(12):2413-24.

Clinical Rheumatology 2015;34(7):1171-80.

Raw IF: 3.151 Normalized IF: 3

Raw IF: 1.696 Normalized IF: 1

Passeri E, Bugiardini E, Sansone VA, Pizzocaro A, Fulceri C, Valaperta R, Borgato S, Costa E, Bandera F, Ambrosi B, Meola G, Persani L, Corbetta S.

Bizjak M, Selmi C, Praprotnik S, Bruck O, Perricone C, Ehrenfeld M, Shoenfeld Y.

Gonadal failure is associated with visceral adiposity in myotonic dystrophies.

European Journal of Clinical Investigation 2015;45(7):702-10.

Raw IF: 2.734 Normalized IF: 3 Peverelli E, Treppiedi D, Giardino E, Vitali E, Lania AG, Mantovani G.

Dopamine and somatostatin analogues resistance of pituitary tumors: focus on cytoskeleton involvement.

Silicone implants and lymphoma: the role of inflammation.

Journal of Autoimmunity 2015;65:64-73.

Raw IF: 8.41 Normalized IF: 4 Boonnate P, Waraasawapati S, Hipkaeo W, Pethlert S, Sharma A, Selmi C, Prasongwattana V, Cha’on U.

Monosodium glutamate dietary consumption decreases pancreatic β-cell mass in adult Wistar rats.

PLoS One 2015;10(6):e0131595.

Raw IF: 3.234 Normalized IF: 3

Frontiers in Endocrinology 2015;6:187.

Raw IF: 0 Normalized IF: 0 Toini A, Dolci A, Ferrante E, Verrua E, Malchiodi E, Sala E, Lania AG, Chiodini I, Beck-Peccoz P, Arosio M, Spada A, Mantovani G.

Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma.

European Journal of Endocrinology 2015;172(4):363-9.

Raw IF: 4.069 Normalized IF: 3 Vitali E, Cambiaghi V, Spada A, Tresoldi A, Zerbi A, Peverelli E, Carnaghi C, Mantovani G, Lania AG°.

62

Cantarini L, Talarico R, Generali E, Emmi G, Lopalco G, Costa L, Silvestri E, Caso F, Franceschini R, Cimaz R, Iannone F, Galeazzi M, Selmi C.

Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study.

International Journal of Rheumatic Diseases. Epub 2015 Aug 18.

Raw IF: 1.469 Normalized IF: 2 Cantarini L*, Vitale A*, Bersani G, Nieves LM, Cattalini M, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Galeazzi M, Ceribelli A, Brunetta E, Selmi C*, Rigante D*.

cAMP effects in neuroendocrine tumors: The role of Epac and PKA in cell proliferation and adhesion.

PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.

Experimental Cell Research 2015;339(2):241-51.

Clinical Rheumatology 2016;35(2):501-5.

Raw IF: 3.246 Normalized IF: 4

Raw IF: 1.696 Normalized IF: 2

Caso F, Costa L, Del Puente A, Donato R, Selmi C, Fabbroni M, Scarpa R, Galeazzi M, Frediani B, Cantarini L.

Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis.

Clinical and Experimental Rheumatology 2015;33(1):411-3.

Raw IF: 2.724 Normalized IF: 2 Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJ, Franceschini F, Neri R, Castañeda S, Giraldo WA, Caporali R, Iannone F, Fusaro E, Paolazzi G, Pellerito R, Schwarting A, Saketkoo LA, OrtegoCenteno N, Quartuccio L, Bartoloni E, Specker C, Murcia TP, La Corte R, Furini F, Foschi V, Corral JB, Airò P, Cavazzana I, Martínez-Barrio J, Hinojosa M, Giannini M, Barsotti S, Menke J, Triantafyllias K, Vitetta R, Russo A, Bajocchi G, Bravi E, Barausse G, Bortolotti R, Selmi C, Parisi S, Montecucco C, González-Gay MA; AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group.

Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study.

Medicine 2015;94(32):e1144.

Raw IF: 5.723 Normalized IF: 6 Cavazzana I, Fredi M, Selmi C, Tincani A, Franceschini F.

The clinical and histological spectrum of idiopathic inflammatory myopathies.

Clinical Reviews in Allergy & Immunology. Epub 2015 Oct 29.

Raw IF: 5.463 Normalized IF: 3 Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators.

(Collaborators: Podda M, Selmi C, Meda F).

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.

European Journal of Internal Medicine 2015;26(4):243-9.

Raw IF: 2.891 Normalized IF: 1.2

Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, Pasina L, Franchi C, Kamal Eldin T, Marengoni A, Salerno F, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators.

(Collaborators: Podda M, Selmi C, Meda F).

Isailovic N, Daigo K, Mantovani A*°, Selmi C*°.

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

Raw IF: 1.626 Normalized IF: 4

European Journal of Internal Medicine 2014;25(7):617-23.

Raw IF: 2.891 Normalized IF: 1.2 De Santis M, Cavaciocchi F, Ceribelli A, Crotti C, Generali E, Fabbriciani G, Selmi C°, Massarotti M.

Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.

Lupus 2015;24(4-5):442-7.

Raw IF: 2.197 Normalized IF: 2 De Santis M, Selmi C°.

The autoinflammatory side of systemic sclerosis.

Israel Medical Association Journal 2015;17(1):47-9.

Raw IF: 1.013 Normalized IF: 2 Generali E, Cantarini L, Selmi C°.

Ocular involvement in systemic autoimmune diseases.

Clinical Reviews in Allergy & Immunology 2015;49(3):263-70.

Raw IF: 5.463 Normalized IF: 6 Generali E, Ceribelli A, Massarotti MS, Cantarini L, Selmi C°.

Seronegative reactive spondyloarthritis and the skin.

Clinics in Dermatology 2015;33(5):531-7.

Raw IF: 2.47 Normalized IF: 6 Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group.

(Collaborator: Invernizzi P).

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study.

Hepatology. Epub 2015 Nov 24.

Raw IF: 11.055 Normalized IF: 1.6

Interleukin-17 and innate immunity in infections and chronic inflammation.

Journal of Medicinal Food 2015;60:1-11.

Islam AD, Selmi C, Datta-Mitra A, Sonu R, Chen M, Gershwin ME, Raychaudhuri SP.

The changing faces of IgG4-related disease: clinical manifestations and pathogenesis.

Autoimmunity Reviews 2015;14(10):914-22.

Raw IF: 7.933 Normalized IF: 8 Liberal R, Selmi C, Gershwin ME.

Diego and Giorgina Vergani: The two hearts of translational autoimmunity.

Journal of Autoimmunity 2016;66:1-6.

Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK.

A comprehensive overview on myositisspecific antibodies: new and old biomarkers in idiopathic inflammatory myopathy.

Clinical Reviews in Allergy & Immunology. Epub 2015 Sep 30.

Raw IF: 5.463 Normalized IF: 3 Selmi C°.

Autoimmunity in 2014.

Clinical Reviews in Allergy & Immunology 2015;49(2):93-9.

Raw IF: 5.463 Normalized IF: 6 Selmi C, Cantarini L, Kivity S, Dagaan A, Shovman O, Zandman-Goddard G, Perricone C, Amital H, Toubi E, Shoenfeld Y.

Raw IF: 8.41 Normalized IF: 8

The 2014 ACR annual meeting: a bird’s eye view of autoimmunity in 2015.

Pacini G, Carotenuto A, Rentier C, Nuti F, Real Fernández F, Brancaccio D, Sabatino G, Larregola M, Peroni E, Migliorini P, Novellino E, Battezzati PM, Selmi C, Papini AM, Rovero P.

Autoimmunity Reviews 2015;14(7):622-32.

Role of lipoylation of the immunodominant epitope of Pyruvate Dehydrogenase Complex: toward a peptide-based diagnostic assay for Primary Biliary Cirrhosis.

Journal of Medicinal Chemistry 2015;58(16):6619-29.

Raw IF: 5.447 Normalized IF: 3 Pagnini I, Vitale A, Selmi C, Cimaz R, Cantarini L.

Idiopathic inflammatory myopathies: an update on classification and treatment with special focus on juvenile forms.

Clinical Reviews in Allergy & Immunology. Epub 2015 Oct 1.

Raw IF: 5.463 Normalized IF: 3 Rucksaken R, Haonon O, Pinlaor P, Pairojkul C, Roytrakul S, Yongvanit P, Selmi C, Pinlaor S.

Plasma IgG autoantibody against actin-related protein 3 in liver fluke Opisthorchis viverrini infection.

Raw IF: 7.933 Normalized IF: 8 Selmi C°, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, Meroni PL.

Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years.

Autoimmunity Reviews 2016;15(2):162-6.

Raw IF: 7.933 Normalized IF: 8 Selmi C°, Generali E, Cantarini L.

Tumor necrosis factor-alpha at the crossroad between rheumatoid arthritis and autoimmune cholangitis.

Israel Medical Association Journal 2015;17(2):112-3.

Raw IF: 1.013 Normalized IF: 2 Selmi C, Greenspan A, Huntley A, Gershwin ME.

Multicentric reticulohistiocytosis: a critical review.

Parasite Immunology 2015;37(7):340-8.

Current Rheumatology Reports 2015;17(6):511.

Raw IF: 2.143 Normalized IF: 2

Raw IF: 2.871 Normalized IF: 4

63

Papers published 2015

Sun Y, Zhang W, Li B, Zou Z, Selmi C, Gershwin ME.

The coexistence of Sjögren’s syndrome and primary biliary cirrhosis: a comprehensive review.

Clinical Reviews in Allergy & Immunology 2015;48(2-3):301-15.

Raw IF: 5.463 Normalized IF: 3 Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O, Airò P, Carreira PE, Tikly M, Vettori S, Balbir Gurman A, Damjanov N, MüllerLadner U, Distler J, Li M, Häusermann P, Walker UA; EUSTAR coauthors.

(Collaborator: Selmi C).

Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.

Annals of the Rheumatic Diseases. Epub 2015 Jul 31.

Raw IF: 10.377 Normalized IF: 1.6

Gastrointestinal Immunopathology Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D’Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D°, Mikulak J°.

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Scientific Reports 2015;5:13647.

Raw IF: 5.578 Normalized IF: 6 Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R.

European evidence-based consensus: Inflammatory Bowel Disease and malignancies.

Journal of Crohn’s & Colitis 2015;9(11):945-65.

Raw IF: 6.234 Normalized IF: 3 Bonovas S, Moja L, Danese S.

In the presence of conceptual heterogeneity, results of network metaanalysis need to be interpreted with caution.

Gastroenterology 2015;148(7):1483-4.

64

Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D; European Crohn’s and Colitis Organisation and the Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives; European Crohn’s and Colitis Organisation and the Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives.

Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis.

Gastroenterology 2016;150(2):380-388.e4.

Raw IF: 16.716 Normalized IF: 15 D’Alessio S, Tacconi C, Danese S°.

Targeting lymphatics in Inflammatory Bowel Disease.

Oncotarget 2015;6(33):34047-8.

Danese S, Vuitton L, Peyrin-Biroulet L.

Biologic agents for IBD: practical insights.

Nature Reviews Gastroenterology & Hepatology 2015;12(9):537-45.

Raw IF: 12.61 Normalized IF: 10 de Groof EJ, Buskens CJ, Ponsioen CY, Dijkgraaf MG, D’Haens GR, Srivastava N, van Acker GJ, Jansen JM, Gerhards MF, Dijkstra G, Lange JF, Witteman BJ, Kruyt PM, Pronk A, van Tuyl SA, Bodelier A, Crolla RM, West RL, Vrijland WW, Consten EC, Brink MA, Tuynman JB, de Boer NK, Breukink SO, Pierik MJ, Oldenburg B, van der Meulen AE, Bonsing BA, Spinelli A, Danese S, Sacchi M, Warusavitarne J, Hart A, Yassin NA, Kennelly RP, Cullen GJ, Winter DC, Hawthorne AB, Torkington J, Bemelman WA.

Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial.

Trials 2015;16(1):366.

Raw IF: 1.731 Normalized IF: 2

Raw IF: 6.359 Normalized IF: 6

Declerck P, Mellstedt H, Danese S.

Danese S°, Fiorino G, Mary JY, Lakatos PL, D’Haens G, Moja L, D’Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, PeyrinBiroulet L, Colombel JF.

Current Medical Research and Opinion 2015;31(12):2325-30.

Development of red flags index for early referral of adults with symptoms and sighs suggestive of Crohn’s disease: an IOIBD initiative.

Biosimilars - terms of use.

Raw IF: 2.653 Normalized IF: 6 Fernandes C, Allocca M, Danese S, Fiorino G°.

Journal of Crohn’s & Colitis 2015;9(8):601-6.

Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.

Raw IF: 6.234 Normalized IF: 6

Immunotherapy 2015;7(2):175-90.

Raw IF: 2.07 Normalized IF: 2 Danese S, Fiorino G, Peyrin-Biroulet L.

Targeting SMAD7 in Crohn′s disease by Mongersen: therapeutic revolution under way?

Fiorino G, Allocca M, Danese S°.

Gastroenterology 2015;149(4):1121-3.

Clinical Gastroenterology and Hepatology 2015;13(10):1767-9.

Raw IF: 16.716 Normalized IF: 15

Anemia in IBD: the opening of Pandora’s box?

Raw IF: 7.896 Normalized IF: 8 Danese S°, Grisham MB, Hodge J, Telliez JB.

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S°.

American Journal of Physiology. Gastrointestinal and liver physiology. Epub 2015 Nov 25.

Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn’s disease.

Raw IF: 16.716 Normalized IF: 7.5

Raw IF: 3.798 Normalized IF: 6

Bravatà I, Allocca M, Fiorino G, Danese S°.

Danese S°, Peyrin-Biroulet L, Fiorino G.

Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Predicting future disease course in Crohn’s disease by colonoscopy or magnetic resonance: which is the crystal ball?

Current Opinion in Pharmacology 2015;25:67-71.

Gut 2015;64(9):1347-8.

Raw IF: 4.595 Normalized IF: 6

Raw IF: 14.66 Normalized IF: 10

Journal of Crohn’s & Colitis 2015;9(8):633-9.

Raw IF: 6.234 Normalized IF: 6

Translational Research

Fiorino G°, Omodei PD.

Psoriasis and inflammatory bowel disease: two faces of the same coin?

Journal of Crohn’s & Colitis 2015;9(9):697-8.

Raw IF: 6.234 Normalized IF: 6 Furfaro F°, Bezzio C, Maconi G.

Protein-losing enteropathy in inflammatory bowel diseases.

Minerva Gastroenterologica e Dietologica 2015;61(4):261-5.

Raw IF: 0 Normalized IF: 0 Genua M, Becker C, Vetrano S°.

Anti-TNF antibodies and autophagy: a hidden nexus for a successful therapeutic response?

Journal of Crohn’s & Colitis. Epub 2015 Dec 8.

Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, Ripke S, Gusareva ES, Annese V, Hauser SL, Oksenberg JR, Thomsen I, Leslie S; International Inflammatory Bowel Disease Genetics Consortium; Australia and New Zealand IBDGC; Belgium IBD Genetics Consortium; Italian Group for IBD Genetic Consortium; NIDDK Inflammatory Bowel Disease Genetics Consortium; United Kingdom IBDGC; Wellcome Trust Case Control Consortium; Quebec IBD Genetics Consortium, Daly MJ, Van Steen K, Duerr RH, Barrett JC, McGovern DP, Schumm LP, Traherne JA, Carrington MN, Kosmoliaptsis V, Karlsen TH, Franke A, Rioux JD. (Collaborator: Danese S).

High-density mapping of the MHC identifies a shared role for HLADRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.

Nature Genetics 2015;47(2):172-9.

Raw IF: 29.352 Normalized IF: 3

Raw IF: 6.234 Normalized IF: 6 Genua M, Sgambato A, Danese S°.

Editorial: CCR7 is required for leukocyte egression in an experimental model of Crohn’s like ileitis.

Journal of Leukocyte Biology 2015;97(6):1000-2.

Raw IF: 4.289 Normalized IF: 6 Gilardi D, Fiorino G, Allocca M, Bravatà I, Danese S°.

Golimumab: clinical update on its use for ulcerative colitis.

Drugs of Today 2015;51(3):171-16.

Raw IF: 1.197 Normalized IF: 1 Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; and the International Programme to Develop New Indexes for Crohn’s Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn’s Disease IPNIC group. (Collaborator: Danese S).

Validation of the Inflammatory Bowel Disease Disability Index in a populationbased cohort.

Gut. Epub 2015 Dec 8.

Raw IF: 14.66 Normalized IF: 2

Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel JF, Jouet JP, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. (Collaborator: Danese S).

Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial.

JAMA - Journal of the American Medical Association 2015;314(23):2524-34.

Raw IF: 35.289 Normalized IF: 3 Kotze PG, Yamamoto T, Danese S, Suzuki Y, Teixeira FV, de Albuquerque IC, Saad-Hossne R, de Barcelos IF, da Silva RN, Kotze LM, Olandoski M, Sacchi M, Yamada A, Takeuchi K, Spinelli A.

Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for Crohn’s disease: results from the MULTIPER database.

Journal of Crohn’s & Colitis 2015;9(7):541-7.

Raw IF: 6.234 Normalized IF: 6 Lichtenstein GR, Travis S, Danese S, D’Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ.

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.

Marchal Bressenot A, Riddell RH, BoulagnonRombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L.

Review article: the histological assessment of disease activity in ulcerative colitis.

Alimentary Pharmacology & Therapeutics 2015;42(8):957-67.

Raw IF: 5.727 Normalized IF: 3 Marchal-Bressenot A, Salleron J, BoulagnonRombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L.

Development and validation of the Nancy histological index for ulcerative colitis.

Gut. Epub 2015 Oct 13.

Raw IF: 14.66 Normalized IF: 5 Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D’Alessio S°.

Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of Notch1.

Cancer Research 2015;75(22):4895-909.

Raw IF: 9.329 Normalized IF: 8 Moja L, Danese S, Fiorino G, Del Giovane C, Bonovas S.

Systematic review with network metaanalysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease.

Alimentary Pharmacology & Therapeutics 2015;41(11):1055-65.

Raw IF: 5.727 Normalized IF: 6 Nuti F, Fiorino G, Danese S°.

Adalimumab for the treatment of pediatric Crohn’s disease.

Expert Review of Clinical Immunology 2015;11(9):963-72.

Raw IF: 2.484 Normalized IF: 2 Papa A, Papa V, Marzo M, Scaldaferri F, Sofo L, Rapaccini GL, Danese S, Gasbarrini A.

Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing.

Inflammatory Bowel Diseases 2015;21(5):1204-13.

Raw IF: 4.464 Normalized IF: 3

Journal of Crohn’s & Colitis 2015;9(9):738-46.

Raw IF: 6.234 Normalized IF: 3

65

Papers published 2015

Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer S SB, Rycroft B.

Sandborn WJ, Danese S, D’Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S.

Defining disease severity in inflammatory bowel diseases: current and future directions.

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.

Clinical Gastroenterology and Hepatology 2016;14(3):348-354.e17.

Raw IF: 7.896 Normalized IF: 4 Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF.

Selecting therapeutic targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treatto-target.

Alimentary Pharmacology & Therapeutics 2015;41(5):409-18.

Raw IF: 5.727 Normalized IF: 6 Scaldaferri F, Vetrano S.

Mesenchymal stem cells in IBD: unMaSCing their therapeutic mechanisms.

Digestive Diseases and Sciences 2015;60(7):1873-5.

Raw IF: 2.613 Normalized IF: 4 Tacconi C, Correale C, Gandelli A, Spinelli A, Dejana E, D’Alessio S°, Danese S°.

Vascular Endothelial Growth Factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.

Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D’Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L.

IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials.

Gut. Epub 2015 Sep 9.

Raw IF: 14.66 Normalized IF: 5 Yadav SK, Gupta RK, Saraswat VA, Rangan M, Thomas MA, Rutella S, Danese S, Wang E, Marincola FM, Haris M.

Reduced cortical thickness in patients with acute-on-chronic liver failure due to non-alcoholic etiology.

Journal of Translational Medicine 2015;13(1):322.

Raw IF: 3.93 Normalized IF: 2

hepatobiliary Immunopathology

Raw IF: 10.755 Normalized IF: 8

Raw IF: 16.716 Normalized IF: 15

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S°.

Tursi A, Papa A, Danese S°.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

American Journal of Gastroenterology 2015;110(9):1324-38.

Review article: the pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

European Journal of Clinical Pharmacology 2015;71(7):773-99.

Gastroenterology 2015;148(7):1438-51.e8.

Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.

Alimentary Pharmacology & Therapeutics 2015;42(6):664-84.

Raw IF: 5.727 Normalized IF: 6

Raw IF: 2.966 Normalized IF: 4 Reinisch W, Louis E, Danese S.

The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.

Expert Review of Gastroenterology and Hepatology 2015;9(s1):17-26.

Raw IF: 2.417 Normalized IF: 4 Sala E, Genua M, Petti L, Anselmo A, Arena V, Cibella J, Zanotti L, D’Alessio S, Scaldaferri F, Luca G, Arato I, Calafiore R, Sgambato A, Rutella S, Locati M, Danese S, Vetrano S°.

Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine.

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3: Special situations (Spanish version).

Revista de Gastroenterología de México 2015;80(1):74-106.

Raw IF: 0 Normalized IF: 0 Vetrano S°, Genua M.

Cathelicidins: a novel therapy for the treatment of intestinal fibrosis?

Gastroenterology 2015;149(1):163-176.e20.

Cellular and Molecular Gastroenterology and Hepatology 2015;1(1):2-3.

Raw IF: 16.716 Normalized IF: 15

Raw IF: 0 Normalized IF: 0

American Journal of Gastroenterology 2015;110(11):1536-8.

Raw IF: 10.755 Normalized IF: 4 Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Clinical Gastroenterology and Hepatology 2015;13(11):1867-9.

Raw IF: 7.896 Normalized IF: 4 Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Clinics and Research in Hepatology and Gastroenterology 2015;39(5):e-57-9.

Raw IF: 1.638 Normalized IF: 0.5 Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Digestive and Liver Disease 2015;47(11):924-6.

Raw IF: 2.963 Normalized IF: 2

66

Translational Research

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Gastroenterology 2015;149(6):1627-9.

Raw IF: 16.716 Normalized IF: 7.5 Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Gut 2015;64(11):1671-2.

Raw IF: 14.66 Normalized IF: 5

Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators.

Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin M E, Mavilio D°.

(Collaborators: Podda M, Selmi C, Meda F).

Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.

European Journal of Internal Medicine 2015;26(4):243-9.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

Hepatology 2015;62(5):1620-2.

Raw IF: 8.41 Normalized IF: 8

Raw IF: 2.891 Normalized IF: 1.2 Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, Pasina L, Franchi C, Kamal Eldin T, Marengoni A, Salerno F, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators.

(Collaborators: Podda M, Selmi C, Meda F).

Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Journal of Autoimmunity 2016;66:40-50.

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

European Journal of Internal Medicine 2014;25(7):617-23.

Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Liver AISF. Morisco F, Bruno R, Bugianesi E, Burra P, Calvaruso V, Cannoni A, Caporaso N, Caviglia GP, Ciancio A, Fargion S, Federico A, Floreani A, Gaeta GB, Guarino M, Invernizzi P, Licata A, Loguercio C, Mazzella G, Petraglia F, Primignani M, Rodriguez-Castro K, Smedile A, Valenti L, Vanni E, Vannuccini S, Voltolini C, Villa E.

AISF position paper on liver disease and pregnancy.

Digestive and Liver Disease 2016;48(2):120-37.

Raw IF: 2.891 Normalized IF: 1.2

Raw IF: 2.963 Normalized IF: 4

Floreani A, Motta R, Cazzagon N, Franceschet I, Roncalli M, Del Ross T, Rosina F, Lleo A, Mescoli C, Colloredo G, Invernizzi P.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group.

Raw IF: 11.055 Normalized IF: 4 Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DE, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’.

The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis.

Journal of Hepatology 2015;63(5):1285-7.

Digestive and Liver Disease 2015;47(5):432-5.

Raw IF: 11.336 Normalized IF: 4

Raw IF: 2.963 Normalized IF: 4

Boccaccio V°, Russo ML, Carbone M, Bruno S.

Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, Norata GD, Invernizzi P, Kallikourdis M°.

Treatment discontinuation with peginterferon: what to consider.

Expert Review of Clinical Pharmacology 2015;8(6):761-8.

Raw IF: 2.18 Normalized IF: 2 Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC, Floyd JA, Morley KI, Prati D, Lleo A, Cusi D; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium, Gershwin ME, Anderson CA, Lazaridis KN, Invernizzi P, Seldin MF, Sandford RN*, Amos CI*, Siminovitch KA*.

(Collaborators: Bernuzzi F, Bianchi I, Bruno S, Podda M, Ronca V, Rossi S, Sogno I).

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and highlights pathogenic pathways for drug targeting.

Nature Communications 2015;6:8019.

Raw IF: 11.47 Normalized IF: 8

Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment.

Immunobiology 2015;220(8):1025-29.

Raw IF: 3.044 Normalized IF: 4 Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group.

(Collaborator: Invernizzi P).

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study.

Hepatology. Epub 2015 Nov 24.

Raw IF: 11.055 Normalized IF: 1.6

Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.

Gastroenterology. Epub 2015 Aug 7.

Raw IF: 16.716 Normalized IF: 15 Lleo A*, Zhang W*, Zhao M*, Tan Y, Bernuzzi F, Zhu B, Liu Q, Tan Q, Malinverno F, Valenti L, Jiang T, Tan L, Liao W, Coppel R, Invernizzi P#, Lu Q#, Adams DH, Gershwin ME#; PBC Epigenetic Study Group.

(Collaborators: Bianchi I, Ceriani R, Mascia E, Mascheroni C, Podda M, Traiani F).

DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis.

Clinical Epigenetics 2015;7(1):61.

Raw IF: 4.543 Normalized IF: 6 Marzorati S, Invernizzi P, Lleo A°.

Making sense of autoantibodies in cholestatic liver diseases.

Clinics in Liver Disease 2016;20(1):33-46.

Raw IF: 3.66 Normalized IF: 6

67

Papers published 2015

Peng A*, Ke P*, Zhao R, Lu X, Zhang C, Huang X, Tian G, Huang J, Wang J, Invernizzi P, Chen Q, Zhuang J.

Elevated circulating CD14lowCD16+ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization.

Clinical and Experimental Medicine. Epub 2015 Sep 24.

Raw IF: 2.959 Normalized IF: 2 Raggi C*°, Mousa HS*, Correnti M, Sica A, Invernizzi P*.

Cancer stem cells and TumorAssociated Macrophages: a roadmap for multitargeting strategies.

Oncogene 2016;35(6):671-82.

Raw IF: 8.459 Normalized IF: 8 Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, Tinelli C, Spreafico M, Prati D, Ludovisi S, Ferraioli G, Filice C, Aghemo A, Lampertico P, Facchetti F, Bernuzzi F, Invernizzi P, Mondelli MU.

Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.

Gut Epub 2015 Dec 16.

Raw IF: 14.66 Normalized IF: 5 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group.

(Collaborators: Invernizzi P, Bruno S).

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

Alimentary Pharmacology & Therapeutics 2015;42(7):829-44.

Raw IF: 5.727 Normalized IF: 1.2 Zhang H, Bernuzzi F, Lleo A, Ma X, Invernizzi P°.

Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases.

Mediators of Inflammation 2015;2015:436450.

Raw IF: 3.236 Normalized IF: 4 Zhang H, Carbone M, Lleo A, Invernizzi P.

Geoepidemiology, genetic and environmental risk factors for PBC. Digestive Diseases 2015;33 s2:94-101.

68

Raw IF: 2.181 Normalized IF: 2

molecular gastroenterology Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C°, Mantovani A°.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Cell 2015;160(4):700-14.

Raw IF: 32.242 Normalized IF: 15 Colombo M, Mirandola L, Reidy A, Suvorava N, Konala V, Chiaramonte R, Grizzi F, Rahman RL, Jenkins MR, Nugyen DD, Dalhbeck S, Cobos E, Figueroa JA, Chiriva-Internati M.

Targeting tumor initiating cells through inhibition of cancer testis antigens and Notch signaling: a hypothesis.

Ghidini M°, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L.

KRAS mutation in lung metastases from colorectal cancer: prognostic implications.

Cancer Medicine 2016;5(2):256-64.

Raw IF: 2.5 Normalized IF: 2 Grizzi F°, Borroni EM, Vacchini A, Qehajaj D, Liguori M, Stifter S, Chiriva-Internati M, Di Ieva A.

Pituitary adenoma and the chemokine network: a systemic view.

Frontiers in Endocrinology 2015;6:141.

Raw IF: 0 Normalized IF: 0 Grizzi F°, Franceschini B, Di Biccari S, Musardo S, Pedretti E, Chiriva-Internati M, Osipov V, Fernández-Aceñero MJ.

International Reviews of Immunology 2015;34(2):188-99.

Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts.

Raw IF: 4.103 Normalized IF: 3

Histopathology 2015 ;67(3):398-403.

Raw IF: 3.453 Normalized IF: 6 Di Caro G, Castino GF, Bergomas F, Cortese N, Chiriva-Internati M, Grizzi F, Mantovani A, Marchesi F°.

Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.

International Reviews of Immunology 2015;34(2):123-33.

Raw IF: 4.103 Normalized IF: 6 Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F°.

Dual prognostic significance of tumourassociated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Gut. Epub 2015 Jul 8.

Raw IF: 14.66 Normalized IF: 10 Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D’Cunha N, D’Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.

International Reviews of Immunology 2015;34(2):154-87.

Raw IF: 4.103 Normalized IF: 3

Grizzi F, Mirandola L, Qehajaj D, Cobos E, Figueroa JA, Chiriva-Internati M.

Cancer-testis antigens and immunotherapy in the light of cancer complexity.

International Reviews of Immunology 2015;34(2):143-53.

Raw IF: 4.103 Normalized IF: 6 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10

Translational Research

Mirandola L, Figueroa JA, Phan TT, Grizzi F, Kim M, Rahman RL, Jenkins MR, Cobos E, Jumper C, Alalawi R, Chiriva-Internati M.

Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.

Oncotarget 2015;6(5):2812-26.

Raw IF: 6.359 Normalized IF: 3 Seveso M, Grizzi F°, Bozzini G, Mandressi A, Guazzoni G, Taverna G.

Open partial nephrectomy: ancient art or currently available technique?

International Urology and Nephrology 2015;47(12):1923-32.

Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F°.

Inflammation and prostate cancer: friends or foe?

Inflammation Research 2015;64(5):275-86.

Raw IF: 2.347 Normalized IF: 2

Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

World Journal of Urology. Epub 2015 Oct 19.

Raw IF: 2.666 Normalized IF: 6

Transplant Infectious Disease 2015;17(2):242-9.

Sniffing out prostate cancer: a new clinical opportunity.

Raw IF: 2.064 Normalized IF: 4

Central European Journal of Urology 2015;68(39):308-10.

Crocchiolo R°, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B, Bramanti S, Granata A, Vai A, Harbi S, Morabito L, Mohty B, Giordano L, Devillier R, Coso D, Balzarotti M, Chabannon C, CarloStella C, Santoro A, Bouabdallah R, Blaise D.

Raw IF: 0 Normalized IF: 0

Oncology Experimental Therapeutics Carlo-Stella C*°, Ricci F*, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L#, Corradini P#, Santoro A#.

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers.

Oncologist 2015;20(3):323-8.

Taverna G°, Cote RJ, Grizzi F.

Raw IF: 4.865 Normalized IF: 6

Editorial: prostate cancer. What we know and what we would like to know.

Carlo-Stella C°, Santoro A.

Frontiers in Oncology 2015;5:114.

Raw IF: 0 Normalized IF: 0 Taverna G, Cote R, Grizzi F°.

Re: Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: usefulness and limitations of microvessel density measurement.

International Journal of Urology 2016;23(1):105.

Microenvironment-related biomarkers and novel targets in classical Hodgkin lymphoma.

Biomarkers in Medicine 2015;9(8):807-17.

Raw IF: 2.646 Normalized IF: 4 Castagna L, Carlo-Stella C, Mazza R, Santoro A°.

Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.

Raw IF: 2.409 Normalized IF: 4

Mediterranean Journal of Hematology and Infectious Diseases 2015;7(1):e2015015.

Taverna G°, Grizzi F, Colombo P, Seveso M, Giusti G, Proietti S, Fiorini G, Lughezzani G, Casale P, Buffi N, Lazzeri M, Guazzoni G.

Raw IF: 0 Normalized IF:0

Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.

Korean Journal of Urology 2015;56(6):435-442.

Raw IF: 0 Normalized IF: 0

Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Taverna G°, Tidu L, Grizzi F.

Raw IF: 1.519 Normalized IF: 2 Taverna G, Bozzini G, Grizzi F, Seveso M, Mandressi A, Balzarini L, Mrakic F, Bono P, De Franceco O, Buffi N, Lughezzani G, Lazzeri M, Casale P, Guazzoni GF.

Crocchiolo R°, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L.

Castagna L*°, Crocchiolo R*, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Haematologica 2015;100(10):e423-7.

Raw IF: 5.814 Normalized IF: 6 De Mattos-Arruda L*, Bottai G*, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L°.

MicroRNA-21 links epithelialto-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

Oncotarget 2015;6(35):37269-80.

Raw IF: 6.359 Normalized IF: 6 Győrffy B, Bottai G, Fleischer T, Munkácsy G, Budczies J, Paladini L, Boressen-Dale AL, Kristensen VN, Santarpia L°.

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.

International Journal of Cancer. Epub 2015 Jul 14.

Raw IF: 5.085 Normalized IF: 6 Menyhárt O, Santarpia L, Győrffy B.

A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer.

Current Cancer Drug Targets 2015;15(8):665-83.

Raw IF: 3.522 Normalized IF: 4

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Bone Marrow Transplantation 2015;50(4):499-504.

Raw IF: 3.57 Normalized IF: 4

69

Papers published 2015

Roberto A, Castagna L*, Zanon V*, Bramanti S, Crocchiolo R, McLaren JE, Gandolfi S, Tentorio P, Sarina B, Timofeeva I, Santoro A, Carlo-Stella C, Bruno B, Carniti C, Corradini P, Gostick E, Ladell K, Price DA, Roederer M, Mavilio D#°, Lugli E#°.

Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation.

Blood 2015;125(18):2855-64.

Raw IF: 10.452 Normalized IF: 8 Vermezovic J, Adamowicz M, Santarpia L, Rustighi A, Forcato M, Lucano C, Massimiliano L, Costanzo V, Bicciato S, Del Sal G, d’Adda di Fagagna F.

Notch is a direct negative regulator of the DNA-damage response.

Nature Structural & Molecular Biology 2015;22(5):417-24.

Raw IF: 13.309 Normalized IF: 5

physiology Caronni A, Sciumé L, Ferpozzi V, Blasi V, Castellano A, Falini A, Perucca L, Cerri G.

Mirror movements after stroke suggest facilitation from nonprimary motor cortex: a case presentation.

PM & R. The Journal of Injury, Function, and Rehabilitation. Epub 2015 Oct 26.

Raw IF: 1.534 Normalized IF: 4

70

Clinical Research biobank Selmi C°, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, Meroni PL.

Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years.

Autoimmunity Reviews 2016;15(2):162-6.

Raw IF: 7.933 Normalized IF: 8

van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group.

(Collaborator: Gatzmeier W).

The effect of EUSOMA certification on quality of breast cancer care.

EJSO - European Journal of Surgical Oncology 2015;41(10):1423-9.

Raw IF: 3.009 Normalized IF: 6 Vigo C, Gatzemeier W, Sala R, Malacarne M, Santoro A, Pagani M, Lucini D°.

breast unit Brambilla T, Fiamengo B, Tinterri C, Testori A, Grassi MM, Sciarra A, Abbate T, Gatzemeier W, Roncalli M, Di Tommaso L°.

One-step nucleic acid amplification in breast cancer sentinel lymph node: a single institutional experience and a short review.

Frontiers in Medicine 2015;2:37.

Raw IF: 0 Normalized IF: 0 EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. (Collaborator: Tinterri C).

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Lancet 2014;383(9935):2127-35.

Raw IF: 45.217 Normalized IF: 3 Masci G°, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series.

Evidence of altered autonomic cardiac regulation in breast cancer survivors.

Journal of Cancer Survivorship: Research and Practice. Epub 2015 Apr 22.

Raw IF: 3.303 Normalized IF: 4

cardiac surgery Cappai A°, Settepani F, Barbone A, Ornaghi D, Malvindi PG.

Iatrogenic left ventricular false aneurysm.

Journal of Cardiovascular Medicine. Epub 2015 Aug 11.

Kowalewski M, Pawliszak W, Raffa GM, Malvindi PG, Kowalkowska ME, Zaborowska K, Kowalewski J, Tarelli G, Taggart DP, Anisimowicz L.

Safety and efficacy of miniaturized extracorporeal circulation when compared with off-pump and conventional coronary artery bypass grafting: evidence synthesis from a comprehensive Bayesian-framework network metaanalysis of 134 randomized controlled trials involving 22 778 patients.

European Journal of Cardio-Thoracic Surgery. Epub 2015 Nov 3.

Raw IF: 3.304 Normalized IF: 3 Pagnotta P, Mennuni MG°, Ferrante G, Ornaghi D, Bragato R, Cappai A, Presbitero P.

A hybrid double access for transcatheter mitral valve-in-valve implantation.

Annals of Thoracic Surgery 2015;99(6):e149-50.

Raw IF: 3.849 Normalized IF: 6 Raffa GM°, Malvindi PG, Ornaghi D, Citterio E, Cappai A, Basciu A, Barbone A, Fossati F, Tarelli G, Settepani F.

Minimally invasive direct coronary artery bypass in the era of percutaneous coronary intervention.

Journal of Cardiovascular Medicine 2015;16(2):118-24.

Raw IF: 1.51 Normalized IF: 2

Raw IF: 1.51 Normalized IF: 2 Cappai A°, Settepani F, Tarelli G, Malvindi PG.

Vertebral erosion due to spontaneous thoracic aortic false aneurysm.

Texas Heart Institute Journal 2015;42(2):188-9.

Settepani F°, Cappai A, Basciu A, Barbone A, Citterio E, Ornaghi D, Tarelli G.

Hybrid versus conventional treatment of acute type A aortic dissection.

Journal of Cardiac Surgery 2015;30(9):707-13.

Raw IF: 0.649 Normalized IF: 1

Raw IF: 0.89 Normalized IF: 1

Kowalewski M, Pawliszak W, Malvindi PG, Bokszanski MP, Perlinski D, Raffa GM, Kowalkowska ME, Zaborowska K, Navarese EP, Kolodziejczak M, Kowalewski J, Tarelli G, Taggart DP, Anisimowicz L.

Settepani F°, Cappai A, Basciu A, Barbone A, Tarelli G.

Off-pump coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-pump coronary artery bypass grafting: meta-analysis.

Oncologist 2015;20(6):586-92.

Journal of Thoracic and Cardiovascular Surgery 2015;151(1):60-77.e58.

Raw IF: 4.865 Normalized IF: 6

Raw IF: 4.168 Normalized IF: 3

Balanced double aortic arch in an older patient.

Annals of Thoracic Surgery 2015;99(6):2221.

Raw IF: 3.849 Normalized IF: 6

71

Papers published 2015

clinical cardiology Achilli F, Malafronte C, Cesana F, Maggiolini S, Mauro C, De Ferrari GM, Lenatti L, Tespili M, Pasqualini P, Gentile F, Capogrossi MC, Maggioni A, Maseri A, Pontone G, Colombo GI, Pompilio G; STEM-AMI OUTCOME Trial Investigators.

(Collaborators: Lettino M., Pagnotta PA).

Granulocyte-colony stimulating factor for large anterior ST-elevation myocardial infarction: rationale and design of the prospective randomized phase III STEMAMI OUTCOME trial.

American Heart Journal 2015;170(4):652-658.e7.

coronary care Avanzini F, Mafrici A, Riva E, Franzosi MG, Milani V, Giudici V, Marelli G, Mariani G, Piatti PM, Roncaglioni MC; GLICINE-SPIDER Collaborative Group (Collaborators: Presbitero P, Corrada E, Llazo O).

State of the art of current 3-D scoliosis classifications: a systematic review from a clinical perspective.

A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome.

Raw IF: 2.74 Normalized IF: 3

Nutrition Metabolism and Cardiovascular Diseases 2015;25(10):916-23.

Raw IF: 3.323 Normalized IF: 1.2

Raw IF: 4.463 Normalized IF: 1.2 Camera M, Toschi V, Brambilla M, Lettino M, Rossetti L, Canzano P, Di Minno A, Tremoli E.

The role of Tissue Tactor in atherothrombosis and coronary artery disease: insights into Platelet Tissue Factor.

Seminars in Thrombosis and Hemostasis 2015;41(7):737-46.

Raw IF: 3.876 Normalized IF: 3

diagnostic radiology Bomba M, Riva A, Morzenti S, Grimaldi M, Neri F, Nacinovich R.

Global and regional brain volumes normalization in weight-recovered adolescents with anorexia nervosa: preliminary findings of a longitudinal voxel-based morphometry study.

Neuropsychiatric Disease and Treatment 2015;11:637-45.

Lettino M.

Raw IF: 2.154 Normalized IF: 1

PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program.

Cazzato RL, Palussière J, Buy X, Denaro V, Santini D, Tonini G, Grasso RF, Zobel BB, Poretti D, Pedicini V, Balzarini L, Lanza E.

Giornale Italiano di Cardiologia 2015;16(4):211-6.

Raw IF: 0 Normalized IF: 0 Marini M, Pini D, Russo G, Milli M, De Maria R, Di Tano G, Aspromonte N.

The certification of “clinical competence” for advanced heart failure: a need also in Italy?

Giornale Italiano di Cardiologia 2015;16(2):77-82.

Raw IF: 0 Normalized IF: 0 Ottani F, La Vecchia L, Diamanti I, Pozzati A, Gardani L, Fresco C, Lettino M, Cuccia C.

Percutaneous long bone cementoplasty for palliation of malignant lesions of the limbs: a systematic review.

Cardiovascular and Interventional Radiology 2015;38(6):1563-72.

Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S°.

Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease.

Journal of Crohn’s & Colitis 2015;9(8):633-9.

Raw IF: 6.234 Normalized IF: 6 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10 Lanza E, Banfi G, Serafini G, Lacelli F, Orlandi D, Bandirali M, Sardanelli F, Sconfienza LM.

Costa F°, Dorelli G, Ortolina A, Cardia A, Attuati L, Tomei M, Milani D, Balzarini L, Galbusera F, Morenghi E, Fornari M.

Ultrasound-guided percutaneous irrigation in rotator cuff calcific tendinopathy: what is the evidence? A systematic review with proposals for future reporting.

Computed tomography-based imageguided system in spinal surgery: state of the art through 10 years of experience.

Neurosurgery 2015;11(s2):59-68.

Raw IF: 3.62 Normalized IF: 6

Giornale Italiano di Cardiologia 2015;16(5):304-10.

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.

De Sanctis R°, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio P, Bastoni S, Bertuzzi AF, Quagliuolo V, Santoro A.

Drug Design, Development and Therapy 2015;9:5785-91.

Raw IF: 3.028 Normalized IF: 4

72

Journal of Neuroengineering and Rehabilitation 2015;12(1):91.

Raw IF: 2.071 Normalized IF: 4

The heart of Italians. A population survey on the perception and evaluation of the National Health Service by citizens with heart disease and without heart disease (with special reference to cardiology).

Raw IF: 0 Normalized IF: 0

Donzelli S, Poma S, Balzarini L, Borboni A, Respizzi S, Villafane JH, Zaina F, Negrini S.

European Radiology 2015;25(7):2176-83.

Raw IF: 4.014 Normalized IF: 6 Lanza E°, Palussiere J, Buy X, Grasso RF, Beomonte Zobel B, Poretti D, Pedicini V, Balzarini L, Cazzato LR.

Percutaneous image-guided cryoablation of breast cancer: a systematic review.

Journal of Vascular and Interventional Radiology 2015;26(11):1652-7.e1.

Raw IF: 2.409 Normalized IF: 4

Clinical Research

Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6 Marvisi M, Vento MG, Balzarini L, Mancini C, Marvisi C.

Continuous positive airways pressure and uvulopalatopharyngoplasty improves pulmonary hypertension in patients with obstructive sleep apnoea.

Lung 2015;193(2):269-74.

Raw IF: 2.271 Normalized IF: 1 Monti L° , Scardino C, Nardi B, Balzarini L.

Lipoma of the interventricular septum.

European Heart Journal. Epub 2015 Jun 5.

Raw IF: 15.203 Normalized IF: 15 Sclafani F°, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Giordano Beretta G, Zanello A, Roncalli M, Giordano M, Santoro A.

An exploratory biomarker study in metastatic tumours from colorectal cancer patients treated with bevacizumab.

International Journal of Biological Markers 2015;30(1):e73-80.

Raw IF: 1.371 Normalized IF: 2 Taverna G, Bozzini G, Grizzi F, Seveso M, Mandressi A, Balzarini L, Mrakic F, Bono P, De Franceco O, Buffi N, Lughezzani G, Lazzeri M, Casale P, Guazzoni GF.

Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

World Journal of Urology. Epub 2015 Oct 19.

Raw IF: 2.666 Normalized IF: 6

digestive endoscopy Amato A, Radaelli F, Dinelli M, Crosta C, Cengia G, Beretta P, Devani M, Lochis D, Manes G, Fini L, Paggi S, Passoni GR, Repici A; SIED Lombardy group.

Early and delayed complications of polypectomy in a community setting: The SPoC prospective multicentre trial.

Digestive and Liver Disease 2016;48(1):43-8.

Raw IF: 2.963 Normalized IF: 4 Anderloni A°, Galeazzi M, Ballarè M, Pagliarulo M, Orsello M, Del Piano M, Repici A.

Early endoscopic ultrasonography in acute biliary pancreatitis: a prospective pilot study.

World Journal of Gastroenterology 2015;21(36):10427-34.

Bravatà I, Allocca M, Fiorino G, Danese S°.

Integrins and adhesion molecules as targets to treat inflammatory bowel disease.

Current Opinion in Pharmacology 2015;25:67-71.

Raw IF: 4.595 Normalized IF: 6 Carrara S°, Anderloni A, Jovani M, Di Tommaso L, Rahal D, Hassan C, Ridola L, Federico D, Loriga A, Repici A.

A prospective randomized study comparing 25-G and 22-G needles of a new platform for endoscopic ultrasoundguided fine needle aspiration of solid masses.

Digestive and Liver Disease 2016;48(1):49-54.

Raw IF: 2.963 Normalized IF: 4

Raw IF: 2.369 Normalized IF: 4 Anderloni A°, Genco C, Ballarè M, Carmagnola S, Battista S, Repici A.

A case of primary pancreatic non-Hodgkin B-cell lymphoma mimicking autoimmune pancreatitis.

Journal of Gastrointestinal and Liver Diseases 2015;24(2):245-8.

Carrara S°, Rahal D, Repici A.

A case of gastric splenosis mimicking a stromal tumor.

Clinical Gastroenterology and Hepatology. Epub 2015 Oct 23.

Raw IF: 7.896 Normalized IF: 8

Raw IF: 2.202 Normalized IF: 2

Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S°.

Anderloni A°, Murino A, Jovani M, Battista S, Repici A.

Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn’s disease.

Underwater endoscopic mucosal resection of a duodenal neuroendocrine tumor.

Gastrointestinal Endoscopy. Epub 2015 Aug 8.

Raw IF: 5.369 Normalized IF: 6 Anderloni A°, Orellana F, Jovani M, Repici A.

Endoscopic ultrasound-guided drainage of a pancreatic pseudocyst with a novel lumen-apposing metal stent on an electrocautery-enhanced delivery system.

Digestive and Liver Disease 2015;47(10):e17.

Raw IF: 2.963 Normalized IF: 4 Anderloni A°, Repici A.

Role and timing of endoscopy in acute biliary pancreatitis.

World Journal of Gastroenterology 2015;21(40):1205-8.

Raw IF: 2.369 Normalized IF: 4

Journal of Crohn’s & Colitis 2015;9(8):633-9.

Raw IF: 6.234 Normalized IF: 6 Fuccio L, Hassan C, Frazzoni L, Miglio R, Repici A.

Clinical outcomes following stent placement in refractory benign esophageal stricture: a systematic review and meta-analysis.

Endoscopy 2016;48(2):141-8.

Raw IF: 5.053 Normalized IF: 6 Fumagalli U°, Rosati R, De Pascale S, Porta M, Carlani E, Pestalozza A, Repici A.

Repeated surgical or endoscopic myotomy for recurrent dysphagia in patients after previous myotomy for achalasia.

Journal of Gastrointestinal Surgery 2016;20(3):494-9.

Raw IF: 2.798 Normalized IF: 6

Barbieri LA°, Hassan C, Rosati R, Fumagalli Romario U, Correale L, Repici A.

Hassan C, Repici A°.

Systematic review and meta-analysis: efficacy and safety of POEM for achalasia.

Colonoscopy: cold snaring diminutive polyps - the thinner the better!

United European Gastroenterology Journal 2015;3(4):325-34.

Nature reviews Gastroenterology & Hepatology 2015;12(4):191-3.

Raw IF: 2.08 Normalized IF: 2

Raw IF: 12.61 Normalized IF: 10

73

Papers published 2015

Hassan C, Repici A, Sharma P, Correale L, Zullo A, Bretthauer M, Senore C, Spada C, Bellisario C, Bhandari P, Rex DK.

Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis.

Management of high grade dysplasia in Barrett’s oesophagus with underlying oesophageal varices: A retrospective study.

Gut. Epub 2015 Feb 13.

Digestive and Liver Disease 2015;47(9):763-8.

Raw IF: 14.66 Normalized IF: 10

Raw IF: 2.963 Normalized IF: 2

Hassan C, Senore C, Repici A.

Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, Amato A, Berr F, Bhandari P, Bialek A, Conio M, Haringsma J, Langner C, Meisner S, Messmann H, Morino M, Neuhaus H, Piessevaux H, Rugge M, Saunders BP, Robaszkiewicz M, Seewald S, Kashin S, Dumonceau JM, Hassan C, Deprez PH.

Colorectal malignant adenoma: do all high-risk lesions need surgery?

Polskie Archiwum Medycyny Wewnętrznej 2015;125(4):225-6.

Raw IF: 2.121 Normalized IF: 6 Italian Association for the Study of the Pancreas (AISP), Pezzilli R, Zerbi A, Campra D, Capurso G, Golfieri R, Arcidiacono PG, Billi P, Butturini G, Calculli L, Cannizzaro R, Carrara S, Crippa S, De Gaudio R, De Rai P, Frulloni L, Mazza E, Mutignani M, Pagano N, Rabitti P, Balzano G.

Consensus guidelines on severe acute pancreatitis.

Digestive and Liver Disease 2015;47(7):532-43.

Raw IF: 2.963 Normalized IF: 4 Jovani M, Anderloni A, Carrara S, Loriga A, Ciscato C, Ferrara EC, Repici A.

Circumferential endoscopic submucosal dissection of a squamous cell carcinoma in a cirrhotic patient with esophageal varices.

Gastrointestinal Endoscopy 2015;82(5):963-4.

Raw IF: 5.369 Normalized IF: 6 Khashab MA, Messallam AA, Onimaru M, Teitelbaum EN, Ujiki MB, Gitelis ME, Modayil RJ, Hungness ES, Stavropoulos SN, El Zein MH, Shiwaku H, Kunda R, Repici A, Minami H, Chiu PW, Ponsky J, Kumbhari V, Saxena P, Maydeo AP, Inoue H.

International multicenter experience with peroral endoscopic myotomy for the treatment of spastic esophageal disorders refractory to medical therapy (with video).

Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline.

Endoscopy 2015;47(9):829-54.

Raw IF: 5.053 Normalized IF: 3 Radaelli F, Dentali F, Repici A, Amato A, Paggi S, Rondonotti E, Dumonceau JM.

Sharma P, Katzka D, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K.

Quality indicators for the management of Barrett’s esophagus, dysplasia and esophageal adenocarcinoma: international consensus recommendations from AGA symposium.

Gastroenterology 2015;149(6):1599-606.

Raw IF: 16.716 Normalized IF: 15 Strangio G, Zullo A, Ferrara EC, Anderloni A, Carlino A, Jovani M, Ciscato C, Hassan C, Repici A.

Endo-sponge therapy for management of anastomotic leakages after colorectal surgery: a case series and review of literature.

Digestive and Liver Disease 2015;47(6):465-9.

Raw IF: 2.963 Normalized IF: 4

Management of anticoagulation in patients with acute gastrointestinal bleeding.

Digestive and Liver Disease 2015;47(8):621-7.

Raw IF: 2.963 Normalized IF: 2 Radaelli F, Paggi S, Hassan C, Senore C, Fasoli R, Anderloni A, Buffoli F, Savarese MF, Spinzi G, Rex DK, Repici A.

Split-dose preparation for colonoscopy increases adenoma detection rate: a randomised controlled trial in an organised screening programme.

Gut. Epub 2015 Dec 9.

Raw IF: 14.66 Normalized IF: 10 Repici A°, Hassan C.

Cold snaring diminutive polyps: can we make of a polyp … a better polyp?

Endoscopy 2015;47(11) :969-71.

Raw IF: 5.053 Normalized IF: 6

Gastrointestinal Endoscopy 2015;81(5):1170-7.

Repici A, Pohl H.

Raw IF: 5.369 Normalized IF: 6

Revival of a sclerosing agent for prevention of postpolypectomy bleeding.

Murino A, Anderloni A, Hassan C, Fuccio L, Repici A°.

Gastrointestinal Endoscopy 2015;82(2):359-61.

The role of salvage ERCP for the treatment of post-ERCP pancreatitis.

74

Palmer WC, Di Leo M, Jovani M, Heckman MG, Diehl NN, Iyer PG, Wolfsen HC, Wallace MB.

Raw IF: 5.369 Normalized IF: 6

echocardiography Gronda E, Genovese S, Padeletti L, Cacciatore F, Vitale DF, Bragato R, Innocenti L, Schiano C, Sommese L, De Pascale MR, Genovese L, Abete P, Donatelli F, Napoli C.

Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy.

Cardiology Journal 2015;22(4):459-66.

Raw IF: 1.062 Normalized IF: 0.5 Pagnotta P, Mennuni MG°, Ferrante G, Ornaghi D, Bragato R, Cappai A, Presbitero P.

A hybrid double access for transcatheter mitral valve-in-valve implantation.

Annals of Thoracic Surgery 2015;99(6):e149-50.

Raw IF: 3.849 Normalized IF: 6

Electrophysiology and Electrostimulation Gasparini M.

Atrioventricular node ablation.

Endoscopy 2015;47(5):468-9.

Cardiac Electrophysiology Clinics 2015;7(4):749-54.

Raw IF: 5.053 Normalized IF: 3

Raw IF: 0 Normalized IF: 0

Clinical Research

Gasparini M°, Klersy C, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, Boriani G, Proclemer A, Leyva F.

Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: the VALID-CRT risk score.

European Journal of Heart Failure 2015;17(7):717-24.

Raw IF: 6.526 Normalized IF: 6 Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M.

Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer.

Europace 2015;17(8):1251-8.

Raw IF: 3.67 Normalized IF: 4 Landolina M, Lunati M, Boriani G, Ricci RP, Proclemer A, Facchin D, Rordorf R, Morani G, Maines M, Gasparini G, Molon G, Turrini P, Gasparini M; ClinicalService cardiological centres.

Ventricular antitachycardia pacing therapy in heart failure patients with cardiac resynchronization therapy defibrillators: efficacy, safety and impact on mortality.

Heart Rhythm 2016;13(2):472-80.

Raw IF: 5.076 Normalized IF: 6 Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Mark Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S; Document Reviewers.

2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal Implantable Cardioverter-Defibrillator programming and testing: developed in partnership with and endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)Latin American Society of Cardiac Pacing and Electrophysiology. Endorsed by the American College of Cardiology (ACC) and American Heart Association (AHA).

Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, AlKhatib SM, Almendral J, Aguinaga L, Berger RD, Cuesta A, Daubert JP, Dubner S, Ellenbogen KA, Estes NA 3rd, Fenelon G, Garcia FC, Gasparini M, Haines DE, Healey JS, Hurtwitz JL, Keegan R, Kolb C, Kuck KH, Marinskis G, Martinelli M, McGuire M, Molina LG, Okumura K, Proclemer A, Russo AM, Singh JP, Swerdlow CD, Teo WS, Uribe W, Viskin S, Wang CC, Zhang S.

2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal Implantable Cardioverter-Defibrillator programming and testing.

Heart Rhythm 2016;13(2):e50-86.

Raw IF: 5.076 Normalized IF: 6

emergency medicine Aliberti S, Giuliani F, Ramirez J, Blasi F; DURATION Study Group.

(Collaborator: Voza A).

How to choose the duration of antibiotic therapy in patients with pneumonia.

Current Opinion in Infectious Diseases 2015;28(2):177-84.

Raw IF: 5.006 Normalized IF: 3 Aliberti S, Ramirez J, Cosentini R, Valenti V, Voza A, Rossi P, Stolz D, Legnani D, Pesci A, Richeldi L, Peyrani P, Massari FM, Blasi F.

Acute myocardial infarction versus other cardiovascular events in communityacquired pneumonia.

ERJ Open Research. Epub 2015 Sep 15.

Raw IF: 0 Normalized IF: 0 Podestà MA. Faravelli I, Cucchiari D, Reggiani F, Oldani S, Fedeli C, Graziani G°.

Neurological counterparts of hyponatremia: pathological mechanisms and clinical manifestations.

Current Neurology and Neuroscience Reports 2015;15(4):18.

Raw IF: 3.059 Normalized IF: 4

Emergency Neurology and Stroke Unit Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, Csiba L, Szabó L, Sohn SI, Tassinari T, Abdul-Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, Acciarresi M, D’Amore C, Mosconi MG, Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, Tsivgoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De Lodovici ML, Bono G, Baldi A, D’Anna S, Sacco S, Carolei A, Tiseo C, Imberti D, Zabzuni D, Doronin B, Volodina V, Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, Pallesen LP, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Lees KR.

Prognostic value of trans-thoracic echocardiography in patients with acute stroke and atrial fibrillation: findings from the RAF study.

Journal of Neurology 2016;263(2):231-7.

Raw IF: 3.377 Normalized IF: 6 Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, Csiba L, Szabó L, Sohn SI, Tassinari T, Abdul-Rahim AH, Michel P, Cordier M, Vanacker P, Remillard S, Alberti A, Venti M, Scoditti U, Denti L, Orlandi G, Chiti A, Gialdini G, Bovi P, Carletti M, Rigatelli A, Putaala J, Tatlisumak T, Masotti L, Lorenzini G, Tassi R, Guideri F, Martini G, Tsivgoulis G, Vadikolias K, Liantinioti C, Corea F, Del Sette M, Ageno W, De Lodovici ML, Bono G, Baldi A, D’Anna S, Sacco S, Carolei A, Tiseo C, Acciarresi M, D’Amore C, Imberti D, Zabzuni D, Doronin B, Volodina V, Consoli D, Galati F, Pieroni A, Toni D, Monaco S, Baronello MM, Barlinn K, Pallesen LP, Kepplinger J, Bodechtel U, Gerber J, Deleu D, Melikyan G, Ibrahim F, Akhtar N, Mosconi MG, Bubba V, Silvestri I, Lees KR.

Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study.

Stroke 2015;46(8):2175-82.

Raw IF: 5.723 Normalized IF: 6

Gastroenterology and Digestive Endoscopy Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S°.

Europace. Epub 2015 Nov 19.

Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease.

Raw IF: 3.67 Normalized IF: 4

Journal of Crohn’s & Colitis 2015;9(8):633-9.

Raw IF: 6.234 Normalized IF: 6

75

Papers published 2015

Fiorino G°, Omodei PD.

Psoriasis and inflammatory bowel disease: two faces of the same coin?

Journal of Crohn’s & Colitis 2015;9(9):697-8.

Raw IF: 6.234 Normalized IF: 6 Fumagalli U°, Rosati R, De Pascale S, Porta M, Carlani E, Pestalozza A, Repici A.

Repeated surgical or endoscopic myotomy for recurrent dysphagia in patients after previous myotomy for achalasia.

Journal of Gastrointestinal Surgery 2016;20(3):494-9.

Raw IF: 2.798 Normalized IF: 6 Ghidini M°, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L.

KRAS mutation in lung metastases from colorectal cancer: prognostic implications.

Cancer Medicine 2016;5(2):256-64.

Raw IF: 2.5 Normalized IF: 2 Grizzi F°, Franceschini B, Di Biccari S, Musardo S, Pedretti E, Chiriva-Internati M, Osipov V, Fernández-Aceñero MJ.

Sperm protein 17 and AKAP-associated sperm protein cancer/testis antigens are expressed in ciliated hepatic foregut cysts.

General Anaesthesia and Intensive Care Barbic F°, Heusser K, Marchi A, Zamunér AR, Gauger P, Tank J, Jordan J, Diedrich A, Robertson D, Dipaola F, Achenza S, Porta A, Furlan R.

Cardiovascular parameters and neural sympathetic discharge variability before orthostatic syncope: role of sympathetic baroreflex control to the vessels.

Physiological Measurement 2015;36(4):633-41.

Raw IF: 1.808 Normalized IF: 4 Bugada D, De Gregori M, Compagnone C, Muscoli C, Raimondi F, Bettinelli S, Avanzini MA, Cobianchi L, Peloso A, Baciarello M, Dagostino C, Giancotti LA, Ilari S, Lauro F, Grimaldi S, Tasciotti E, Fini M, Saccani Jotti GM, Meschi T, Fanelli G, Allegri M.

Continuous wound infusion of local anesthetic and steroid after major abdominal surgery: study protocol for a randomized controlled trial.

Trials 2015;16(1):357.

Raw IF: 1.731 Normalized IF: 1 Colombo R, Marchi A, Borghi B, Fossali T, Rech R, Castelli A, Corona A, Guzzetti S, Raimondi F.

Histopathology 2015;67(3):398-403.

Pulse photoplethysmographic analysis estimates the sympathetic activity directed to heart and vessels.

Raw IF: 3.453 Normalized IF: 6

Anesthesiology 2015;123(2):336-45.

Raw IF: 5.879 Normalized IF: 6 Jovani M, Anderloni A, Carrara S, Loriga A, Ciscato C, Ferrara EC, Repici A.

Circumferential endoscopic submucosal dissection of a squamous cell carcinoma in a cirrhotic patient with esophageal varices.

Giustiniano E°, Procopio F, Morenghi E, Rocchi L, Del Fabbro D, Ruggieri N, Zito PC, Donadon M, Torzilli G, Raimondi F.

Gastrointestinal Endoscopy 2015;82(5):963-4.

Does inferior-vena-cava collapsibility correlate with fluid regimen and outcome in patients undergoing liver resection?

Raw IF: 5.369 Normalized IF: 6

Journal of Anesthesia & Clinical Research 2015;6:10.

Raw IF: 0 Normalized IF: 0 Salvioli B°, Pellegatta G, Malacarne M, Pace F, Malesci A, Pagani M, Lucini D.

Autonomic nervous system dysregulation in irritable bowel syndrome.

Neurogastroenterology and Motility 2015;27(3):423-30.

Raw IF: 3.587 Normalized IF: 6

Giustiniano E°, Ruggieri N.

A deceptive color-doppler image after endovascular aorta repairing.

Symbiosis Open Journal of Anesthesiology & Pain Management 2015;2(1):1-3.

Raw IF: 0 Normalized IF: 0 Strangio G, Zullo A, Ferrara EC, Anderloni A, Carlino A, Jovani M, Ciscato C, Hassan C, Repici A.

Endo-sponge therapy for management of anastomotic leakages after colorectal surgery: A case series and review of literature.

Digestive and Liver Disease 2015;47(6):465-9.

76

Raw IF: 2.963 Normalized IF: 4

Giustiniano E°, Ruggieri N, Meco M.

Renal resistive index: a tool for postoperative Intensive Care Unitoutcome? A pilot observational study.

Journal of Anesthesia & Critical Care: Open Access 2015;2(5):67.

Raw IF: 0 Normalized IF: 0

Porta A, Bari V, Marchi A, De Maria B, Cysarz D, Van Leeuwen P, Takahashi AC, Catai AM, Gnecchi-Ruscone T.

Complexity analyses show two distinct types of nonlinear dynamics in short heart period variability recordings.

Frontiers in Physiology 2015;6:71.

Raw IF: 3.534 Normalized IF: 3 Porta A, Faes L, Marchi A, Bari V, De Maria B, Guzzetti S, Colombo R, Raimondi F.

Disentangling cardiovascular control mechanisms during head-down tilt via joint transfer entropy and self-entropy decompositions.

Frontiers in Physiology 2015;6:301.

Raw IF: 3.534 Normalized IF: 6 Porta A, Marchi A, Bari V, Heusser K, Tank J, Jordan J, Barbic F, Furlan R.

Conditional symbolic analysis detects nonlinear influences of respiration on cardiovascular control in humans.

Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences 2015;373(2034):pii: 20140096.

Raw IF: 2.147 Normalized IF: 6 Zamunér AR, Barbic F, Dipaola F, Bulgheroni M, Diana A, Atzeni F, Marchi A, Sarzi-Puttini P, Porta A, Furlan R.

Relationship between sympathetic activity and pain intensity in fibromyalgia.

Clinical and Experimental Rheumatology 2015;33(1 s88):53-7.

Raw IF: 2.724 Normalized IF: 4

General Anaesthesia and day hospital Provinciali L, Lattanzi S, Chiarlone R, Fogliardi A, Intelligente F, Irace C, Lanzilotta M, Palomba R, Storelli E, Zampi M.

Topical pharmacologic approach with 5% lidocaine medicated plaster in the treatment of localized neuropathic pain.

Minerva Medica 2014;105(6):515-27.

Raw IF: 0.913 Normalized IF: 1

Clinical Research

General and Minimally Invasive Surgery

General and Oncologic Surgery

Barbieri LA°, Hassan C, Rosati R, Fumagalli Romario U, Correale L, Repici A.

Biondi A, D’Ugo D, Cananzi FC, Papa V, Borasi A, Sicoli F, Degiuli M, Doglietto G, Persiani R.

Systematic review and meta-analysis: efficacy and safety of POEM for achalasia.

Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?

United European Gastroenterology Journal 2015;3(4):325-34.

Raw IF: 2.08 Normalized IF: 2

EJSO - European Journal of Surgical Oncology 2015;41(6):779-86.

Raw IF: 3.009 Normalized IF: 3 Elmore U, Fumagalli Romario U, Vignali A, Sosa MF, Angiolini MR, Rosati R.

Laparoscopic anterior resection with transanal total mesorectal excision for rectal cancer: preliminary experience and impact on postoperative bowel function.

Journal of Laparoendoscopic & Advanced Surgical Techniques 2015;25(5):364-9.

Raw IF: 1.335 Normalized IF: 2 Fumagalli U°, Rosati R, De Pascale S, Porta M, Carlani E, Pestalozza A, Repici A.

Repeated surgical or endoscopic myotomy for recurrent dysphagia in patients after previous myotomy for achalasia.

Journal of Gastrointestinal Surgery 2016;20(3):494-9.

Raw IF: 2.798 Normalized IF: 6 Moonen A, Annese V, Belmans A, Bredenoord AJ, Bruley des Varannes S, Costantini M, Dousset B, Elizalde JI, Fumagalli U, Gaudric M, Merla A, Smout AJ, Tack J, Zaninotto G, Busch OR, Boeckxstaens GE.

Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.

Gut. Epub 2015 Nov 27.

Raw IF: 14.66 Normalized IF: 10 Tozzi A°, Iftode C, Cozzi L, Ascolese AM, Battista S, Cavina R, Clerici E, Comito T, D’Agostino GR, DE Rose F, Franzese C, Garassino I, Fumagalli Romario U, Navarria P, Rosati R, Spaggiari P, Tomatis S, Scorsetti M.

Neoadjuvant chemoradiotherapy with volumetric-modulated arc therapy for medium-distal oesophageal and gastrooesophageal junction carcinoma.

Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R.

Neo-adjuvant chemo(radio)therapy in gastric cancer: current status and future perspectives.

World Journal of Gastrointestinal Oncology 2015;7(12):389-400.

Raw IF: 0 Normalized IF: 0 De Pasquale L, Sartori PV, Vicentini L, Beretta E, Boniardi M, Leopaldi E, Gini P, La Manna L, Cozzaglio L, Steffano GB, Andreani S, Badiali S, Cantoni GM, Galimberti A, Ghilardi G, Gusmeroli M, Maggiore R, Morenghi E, Pauna J, Poggi L, Testa V.

Necessity of therapy for postthyroidectomy hypocalcaemia: a multicentre experience.

Langenbeck’s Archives of Surgery 2015;400(3):31924.

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG, Gronchi A.

Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide.

Journal of Clinical Oncology. Epub 2015 Sep 8.

Raw IF: 18.428 Normalized IF: 15 Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, Cozzaglio L, Pedrazzani C, Berardi S, Baiocchi GL, Roviello F, Portolani N, de Manzoni G, Costamagna G, Doglietto GB, Pacelli F.

Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter Western experience.

World Journal of Surgery. Epub 2015 Nov 9.

Raw IF: 2.642 Normalized IF: 6

General Medicine and Hepatology Boccaccio V°, Russo ML, Carbone M, Bruno S.

Raw IF: 2.191 Normalized IF: 4

Treatment discontinuation with peginterferon: what to consider.

De Sanctis R°, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio P, Bastoni S, Bertuzzi AF, Quagliuolo V, Santoro A.

Expert Review of Clinical Pharmacology 2015;8(6):761-8.

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.

Drug Design, Development and Therapy 2015;9 :5785-91.

Raw IF: 3.028 Normalized IF: 4

Raw IF: 2.18 Normalized IF: 2 Lleo A*, Zhang W*, Zhao M*, Tan Y, Bernuzzi F, Zhu B, Liu Q, Tan Q, Malinverno F, Valenti L, Jiang T, Tan L, Liao W, Coppel R, Invernizzi P#, Lu Q#, Adams DH, Gershwin ME#; PBC Epigenetic Study Group.

(Collaborators: Bianchi I, Ceriani R, Mascia E, Mascheroni C, Podda M, Traiani F).

Navarria P, Ascolese AM, Cozzi L°, Tomatis S, D’Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M.

DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis.

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.

Clinical Epigenetics 2015;7(1):61.

Anticancer Research 2015;35(7):4109-16.

European Journal of Cancer 2015;51(5):668-74.

Raw IF: 1.826 Normalized IF: 2

Raw IF: 5.417 Normalized IF: 6

Raw IF: 4.543 Normalized IF: 6

77

Papers published 2015

Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6 Scorsetti M°, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D’Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G.

The challenge of inoperable hepatocellular carcinoma (HCC): results of a singleinstitutional experience on stereotactic body radiation therapy (SBRT).

Journal of Cancer Research and Clinical Oncology 2015;141(7):1301-9.

Raw IF: 3.081 Normalized IF: 4

General Medicine and Pneumology Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10

General Surgery; Liver Surgery de Groof EJ, Buskens CJ, Ponsioen CY, Dijkgraaf MG, D’Haens GR, Srivastava N, van Acker GJ, Jansen JM, Gerhards MF, Dijkstra G, Lange JF, Witteman BJ, Kruyt PM, Pronk A, van Tuyl SA, Bodelier A, Crolla RM, West RL, Vrijland WW, Consten EC, Brink MA, Tuynman JB, de Boer NK, Breukink SO, Pierik MJ, Oldenburg B, van der Meulen AE, Bonsing BA, Spinelli A, Danese S, Sacchi M, Warusavitarne J, Hart A, Yassin NA, Kennelly RP, Cullen GJ, Winter DC, Hawthorne AB, Torkington J, Bemelman WA.

Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial.

Giustiniano E°, Procopio F, Morenghi E, Rocchi L, Del Fabbro D, Ruggieri N, Zito PC, Donadon M, Torzilli G, Raimondi F.

Does inferior-vena-cava collapsibility correlate with fluid regimen and outcome in patients undergoing liver resection?

Journal of Anesthesia & Clinical Research 2015;6:10.

Raw IF: 0 Normalized IF: 0 Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, Lugli E, Torzilli G, Gershwin M E, Mavilio D°.

Trials 2015;16(1):366.

Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.

Raw IF: 1.731 Normalized IF: 2

Journal of Autoimmunity 2016;66:40-50.

Raw IF: 8.41 Normalized IF: 8 De Nes LC°, Montorsi M, Spinelli A.

Double single-port procedure for transanal intersphincteric proctectomy and abdominal ileorectal anastomosis: video vignette.

Colorectal Disease 2016;18(2):217-8.

Italian Association for the Study of the Pancreas (AISP), Pezzilli R, Zerbi A, Campra D, Capurso G, Golfieri R, Arcidiacono PG, Billi P, Butturini G, Calculli L, Cannizzaro R, Carrara S, Crippa S, De Gaudio R, De Rai P, Frulloni L, Mazza E, Mutignani M, Pagano N, Rabitti P, Balzano G.

Raw IF: 2.351 Normalized IF: 2

Consensus guidelines on severe acute pancreatitis.

De Nes LC°, Spinelli A, Bacchelli C, Montorsi M.

Digestive and Liver Disease 2015;47(7):532-43.

Single port laparoscopic Hartmann reversal through the stoma site: video vignette.

Raw IF: 2.963 Normalized IF: 4

Colorectal Disease 2016;18(2):215.

Raw IF: 2.351 Normalized IF: 2 Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F°.

Dual prognostic significance of tumourassociated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Gut. Epub 2015 Jul 8.

Raw IF: 14.66 Normalized IF: 10 Donadon M°, Costa G, Cimino M, Procopio F, Del Fabbro D, Palmisano A, Torzilli G.

Diagnosis and management of bile leaks after hepatectomy: results of a prospective analysis of 475 hepatectomies.

World Journal of Surgery. Epub 2015 Jul 7.

Raw IF: 2.642 Normalized IF: 6

Jais B, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, Bassi C, Manfredi R, Moran R, Lennon AM, Zaheer A, Wolfgang C, Hruban R, Marchegiani G, Fernández Del Castillo C, Brugge W, Ha Y, Kim MH, Oh D, Hirai I, Kimura W, Jang JY, Kim SW, Jung W, Kang H, Song SY, Kang CM, Lee WJ, Crippa S, Falconi M, Gomatos I, Neoptelomos J, Milanetto AC, Sperti C, Ricci C, Casadei R, Bissolati M, Balzano G, Frigerio I, Girelli R, Delhaye M, Bernier B, Wang H, Jang KT, Song DH, Huggett MT, Oppong KW, Pererva L, Kopchak KV, Del Chiaro M, Segersvard R, Lee LS, Conwell D, Osvaldt A, Campos V, Aguero Garcete G, Napoleon B, Matsumoto I, Shinzeki M, Bolado F, Fernandez JM, Keane MG, Pereira SP, Acuna IA, Vaquero EC, Angiolini MR, Zerbi A, Tang J, Leong RW, Faccinetto A, Morana G, Petrone MC, Arcidiacono PG, Moon JH, Choi HJ, Gill RS, Pavey D, Ouaïssi M, Sastre B, Spandre M, De Angelis CG, Rios-Vives MA, Concepcion-Martin M, Ikeura T, Okazaki K, Frulloni L, Messina O, Lévy P.

Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas).

Gut 2016;65(2):305-12.

Raw IF: 14.66 Normalized IF: 10

78

Clinical Research

Kotze PG, Spinelli A, da Silva RN, de Barcelos IF, Teixeira FV, Saad-Hossne R, de Albuquerque IC, Olandoski M, da Silva Kotze LM, Suzuki Y, Yamada A, Takeuchi K, Sacchi M, Yamamoto T.

Sciarra A, Di Tommaso L, Nakano M, Destro A, Torzilli G, Donadon M, Maggioni M, Bosari S, Bulfamante G, Matsuda M, Fujii H, Ichikawa T, Morisaka H, Sano K, Ichikawa S, Roncalli M°.

Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn’s Disease: an International, Multicenter, and Observational Study.

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications.

Intestinal Research 2015;13(3):259-265.

Raw IF: 0 Normalized IF: 0 Kotze PG, Yamamoto T, Danese S, Suzuki Y, Teixeira FV, de Albuquerque IC, Saad-Hossne R, de Barcelos IF, da Silva RN, Kotze LM, Olandoski M, Sacchi M, Yamada A, Takeuchi K, Spinelli A.

Conventional versus biological therapy for prevention of postoperative endoscopic recurrence in patients with Crohn's disease: an international, multicenter, and observational study.

Journal of Crohn’s & Colitis 2015;9(7):541-7.

Raw IF: 6.234 Normalized IF: 6 Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Journal of Hepatology 2016;64(1):87-93.

Raw IF: 11.336 Normalized IF: 8

Annals of Surgery 2015;262(1):e30-1.

The challenge of inoperable hepatocellular carcinoma (HCC): results of a singleinstitutional experience on stereotactic body radiation therapy (SBRT).

Viganò L, Birnbaum DJ.

Journal of Cancer Research and Clinical Oncology 2015;141(7):1301-9.

Raw IF: 3.081 Normalized IF: 4

Raw IF: 2.365 Normalized IF: 2 Russolillo N, Viganò L, Razzore P, Langella S, Motta M, Bertuzzo F, Papotti M, Ferrero A.

Survival prognostic factors of gastroenteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastroenteric and pancreatic locations.

EJSO - European Journal of Surgical Oncology 2015;41(6):751-7.

Raw IF: 3.009 Normalized IF: 6

EJSO - European Journal of Surgical Oncology 2015;41(10):1444-5.

Raw IF: 3.009 Normalized IF: 3

Anal fistula plug for perianal fistulising Crohn's disease: an important trial for Inflammatory Bowel Disease surgeons..

Liver resection in patients with eight or more colorectal liver metastases.

Journal of Crohn’s & Colitis 2016;10(2):125-6.

Minimally invasive colorectal surgery: do we all speak the same language?

BMC Gastroenterology 2015;15(1):76.

Reply to: “Gallbladder cancer: nihilism abates, optimism prevails”.

Viganò L°, Capussotti L, Majno P, Toso C, Ferrero A, De Rosa G, Rubbia-Brandt L, Mentha G.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Laparoscopic colonic resection for splenic flexure cancer: our experience.

Raw IF: 8.327 Normalized IF: 4

Spinelli A°, Kotze PG.

Raw IF: 6.234 Normalized IF: 6

Pisani Ceretti A, Maroni N, Sacchi M, Bona S, Angiolini MR, Bianchi P, Opocher E, Montorsi M.

Reply to letter: “A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West Study Group”: when the study setting “ignores” the patients.

Scorsetti M°, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D’Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

Raw IF: 5.383 Normalized IF: 6

Torzilli G°, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Makuuchi M.

Spinelli A, Montroni I.

British Journal of Surgery 2015;102(1):92-101.

Raw IF: 5.542 Normalized IF: 6 Viganò L°, Conci S, Cescon M, Fava C, Capelli P, D’Errico A, Torzilli G, Tommaso LD, Giuliante F, Vecchio FM, Salizzoni M, David E, Pinna AD, Guglielmi A, Capussotti L.

Raw IF: 2.351 Normalized IF: 4

Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC.

Tacconi C, Correale C, Gandelli A, Spinelli A, Dejana E, D’Alessio S°, Danese S°.

Journal of Hepatology 2015;63(1):93-101.

Colorectal Disease 2015;17(10):837-8.

Vascular Endothelial Growth Factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.

Gastroenterology 2015;148(7):1438-51.e8.

Raw IF: 16.716 Normalized IF: 15 Torzilli G°, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Makuuchi M.

Reply to Letter: “Dissecting EASL/ AASLD recommendations with a more careful knife: a comment on ‘surgical misinterpretation’ of the BCLC staging system”: real misinterpretation or lack of clarity within the BCLC? Annals of Surgery 2015;262(1):e18-9.

Raw IF: 8.327 Normalized IF: 4

Raw IF: 11.336 Normalized IF: 8 Viganò L, Costa G, Procopio F, Donadon M, Cimino M, Del Fabbro D, Gatti A, Torzilli G°.

Parenchyma-sparing liver surgery for large segment 1 tumors: ultrasoundguided lateral and superior approaches as safe alternatives to major hepatectomy.

Journal of the American College of Surgeons 2015;221(4):e65-73.

Raw IF: 5.122 Normalized IF: 6 Vitali E, Cambiaghi V, Spada A, Tresoldi A, Zerbi A, Peverelli E, Carnaghi C, Mantovani G, Lania AG°.

cAMP effects in neuroendocrine tumors: the role of Epac and PKA in cell proliferation and adhesion.

Experimental Cell Research 2015;339(2):241-51.

Raw IF: 3.246 Normalized IF: 4

79

Papers published 2015

Yeung TM, Sacchi M, Mortensen NJ*, Spinelli A*.

Assessment of the quality of patientorientated information on surgery for Crohn’s disease on the internet.

Diseases of the Colon and Rectum 2015;58(9):857-61.

Raw IF: 3.749 Normalized IF: 6 Zerbi A°, Capretti G.

Levi Setti PE°, Borini A, Patrizio P, Bolli S, Vigiliano V, De Luca R, Scaravelli G.

ART results with frozen oocytes: data from the Italian ART registry (2005-2013).

Journal of Assisted Reproduction and Genetics 2016;33(1):123-8.

Raw IF: 1.718 Normalized IF: 2

Commentary to paper “Primary versus secondary delayed gastric emptying (DGE) grades B and C of the International Study Group of Pancreatic Surgery after pancreatoduodenectomy: a retrospective analysis on a group of 132 patients”.

Patrizio P, Vaiarelli A, Levi Setti PE, Tobler KJ, Shoham G, Leong M, Shoham Z.

Updates in Surgery 2015;67(3):311-2.

Raw IF: 3.015 Normalized IF: 3

How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics.

Reproductive BioMedicine Online 2015;30(6):581-92.

Raw IF: 0 Normalized IF: 0

ginaecology

Leone Roberti Maggiore U, Bizzarri N, Scala C, Tafi E, Siesto G, Alessandri F, Ferrero S.

Symptomatic endometriosis of the posterior cul-de-sac is associated with impaired sleep quality, excessive daytime sleepiness and insomnia: a case-control study.

European Journal of Obstetrics & Gynecology and Reproductive Biology. Epub 2015 Nov 29.

Raw IF: 1.695 Normalized IF: 1

Haemodynamics, Invasive Cardiology and Coronary Care Achilli F, Malafronte C, Cesana F, Maggiolini S, Mauro C, De Ferrari GM, Lenatti L, Tespili M, Pasqualini P, Gentile F, Capogrossi MC, Maggioni A, Maseri A, Pontone G, Colombo GI, Pompilio G; STEM-AMI OUTCOME Trial Investigators.

(Collaborators: Lettino M., Pagnotta PA).

Granulocyte-colony stimulating factor for large anterior ST-elevation myocardial infarction: rationale and design of the prospective randomized phase III STEMAMI OUTCOME trial.

American Heart Journal 2015;170(4):652-658.e7.

Gynaecology and Reproductive Medicine Delle Piane L, Rinaudo PF, Miller WL.

150 years of congenital adrenal hyperplasia: translation and commentary of De Crecchio’s classic paper from 1865.

Endocrinology 2015;156(4):1210-7.

Raw IF: 4.503 Normalized IF: 6 Di Rosa A, Albani E, Morenghi E, Iommiello VM, Levi Setti PE°.

A new method to assess oxidative stress in ART cycles.

Gynecological Endocrinology 2016;32(3):210-2.

Raw IF: 1.333 Normalized IF: 1 Iommiello VM°, Albani E, Di Rosa A, Marras A, Menduni F, Morreale G, Levi SL, Pisano B, Levi Setti PE.

80

Raw IF: 4.463 Normalized IF: 1.2 Attizzani GF, Ohno Y, Latib A, Petronio AS, De Carlo M, Giannini C, Ettori F, Curello S, Fiorina C, Bedogni F, Testa L, Bruschi G, De Marco F, Presbitero P, Rossi ML, Boschetti C, Picarelli S, Poli A, Barbanti M, Martina P, Colombo A, Tamburino C.

Transcatheter aortic valve implantation under angiographic guidance with and without adjunctive transesophageal echocardiography.

American Journal of Cardiology 2015;116(4):604-11.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

(Collaborators: Presbitero P, Di Pizzo A).

Long-term use of ticagrelor in patients with prior myocardial infarction.

New England Journal of Medicine 2015;372(19):1791-800.

Raw IF: 55.873 Normalized IF: 3 Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

(Collaborators: Presbitero P, Rossi ML).

Ezetimibe added to statin therapy after acute coronary syndromes.

New England Journal of Medicine 2015;372(25):2387-97.

Raw IF: 55.873 Normalized IF: 3 Capranzano P, Kunadian V, Mauri J, Petronio AS, Salvatella N, Appelman Y, Gilard M, Mikhail GW, Schüpke S, Radu MD, Vaquerizo B, Presbitero P, Morice MC, Mehilli J.

Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey.

EuroIntervention 2016;12(1):53-9.

Raw IF: 3.769 Normalized IF: 3 Conrotto F, D’Ascenzo F, Presbitero P, Humphries KH, Webb JG, O’Connor SA, Morice MC, Lefèvre T, Grasso C, Sbarra P, Taha S, Omedè P, Grosso Marra W, Salizzoni S, Moretti C, D’Amico M, Biondi-Zoccai G, Gaita F, Marra S.

Effect of gender after transcatheter aortic valve implantation: a meta-analysis.

Annals of Thoracic Surgery 2015;99(3):809-16.

Raw IF: 3.849 Normalized IF: 3

Raw IF: 3.276 Normalized IF: 4 Avanzini F, Mafrici A, Riva E, Franzosi MG, Milani V, Giudici V, Marelli G, Mariani G, Piatti PM, Roncaglioni MC; GLICINE-SPIDER Collaborative Group.

(Collaborators: Presbitero P, Corrada E, Llazo O).

Ejaculate oxidative stress is related with sperm DNA fragmentation and round cells.

A multicenter observational study on the management of hyperglycemia in patients with acute coronary syndrome.

International Journal of Endocrinology 2015;2015:321901.

Nutrition Metabolism and Cardiovascular Diseases 2015;25(10):916-23.

Raw IF: 1.948 Normalized IF: 2

Raw IF: 3.323 Normalized IF: 1.2

Cortese B, Aranzulla TC, Godino C, Chizzola G, Zavalloni D, Tavasci E, De Benedictis M, Ettori F, Presbitero P, Colombo A.

Drug-eluting stent use after coronary atherectomy: results from a multicentre experience - The ROTALINK I study.

Journal of Cardiovascular Medicine. Epub 2015 Jan 7.

Raw IF: 1.51 Normalized IF: 1

Clinical Research

Covolo E, Saia F, Napodano M, Frigo AC, Agostoni P, Mojoli M, Fraccaro C, Ciuca C, Presbitero P, Moretti C, D’Ascenzo F, Tarantini G.

Comparison of balloon-expandable versus self-expandable valves for transcatheter aortic valve implantation in patients with low-gradient severe aortic stenosis and preserved left ventricular ejection fraction.

American Journal of Cardiology 2015;115(6):810-5.

Raw IF: 3.276 Normalized IF: 4 D’Ascenzo F, Conrotto F, Salizzoni S, Rossi ML, Nijhoff F, Gasparetto V, Barbanti M, Mennuni M, Omedè P, Grosso Marra W, Quadri G, Giordana F, Tamburino C, Tarantini G, Presbitero P, Napodanno M, Stella P, Biondi-Zoccai G, Agostoni P, D’Amico M, Moretti C, Rinaldi M, Marra S, Gaita F.

Incidence, predictors, and impact on prognosis of systolic pulmonary artery pressure and its improvement after transcatheter aortic valve implantation: a multicenter registry.

Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R.

Mennuni MG, Zavalloni D, Presbitero P°.

Impact of clinical presentation (stable angina pectoris vs unstable angina pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on long-term outcomes in women undergoing percutaneous coronary intervention with drug-eluting stents.

Moretti C, D’Ascenzo F, Mennuni M, Taha S, Brambilla N, Nijhoff F, Fraccaro C, Barbanti M, Tamburino C, Tarantini G, Rossi ML, Presbitero P, Napodanno M, Stella P, Bedogni F, Omedè P, Conrotto F, Montefusco A, Giordana F, Biondi Zoccai G, Agostoni P, D’Amico M, Rinaldi M, Marra S, Gaita F.

American Journal of Cardiology 2015;116(6):845-52.

Raw IF: 3.276 Normalized IF: 4 Latib A, Ruparelia N, Menozzi A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Sgueglia GA, Buffoli F, Tamburino C, Varbella F, Colombo A.

3-year follow-up of the Balloon Elution and Late Loss Optimization Study (BELLO).

Journal of Invasive Cardiology 2015;27(2):114-9.

JACC. Cardiovascular Interventions 2015;8(8):1132-4.

Raw IF: 0.949 Normalized IF: 1

Raw IF: 7.245 Normalized IF: 4

de Donato G, Setacci C, Umemoto T, Reimers B.

Lettieri C, Zavalloni D, Rossini R, Morici N, Ettori F, Leonzi O, Latib A, Ferlini M, Trabattoni D, Colombo P, Galli M, Tarantini G, Napodano M, Piccaluga E, Passamonti E, Sganzerla P, Ielasi A, Coccato M, Martinoni A, Musumeci G, Zanini R, Castiglioni B.

Commentary: inside of the interaction between the plaque and the stent: optical coherence tomography during carotid artery stenting.

Journal of Endovascular Therapy 2015;22(6):950-1.

Raw IF: 3.353 Normalized IF: 6

Management and long-term prognosis of spontaneous coronary artery dissection.

American Journal of Cardiology 2015;116(1):66-73.

Ferrante G°, Valgimigli M, Pagnotta P, Presbitero P.

Bivalirudin versus heparin in patients with acute myocardial infarction: a metaanalysis of randomized trials.

Catheterization and Cardiovascular Interventions 2015;86(3):378-89.

Raw IF: 2.107 Normalized IF: 4 Gasparini GL, Milone F, Oreglia JA, Presbitero P.

Effective recanalization of a double chronic total occlusion by two retrograde approaches.

Giornale Italiano di Cardiologia 2015;16(2):108-11.

Raw IF: 0 Normalized IF: 0 Gasparini GL°, Oreglia JA, Milone F, Presbitero P.

Avoid overtreatment in the setting of chronic total occlusions: the role of blood flow restoration in positive vascular remodeling.

International Journal of Cardiology 2015;184C:41415.

Raw IF: 4.036 Normalized IF: 3

Role, risk and benefit of interventional cardiology procedures during pregnancy.

Interventional Cardiology 2015;7(2):191-8.

Raw IF: 0 Normalized IF: 0

Meta-analysis of comparison between self-expandable and balloon-expandable valves for patients having transcatheter aortic valve implantation.

American Journal of Cardiology 2015;115(12):1720-5.

Raw IF: 3.276 Normalized IF: 4 Naganuma T, Latib A, Sgueglia GA, Menozzi A, Castriota F, Micari A, Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P, Panoulas VF, Buffoli F, Tamburino C, Varbella F, Colombo A.

A 2-year follow-up of a randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxeleluting stent in small coronary vessels the BELLO study.

International Journal of Cardiology 2015;184C:17-21.

Raw IF: 4.036 Normalized IF: 6 Pagnotta P, Mennuni MG°, Ferrante G, Ornaghi D, Bragato R, Cappai A, Presbitero P.

Raw IF: 3.276 Normalized IF: 4

A hybrid double access for transcatheter mitral valve-in-valve implantation.

Mennuni MG, Halperin JL, Bansilal S, Schoos MM, Theodoropoulos KN, Meelu OA, Sartori S, Giacoppo D, Bernelli C, Moreno PR, Krishnan P, Baber U, Lucarelli C, Dangas GD, Sharma SK, Kini AS, Tamburino C, Chieffo A, Colombo A, Presbitero P, Mehran R.

Annals of Thoracic Surgery 2015;99(6):e149-50.

Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR Registry).

Paravalvular leak leading to severe aortic valve regurgitation after TAVI: percutaneous closure strategy.

American Journal of Cardiology 2015;116(1):37-42.

Raw IF: 3.276 Normalized IF: 4 Mennuni MG, Pagnotta PA, Stefanini GG°.

Coronary stents: the impact of technological advances on clinical outcomes.

Annals of Biomedical Engineering. Epub 2015 Aug 12.

Raw IF: 3.195 Normalized IF: 6

Raw IF: 3.849 Normalized IF: 6 Rossi ML°, Belli G, Pagnotta P, Lucarelli C, Presbitero P.

Heart, Lung & Circulation 2015;24(9):936-9.

Raw IF: 1.438 Normalized IF: 2 Scacciatella P, Meynet I, Presbitero P, Giorgi M, Lucarelli C, Zavalloni Parenti D, Biava LM, Marra S.

Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: A two-center registry study.

Catheterization and Cardiovascular Interventions.

Epub 2015 Jun 23.

Raw IF: 2.107 Normalized IF: 1

81

Papers published 2015

Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Jüni P, Windecker S.

Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.

Lancet 2015;386(9994):655-64.

Raw IF: 45.217 Normalized IF: 15 Stefanini GG, Kolh P.

Structure and functioning of the Heart Team: primum non nocere.

European Journal of Cardio-Thoracic Surgery 2015;48(4):529-30.

Raw IF: 3.304 Normalized IF: 6 Stefanini GG, Meier B.

An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use?

Interventional Cardiology 2015;7(5):191-8.

Raw IF: 0 Normalized IF: 0 Stefanini GG°, Panico C.

CAD in TAVI patients: relevance of disease complexity.

EuroIntervention 2015;11(4):373-5.

Raw IF: 3.769 Normalized IF: 6 Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P; MATRIX Investigators.

(Collaborator: Zavalloni Parenti D).

Bivalirudin or unfractionated heparin in acute coronary syndromes.

New England Journal of Medicine 2015;373(11):9971009.

Raw IF: 55.873 Normalized IF: 15 Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P; MATRIX Investigators.

(Collaborator: Zavalloni Parenti D).

Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.

82

Lancet 2015;385(9986):2465-76.

Raw IF: 45.217 Normalized IF: 15

Hip and Knee Prosthetic Surgery Baldini A, Castellani L, Traverso F, Balatri A, Balato G, Franceschini V.

The difficult primary total knee arthroplasty: a review.

The Bone & Joint Journal 2015;97-B(10 supplA):30-9.

Raw IF: 1.961 Normalized IF: 2 Grappiolo G, Loppini M, Longo UG, Traverso F, Mazziotta G, Denaro V.

Trabecular metal augments for the management of Paprosky type III defects without pelvic discontinuity.

internal medicine Barbic F°, Heusser K, Marchi A, Zamunér AR, Gauger P, Tank J, Jordan J, Diedrich A, Robertson D, Dipaola F, Achenza S, Porta A, Furlan R.

Cardiovascular parameters and neural sympathetic discharge variability before orthostatic syncope: role of sympathetic baroreflex control to the vessels.

Physiological Measurement 2015;36(4):633-41.

Raw IF: 1.808 Normalized IF: 4 Boccaccio V°, Russo ML, Carbone M, Bruno S.

Treatment discontinuation with peginterferon: what to consider.

Journal of Arthroplasty. Epub 2013 Jan 10.

Expert Review of Clinical Pharmacology 2015;8(6):761-8.

Raw IF: 2.666 Normalized IF: 6

Raw IF: 2.18 Normalized IF: 2

Palagano E, Blair HC, Pangrazio A, Tourkova I, Strina D, Angius A, Cuccuru G, Oppo M, Uva P, Van Hul W, Boudin E, Superti-Furga A, Faletra F, Nocerino A, Ferrari MC, Grappiolo G, Monari M, Montanelli A, Vezzoni P, Villa A, Sobacchi C°.

Bruno S°, Sewpaul P, Russo ML, Boccaccio V, Almasio PL, Giannini EG.

Buried in the middle, but guilty: intronic mutations in the TCIRG1 gene cause human autosomal recessive osteopetrosis.

Journal of Bone and Mineral Research 2015;30(10):1814-21.

Raw IF: 6.832 Normalized IF: 6 Rajakulendran K, Strambi F, Ruggeri R, Field RE.

A cannulated tri-tapered femoral stem for total hip arthroplasty: clinical and radiological results at ten years.

Journal of Arthroplasty. Epub 2015 Apr 24.

Raw IF: 2.666 Normalized IF: 3 Scardino M°, Grappiolo G, Gurgone A, Mazziotta G, Astore F, Ferrari M.

Single-shot epidural-spinal anesthesia followed by oral oxycodone/naloxone and ketoprofen combination in patients undergoing total hip replacement: analgesic efficacy and tolerability.

Minerva Anestesiologica 2015;81(1):19-27.

Raw IF: 2.134 Normalized IF: 4

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: a post hoc analysis of eltrombopag studies.

Digestive and Liver Disease 2015;47(10):864-8.

Raw IF: 2.963 Normalized IF: 4 Cantarini L*, Vitale A*, Bersani G, Nieves LM, Cattalini M, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Galeazzi M, Ceribelli A, Brunetta E, Selmi C*, Rigante D*.

PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.

Clinical Rheumatology 2016;35(2):501-5.

Raw IF: 1.696 Normalized IF: 2 Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC, Floyd JA, Morley KI, Prati D, Lleo A, Cusi D; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium, Gershwin ME, Anderson CA, Lazaridis KN, Invernizzi P, Seldin MF, Sandford RN*, Amos CI*, Siminovitch KA*.

(Collaborators: Bernuzzi F, Bianchi I, Bruno S, Podda M, Ronca V, Rossi S, Sogno I).

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and highlights pathogenic pathways for drug targeting.

Nature Communications 2015;6:8019.

Raw IF: 11.47 Normalized IF: 8

Clinical Research

Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators.

(Collaborators: Podda M, Selmi C, Meda F).

Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.

Marchi A, Bari V, De Maria B, Cerutti S, Heusser K, Tank J, Jordan J, Barbic F, Furlan R, Porta A.

Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, Pasina L, Franchi C, Kamal Eldin T, Marengoni A, Salerno F, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators.

(Collaborators: Podda M, Selmi C, Meda F).

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

Conditional symbolic analysis detects nonlinear influences of respiration on cardiovascular control in humans.

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

Journal of Antimicrobial Chemotherapy. Epub 2015 Dec 17.

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.

European Journal of Internal Medicine 2015;26(4):243-9.

Raw IF: 2.891 Normalized IF: 1.2

European Journal of Internal Medicine 2014;25(7):617-23.

Raw IF: 2.891 Normalized IF: 1.2 Costantino G, Sun BC, Barbic F, Bossi I, Casazza G, Dipaola F, McDermott D, Quinn J, Reed MJ, Sheldon RS, Solbiati M, Thiruganasambandamoorthy V, Beach D, Bodemer N, Brignole M, Casagranda I, Del Rosso A, Duca P, Falavigna G, Grossman SA, Ippoliti R, Krahn AD, Montano N, Morillo CA, Olshansky B, Raj SR, Ruwald MH, Sarasin FP, Shen WK, Stiell I, Ungar A, Gert van Dijk J, van Dijk N, Wieling W, Furlan R.

Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department.

European Heart Journal. Epub 2015 Aug 4.

Raw IF: 15.203 Normalized IF: 15 Cozzolino D, Grandone A, Cittadini A, Palmiero G, Esposito G, De Bellis A, Furlan R, Perrotta S, Perrone L, Torella D, Miraglia Del Giudice E.

Subclinical myocardial dysfunction and cardiac autonomic dysregulation are closely associated in obese children and adolescents: the potential role of insulin resistance.

PLoS One 2015;10(4):e0123916.

Raw IF: 3.234 Normalized IF: 3

Raw IF: 5.313 Normalized IF: 6 Kenny RA, Brignole M, Dan GA, Deharo JC, van Dijk JG, Doherty C, Hamdan M, Moya A, Parry SW, Sutton R, Ungar A, Wieling W; External contributors to the Task Force:, Asgari M, BaronEsquivias G, Blanc JJ, Casagranda I, Cunnigham C, Fedorowski A, Furlan R, Gall N, De Lange FJ, Mcmahon G, Mitro P, Pietrucha A, Podoleanu C, Raviele A, Benditt D, Krahn A, Morillo CA, Olshansky B, Raj S, Sheldon R, Shen WK, Sun B, Hachul D, Abe H, Furukawa T; Document reviewers: Review coordinators, Gorenek B, Lip GY, Glikson M, Ritter P, Hurwitz J, Macfadyen R, Rankin A, Mont L, Svendsen J, Kusumoto F, Cohen M, Savelieva I.

Syncope Unit: rationale and requirement – the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society.

Evaluation of the correlation between cardiac and sympathetic baroreflex sensitivity before orthostatic syncope.

Conference proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2015;2063-6.

Raw IF: 0 Normalized IF: 0 Porta A, Marchi A, Bari V, Heusser K, Tank J, Jordan J, Barbic F, Furlan R.

Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences 2015;373(2034): pii: 20140096.

Raw IF: 2.147 Normalized IF: 6 Santambrogio R, Bruno S, Kluger MD, Costa M, Salceda J, Belli A, Laurent A, Barabino M, Opocher E, Azoulay D, Cherqui D.

Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma.

Digestive and Liver Disease. Epub 2015 Nov 23.

Raw IF: 2.963 Normalized IF: 4 Selmi C°, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, Porrati L, Achenza MI, De Santis M, Cavaciocchi F, Massarotti M, Isailovic N, Paleari V, Invernizzi P, Matthias T, Zucchi A, Meroni PL.

Europace 2015;17(9):1325-40.

Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years.

Raw IF: 3.67 Normalized IF: 0.8

Autoimmunity Reviews 2016;15(2):162-6.

Lleo A*, Zhang W*, Zhao M*, Tan Y, Bernuzzi F, Zhu B, Liu Q, Tan Q, Malinverno F, Valenti L, Jiang T, Tan L, Liao W, Coppel R, Invernizzi P#, Lu Q#, Adams DH, Gershwin ME#; PBC Epigenetic Study Group.

(Collaborators: Bianchi I, Ceriani R, Mascia E, Mascheroni C, Podda M, Traiani F).

DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis.

Raw IF: 7.933 Normalized IF: 8 Zamunér AR, Barbic F, Dipaola F, Bulgheroni M, Diana A, Atzeni F, Marchi A, Sarzi-Puttini P, Porta A, Furlan R.

Relationship between sympathetic activity and pain intensity in fibromyalgia.

Clinical and Experimental Rheumatology 2015;33(1 s88):53-7.

Raw IF: 2.724 Normalized IF: 4

Clinical Epigenetics 2015;7(1):61.

Raw IF: 4.543 Normalized IF: 6

83

Papers published 2015

Zamunér AR, Porta A, Andrade CP, Marchi A, Forti M, Furlan R, Barbic F, Catai AM, Silva E.

Denti M, Tornese D, Melegati G, Schonhuber H, Quaglia A°, Volpi P.

Cardiovascular control in women with fibromyalgia syndrome: do casual methods provide non redundant information compared to more traditional approaches?

Combined chronic anterior cruciate ligament and posterior cruciate ligament reconstruction: functional and clinical results.

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 2015;309(19):R79-84.

Raw IF: 3.106 Normalized IF: 4 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group.

(Collaborators: Invernizzi P, Bruno S).

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

Alimentary Pharmacology & Therapeutics 2015;42(7):829-44.

Raw IF: 5.727 Normalized IF: 1.2

Knee Orthopaedics and Sport Traumatology Bait C°, Denti M, Prospero E, Quaglia A, Orgiani A, Volpi P.

Posterior cruciate ligament reconstruction with “all-inside” technique: a technical note.

Muscles, Ligaments and Tendons Journal 2015;4(4):467-70.

Raw IF: 0 Normalized IF: 0 Bisciotti GN, Auci A, Di Marzo F, Galli R, Pulici L, Carimati G, Quaglia A, Volpi P°.

Groin pain syndrome: an association of different pathologies and a case presentation.

Muscles, Ligaments and Tendons Journal 2015;5(3):214-22.

Raw IF: 0 Normalized IF: 0 Brambilla L, Pulici L, Carimati G, Quaglia A, Prospero E, Bait C, Morenghi E, Portinaro N, Denti M, Volpi P°.

Prevalence of associated lesions in anterior cruciate ligament reconstruction: correlation with surgical timing and with patient age, sex, and body mass index.

American Journal of Sports Medicine 2015;43(12):2966-73.

84

Raw IF: 4.362 Normalized IF: 6

Knee Surgery, Sports Traumatology, Arthroscopy 2015;23(10):2853-8.

Raw IF: 3.053 Normalized IF: 6 Volpi P°, Cervellin M, Bait C, Prospero E, Mousa H, Redaelli A, Quaglia A, Denti M.

Trans-physeal anterior cruciate ligament reconstruction in adolescents.

Knee Surgery, Sports Traumatology, Arthroscopy.

Epub 2015 Feb 4.

Raw IF: 3.053 Normalized IF: 6

Crocchiolo R°, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L.

Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Transplant Infectious Disease 2015;17(2):242-9.

Raw IF: 2.064 Normalized IF: 4 Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F°.

Dual prognostic significance of tumourassociated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.

Gut. Epub 2015 Jul 8.

Raw IF: 14.66 Normalized IF: 10

laboratory tests Assandri R°, Monari M, Colombo A, Dossi A, Montanelli A.

Pentraxin 3 plasma levels and disease activity in systemic Lupus erythematosus.

Autoimmune Diseases 2015;2015:354014.

Raw IF: 0 Normalized IF: 0 Assandri R°, Monari M, Colombo A, Montanelli A.

Pentraxin 3 serum levels in celiac patients: evidences and perspectives.

Recent Patents on Food, Nutrition & Agriculture 2014;6(2):82-92.

Raw IF: 0 Normalized IF: 0 Assandri R, Monari M, Colombo A, Montanelli A.

Innate immune system: the no man’s land where discover new biomarkers for glutenrelated-disorders.

Gastroenterology and Hepatology from Bed to Bench 2015;8(2):95-8.

Raw IF: 0 Normalized IF: 0 Bettio D°, Venci A, Achille V, Alloisio M, Santoro A.

Infante M°, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M.

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.

International Journal of Cancer 2016;138(4):983-91.

Raw IF: 5.085 Normalized IF: 6 Monari M, Foglia E, Montanelli A, Assandri R, Lagioia M, Ferrario L, Garagiola E, Porazzi E, Croce D.

Economic, organizational and budget impact of a new diagnostic plan for HCV detection: what’s “new”?

La Rivista Italiana della Medicina di Laboratorio Italian Journal of Laboratory Medicine 2015;11(4): 236-242.

Raw IF: 0 Normalized IF: 0 Palagano E, Blair HC, Pangrazio A, Tourkova I, Strina D, Angius A, Cuccuru G, Oppo M, Uva P, Van Hul W, Boudin E, Superti-Furga A, Faletra F, Nocerino A, Ferrari MC, Grappiolo G, Monari M, Montanelli A, Vezzoni P, Villa A, Sobacchi C°.

Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: a case report.

Buried in the middle, but guilty: intronic mutations in the TCIRG1 gene cause human autosomal recessive osteopetrosis.

Experimental and Therapeutic Medicine 2016;11(1):98-100.

Journal of Bone and Mineral Research 2015;30(10):1814-21.

Raw IF: 1.269 Normalized IF: 1

Raw IF: 6.832 Normalized IF: 6

Clinical Research

Ristagno G, Varpula T, Masson S, Greco M, Bottazzi B, Milani V, Aleksova A, Sinagra G, Assandri R, Tiainen M, Vaahersalo J, Kurola J, Barlera S, Montanelli A, Latini R, Pettilä V, Bendel S, Skrifvars MB; FINNRESUSCI Study Group.

Blaise D, Fürst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, Picard C, Chabannon C, Weiller PJ, Faucher C, Mohty B, Vey N, Castagna L.

Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death.

Haploidentical T-cell replete transplantation with post-transplant cyclophosphamide for patients in or above the 6th decade of age compared with allogeneic hematopoietic stem cell transplantation from an HLA-matched related or unrelated donor.

Clinical Chemistry and Laboratory Medicine 2015;53(11):1847-57.

Raw IF: 2.707 Normalized IF: 6 Verdesca S, Cucchiari D°, Monari M, Podestà MA, Badalamenti S.

Sulfamethoxazole crystalluria.

Giornale Italiano di Nefrologia 2015;32(3):pii: gin/32.3.5.

Raw IF: 0 Normalized IF: 0

Medical Oncology and Haematology Bernardi M, Zappasodi P, Fracchiolla N, Marbello L, Todisco E, Pagani C, Carrabba M, Rossi M, Guidotti F, Mancini V, Santoro A, Borlenghi E, Ciceri F, Morra E, Rossi G.

Post-remission intensive treatment after induction chemotherapy is feasible in selected elderly patients with acute myeloid leukemia and age ≥ 75 years: a retrospective analysis of the Rete Ematologica Lombarda.

American Journal of Hematology 2015;90(6):E123-25.

Raw IF: 3.798 Normalized IF: 3 Bettio D°, Venci A, Achille V, Alloisio M, Santoro A.

Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: a case report.

Experimental and Therapeutic Medicine 2016;11(1):98-100.

Raw IF: 1.269 Normalized IF: 1 Biglia N, Torrisi R, D’Alonzo M, Codacci Pisanelli G, Rota S, Peccatori FA.

Attitudes on fertility issues in breast cancer patients: an Italian survey.

Gynecological Endocrinology 2015;31(6):458-64.

Raw IF: 1.333 Normalized IF: 1

Biology of Blood and Marrow Transplantation 2016;22(1):119-24.

Raw IF: 3.404 Normalized IF: 2 Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD.

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, doubleblind, placebo-controlled, phase 3 trial.

Lancet Oncology 2015;16(5):531-40.

Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C.

Primary refractory and early-relapsed Hodgkin lymphoma: strategies for therapeutic targeting based on the tumor microenvironment.

Journal of Pathology 2015;237(1):4-13.

Raw IF: 7.429 Normalized IF: 8 Carlo-Stella C*°, Ricci F*, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L#, Corradini P#, Santoro A#

Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four italian centers.

Oncologist 2015;20(3):323-8.

Raw IF: 4.865 Normalized IF: 6 Carlo-Stella C°, Santoro A.

Microenvironment-related biomarkers and novel targets in classical Hodgkin lymphoma.

Biomarkers in Medicine 2015;9(8):807-17.

Raw IF: 24.69 Normalized IF: 15

Raw IF: 2.646 Normalized IF: 4

Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D‫׳‬Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E.

Castagna L°, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, Cheikh JE, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D.

Clinical outcomes in a contemporary series of “young” patients with castrationresistant prostate cancer who were 60 years and younger.

Urologic Oncology 2015;33(6):265.e15-21.

Raw IF: 2.768 Normalized IF: 6 Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA.

Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.

Bone Marrow Transplantation. Epub 2015 Nov 23.

Raw IF: 3.57 Normalized IF: 2 Castagna L, Carlo-Stella C, Mazza R, Santoro A°.

Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Mediterranean Journal of Hematology and Infectious Diseases 2015;7(1):e2015015.

Raw IF: 0 Normalized IF: 0

Future Oncology 2015;11(9):1429-35.

Raw IF: 2.477 Normalized IF: 1 Cappuzzo F*, Finocchiaro G*, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A.

Castagna L*°, Crocchiolo R*, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A.

Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Journal of Thoracic Oncology 2015;10(4):665-72.

Bone Marrow Transplantation 2015;50(4):499-504.

Raw IF: 5.282 Normalized IF: 6

Raw IF: 3.57 Normalized IF: 4

85

Papers published 2015

Ceresoli GL, De Vincenzo F, Sauta MG, Bonomi M, Zucali PA.

De Rose F°, Cozzi L, Navarria P, Ascolese AM, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M.

Garciaz S, Castagna L, Bouabdallah R, Fürst S, Bramanti S, Coso D, Crocchiolo R, El-Cheikh J, Broussais F, Chabannon C, Santoro A, Blaise D.

Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients.

Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.

Clinical Oncology 2016;28(1):13-20.

Bone Marrow Transplantation 2015;50(6):865-67.

Raw IF: 2.033 Normalized IF: 4

Raw IF: 3.398 Normalized IF: 4

Raw IF: 3.57 Normalized IF: 4

Ceresoli GL, Zucali PA°.

De Sanctis R°, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio P, Bastoni S, Bertuzzi AF, Quagliuolo V, Santoro A.

Gentile M, Vigna E, Recchia AG, Morabito L, Mendicino F, Giagnuolo G, Morabito F.

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.

European Journal of Haematology 2015;95(5):377-88.

Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.

Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015;59(4):374-80.

Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.

Cancer Treatment Reviews 2015;41(10):853-8.

Raw IF: 7.588 Normalized IF: 8

Drug Design, Development and Therapy 2015;9:5785-91.

Crocchiolo R°, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, Tordato F, Mauro E, Timofeeva I, Lugli E, Mavilio D, Carlo-Stella C, Santoro A, Castagna L.

Raw IF: 3.028 Normalized IF: 4

Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis.

Transplant Infectious Disease 2015;17(2):242-9.

Raw IF: 2.064 Normalized IF: 4 Crocchiolo R°, Castagna L, Garciaz S, Fürst S, El Cheikh J, Sarina B, Bramanti S, Granata A, Vai A, Harbi S, Morabito L, Mohty B, Giordano L, Devillier R, Coso D, Balzarotti M, Chabannon C, CarloStella C, Santoro A, Bouabdallah R, Blaise D.

Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Haematologica 2015;100(10):e423-7.

Raw IF: 5.814 Normalized IF: 6 De Mattos-Arruda L*, Bottai G*, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L°.

MicroRNA-21 links epithelialto-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

Oncotarget 2015;6(35):37269-80.

Raw IF: 6.359 Normalized IF: 6

Devillier R*, Bramanti S*, Fürst S, Sarina B, ElCheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L*, Blaise D*.

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Bone Marrow Transplantation 2016;51(2):194-8.

Raw IF: 3.57 Normalized IF: 4 El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A, Vai A, Lemarie C, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.

Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies.

Cancer 2015;121(11):1809-16.

Raw IF: 4.889 Normalized IF: 6 El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.

Comparison of three distinct prophylactic agents against invasive fungal infections in patients undergoing haplo-identical hematopoietic stem cell transplantation and post-transplant cyclophosphamide.

Mediterranean Journal of Hematology and Infectious Diseases 2015;7(1):e2015048.

Raw IF: 0 Normalized IF: 0 Finocchiaro G°, Toschi L, Gianoncelli L, Baretti M, Santoro A.

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.

Annals of Translational Medicine 2015;3(6):83.

86

Raw IF: 0 Normalized IF: 0

Bendamustine in multiple myeloma.

Raw IF: 2.066 Normalized IF: 1 Ghidini M°, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L.

KRAS mutation in lung metastases from colorectal cancer: prognostic implications.

Cancer Medicine 2016;5(2):256-64.

Raw IF: 2.5 Normalized IF: 2 Giovannetti E, Zucali PA, Rolfo C, Assaraf YG, Peters GJ.

Prognostic and predictive roles of thymidylate synthase expression in lung cancer: the debate is still open.

Journal of Clinical Oncology 2016;34(5): 511-2.

Raw IF: 18.428 Normalized IF: 7.5 Henderson TO, Moskowitz CS, Chou JF, Bradbury AR, Neglia JP, Dang CT, Onel K, Novetsky Friedman D, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring WM, Robison LL, Armstrong GT, Diller LR, Oeffinger KC.

Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: a report from the childhood cancer survivor study.

Journal of Clinical Oncology. Epub 2015 Dec 23.

Raw IF: 18.428 Normalized IF: 7.5

Clinical Research

Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Masci G°, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG, Gronchi A.

Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series.

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

Raw IF: 4.865 Normalized IF: 6

Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10 Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6 Mancosu P°, Navarria P, Castagna L, Reggiori G, Stravato A, Gaudino A, Sarina B, Tomatis S, Scorsetti M.

Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. Physica Medica 2015;31(7):677-82.

Raw IF: 2.403 Normalized IF: 4 Mancosu P°, Navarria P, Reggiori G, Cozzi L, Fogliata A, Gaudino A, Lobefalo F, Paganini L, Palumbo V, Sarina B, Stravato A, Castagna L, Tomatis S, Scorsetti M.

In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study.

Radiation Oncology 2015;10(1):86.

Raw IF: 2.546 Normalized IF: 4 Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F.

Oncologist 2015;20(6):586-92.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators.

(Collaborator: Santoro A).

Nivolumab versus everolimus in advanced renal-cell carcinoma.

New England Journal of Medicine 2015;373(19):1803-13.

Raw IF: 55.873 Normalized IF: 3 Musto P, Fraticelli VL, Mansueto G, Madonna E, Nozza A, Andriani A, Mussetti A, Ballanti S, Bongarzoni V, Baraldi A, Patriarca F, Vincelli D, Falcone A, Derudas D, Califano C, Zambello R, Mele G, Fragasso A, Baldini L, Storti S.

Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon.

Journal of Clinical Oncology. Epub 2015 Sep 8.

Raw IF: 18.428 Normalized IF: 15 Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A.

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.

Future Oncology 2015;11(4):703-12.

Raw IF: 2.477 Normalized IF: 2 Personeni N°, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A.

FOLFIRI and cetuximab every second week for first-line treatment of KRAS wild-type metastatic colorectal cancer according to PTEN expression: a phase II study.

Clinical Colorectal Cancer. Epub 2015 Mar 6.

Raw IF: 2.813 Normalized IF: 4

Leukemia & Lymphoma. Epub 2015 Mar 3.

Raw IF: 2.891 Normalized IF: 2 Navarria P, Ascolese AM, Cozzi L°, Tomatis S, D’Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M.

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.

European Journal of Cancer 2015;51(5):668-74.

Raw IF: 5.417 Normalized IF: 6 Noviello M, Forcina A, Veronica V, Crocchiolo R, Stanghellini MT, Carrabba M, Greco R, Vago L, Giglio F, Assanelli A, Carbone MR, Magnani Z, Crippa F, Corti C, Bernardi M, Peccatori J, Bordignon C, Ciceri F, Bonini C, Bondanza A.

Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R.

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.

Radiotherapy and Oncology 2015;117(2):315-21.

Raw IF: 4.363 Normalized IF: 3 Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients.

Early recovery of CMV immunity after HLAhaploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.

Journal of Thoracic Oncology. Epub 2015 Aug 20.

Bone Marrow Transplantation 2015;50(9):1262-4.

American Journal of Hematology 2015;90(6):499503.

Raw IF: 5.282 Normalized IF: 6

Raw IF: 3.57 Normalized IF: 2

Raw IF: 3.798 Normalized IF: 6

87

Papers published 2015

Rimassa L, Personeni N, Santoro A.

Tivantinib for hepatocellular carcinoma.

Expert Opinion on Orphan Drugs 2015;3(3):343-51.

Raw IF: 0.529 Normalized IF: 1 Rimassa L°, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, Masi G, Abbadessa G, Lamar M, Goldberg T, Porta C.

Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of the Italian centers.

Tumori 2015;101(2):139-43.

Raw IF: 1.269 Normalized IF: 1 Roberto A, Castagna L*, Zanon V*, Bramanti S, Crocchiolo R, McLaren JE, Gandolfi S, Tentorio P, Sarina B, Timofeeva I, Santoro A, Carlo-Stella C, Bruno B, Carniti C, Corradini P, Gostick E, Ladell K, Price DA, Roederer M, Mavilio D#°, Lugli E#°.

Role of naïve-derived T memory stem cells in T cell reconstitution following allogeneic transplantation.

Blood 2015;125(18):2855-64.

Raw IF: 10.452 Normalized IF: 8 Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M.

The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.

American Journal of Hematology 2015;90(1):56-61.

Raw IF: 3.798 Normalized IF: 6 Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B.

Phase III, multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic non-squamous non-small-cell lung cancer.

Journal of Clinical Oncology 2015;33(24):2667-74.

Raw IF: 18.428 Normalized IF: 15

Sclafani F°, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Giordano Beretta G, Zanello A, Roncalli M, Giordano M, Santoro A.

An exploratory biomarker study in metastatic tumours from colorectal cancer patients treated with bevacizumab.

International Journal of Biological Markers 2015;30(1):e73-80.

Raw IF: 1.371 Normalized IF: 2 Scorsetti M, Navarria P, Pessina F, Ascolese AM, D’Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, Simonelli M, Clerici E, Soffietti R, Santoro A, Cozzi L°, Bello L.

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.

BMC Cancer 2015;15:486.

Raw IF: 3.362 Normalized IF: 4 Simonelli M°, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A.

Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases of heavilypretreated metastatic thymoma with striking responses to sorafenib in combination with lapatinib.

Future Oncology 2015;11(8):1223-32.

Raw IF: 2.477 Normalized IF: 2 Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M.

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Haematologica 2015;100(12):e501-4.

Raw IF: 5.814 Normalized IF: 6 Tozzi A°, Iftode C, Cozzi L, Ascolese AM, Battista S, Cavina R, Clerici E, Comito T, D’Agostino GR, DE Rose F, Franzese C, Garassino I, Fumagalli Romario U, Navarria P, Rosati R, Spaggiari P, Tomatis S, Scorsetti M.

Neoadjuvant chemoradiotherapy with volumetric-modulated arc therapy for medium-distal oesophageal and gastrooesophageal junction carcinoma.

Anticancer Research 2015;35(7):4109-16.

Raw IF: 1.826 Normalized IF: 2

Tralongo P, Dal Maso L, Surbone A, Santoro A, Tirelli U, Sacchini V, Pinto C, Crispino S, Ferraù F, Mandoliti G, Tonini G, Russo A, Santini D, Madeddu A, Panebianco V, Pergolizzi S, Respini D, Rolfo C, Bongiovanni M, De Lorenzo F, Spatola C, Di Raimondo F, Terenziani M, Peeters M, Castoro C.

Use of the word “cured” for cancer patients - implications for patients and physicians: the Siracusa charter.

Current Oncology 2015;22(1):E38-40.

Raw IF: 1.785 Normalized IF: 0.5 Veronesi G°, Bottoni E, Finocchiaro G, Alloisio M.

When is surgery indicated for small-cell lung cancer?

Lung Cancer 2015;90(3):582-9.

Raw IF: 3.958 Normalized IF: 6 Vigo C, Gatzemeier W, Sala R, Malacarne M, Santoro A, Pagani M, Lucini D°.

Evidence of altered autonomic cardiac regulation in breast cancer survivors.

Journal of Cancer Survivorship: Research and Practice. Epub 2015 Apr 22.

Raw IF: 3.303 Normalized IF: 4 Vitali E, Cambiaghi V, Spada A, Tresoldi A, Zerbi A, Peverelli E, Carnaghi C, Mantovani G, Lania AG°.

cAMP effects in neuroendocrine tumors: the role of Epac and PKA in cell proliferation and adhesion.

Experimental Cell Research 2015;339(2):241-51.

Raw IF: 3.246 Normalized IF: 4 Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group.

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebocontrolled, phase 3 study.

Lancet. Epub 2015 Dec 15.

Raw IF: 45.217 Normalized IF: 15 Zinzani PL, Corradini P, Gianni AM, Federico M, Santoro A, Vitolo U, Barosi G, Tura S.

Brentuximab vedotin in CD30-positive lymphomas. A SIE, SIES, GITMO position paper.

Clinical Lymphoma, Myeloma & Leukemia 2015;15(9):507-13.

88

Raw IF: 2.02 Normalized IF: 1

Clinical Research

nephrology and dialisis Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.

(Collaborator: Berra C).

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

American Heart Journal 2015;169(5):631-639e7.

Raw IF: 4.463 Normalized IF: 1.2 Colombo G, Reggiani F, Podestà MA, Garavaglia ML, Portinaro NM, Milzani A, Badalamenti S, Dalle-Donne I.

Podestà MA. Faravelli I, Cucchiari D, Reggiani F, Oldani S, Fedeli C, Graziani G°.

Verdesca S, Cucchiari D°, Monari M, Podestà MA, Badalamenti S.

Neurological counterparts of hyponatremia: pathological mechanisms and clinical manifestations.

Sulfamethoxazole crystalluria.

Current Neurology and Neuroscience Reports 2015;15(4):18.

Giornale Italiano di Nefrologia 2015;32(3):pii: gin/32.3.5.

Raw IF: 0 Normalized IF: 0

Raw IF: 3.059 Normalized IF: 4 Ponticelli C°, Glassock RJ.

neurologic rehabilitation

IgA nephritis with declining renal function: treatment with corticosteroids may be worthwhile.

Bernardini B°, Fracchia S.

Journal of the American Society of Nephrology 2015;26(9):2071-3.

Journal of Clinical Epidemiology 2016;71:114-5.

Raw IF: 9.343 Normalized IF: 8

Comorbidity indices disillusion.

Raw IF: 3.417 Normalized IF: 3

Ponticelli C, Glassock RJ.

Neurology I

Plasma protein thiolation index (PTI) as a biomarker of thiol-specific oxidative stress in haemodialyzed patients.

In reply - New oral anticoagulants in elderly adults with chronic kidney disease.

Mayo Clinic Proceedings 2015;90(11):1589-90.

Albanese A°, Romito LM, Calandrella D.

Free Radical Biology and Medicine 2015;89:443-51.

Raw IF: 6.262 Normalized IF: 3

Therapeutic advances in dystonia.

Raw IF: 5.736 Normalized IF: 6 Cucchiari D, Angelini C.

Renal involvement in idiopathic inflammatory myopathies.

Clinical Reviews in Allergy & Immunology. Epub 2015 Nov 14.

Movement Disorders 2015;30(11):1547-56.

Ponticelli C°, Moroni G.

Raw IF: 5.68 Normalized IF: 6

Immunosuppression in pregnant women with systemic lupus erythematosus.

Del Sorbo F, Albanese A°.

Expert Review of Clinical Immunology 2015;11(5):549-52.

Raw IF: 2.484 Normalized IF: 2

Raw IF: 5.463 Normalized IF: 6 Ponticelli C°, Sala G, Glassock RJ. Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, Gallieni M, Rosner M, Ponticelli C.

Glomerular diseases and cancer: evaluation of underlying malignancy.

Journal of Nephrology. Epub 2015 Oct 26.

Raw IF: 1.454 Normalized IF: 2 Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. (Collaborator: Berra C).

Drug management in the elderly adult with chronic kidney disease: a review for the primary care physician.

Mayo Clinic Proceedings 2015;90(5):633-45.

Raw IF: 6.262 Normalized IF: 6 Ponticelli C.

Innate immunity and transplantation.

Giornale Italiano di Nefrologia 2015;32(s64):pii:gin/32.S64.9.

Botulinum neurotoxins for the treatment of focal dystonias: review of rating tools used in clinical trials.

Toxicon 2015;107(Pt A):89-97.

Raw IF: 2.492 Normalized IF: 4

neurology II Benedetti MD, Pugliatti M, D’Alessandro R, Beghi E, Chiò A, Logroscino G, Filippini G, Galeotti F, Massari M, Santuccio C, Raschetti R; ITANG Study Group.

(Collaborators: Nobile Orazio E, Terenghi F).

Raw IF: 0 Normalized IF: 0

Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.

A multicentric prospective incidence study of Guillain-Barré syndrome in Italy. The ITANG Study.

Ponticelli C.

Neuroepidemiology 2015;45(2):90-9.

New England Journal of Medicine 2015;373(23):2247-57.

The impact of cold ischemia time on renal transplant outcome.

Raw IF: 2.558 Normalized IF: 0.8

Raw IF: 55.873 Normalized IF: 3

Kidney International 2015;87(29):272-5.

Cocito D, Merola A, Romagnolo A, Peci E, Toscano A, Mazzeo A, Gentile L, Russo M, Fazio R, Filosto M, Siciliano G, Schirinzi E, Nobile-Orazio E, Lopiano L.

Raw IF: 8.563 Normalized IF: 8 Podestà MA, Cucchiari D, Ponticelli C.

The diverging roles of dendritic cells in kidney allotransplantation.

Transplantation Reviews 2015;29(3):114-20.

Raw IF: 3.816 Normalized IF: 6

Sala G, Badalamenti S, Ponticelli C.

The renal connexome and possible roles of connexins in kidney diseases

Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?

American Journal of Kidney Diseases. Epub 2015 Nov 21.

Journal of Neurology, Neurosurgery, and Psychiatry.

Epub 2015 Jun 24.

Raw IF: 5.9 Normalized IF: 6

Raw IF: 6.807 Normalized IF: 3

89

Papers published 2015

Draak TH, Pruppers MH, van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, van den Berg LH, van Doorn PA, Cornblath DR, Hahn AF, Faber CG, Merkies IS; PeriNomS study group.

Grip strength comparison in immunemediated neuropathies: Vigorimeter versus Jamar.

Journal of the Peripheral Nervous System 2015;3:269-76.

Raw IF: 2.758 Normalized IF: 4 Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, van den Berg LH, van Doorn PA, Cornblath DR, Faber CG, Merkies IS.

Comparing the NIS vs MRC and INCAT sensory scale through Rasch analyses.

Journal of the Peripheral Nervous System 2015;20(3):277-88.

Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM.

Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy.

Cochrane Database of Systematic Reviews 2015;3:CD003217.

Raw IF: 6.032 Normalized IF: 3

Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test?

European Journal of Neurology 2015;22(5):879-82.

Raw IF: 4.055 Normalized IF: 6 Nobile-Orazio E°, Gallia F.

Update on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Current Opinion in Neurology 2015;28(5):480-5.

Raw IF: 5.307 Normalized IF: 6 Pruppers MH, Draak TH, Vanhoutte EK, Van der Pol WL, Gorson KC, Léger JM, Nobile-Orazio E, van den Berg LH, Faber CG, Merkies IS.

Outcome measures in MMN revisited: further improvement needed.

Journal of the Peripheral Nervous System 2015;59(2):306-18.

European Journal of Endocrinology 2016;174(2):241-50.

Impairment measures versus inflammatory-RODS in GBS and CIDP: A responsiveness comparison.

Hypofractionated stereotactic radiation therapy in recurrent high-grade glioma: a new challenge.

Journal of the Peripheral Nervous System 2015;20(3):289-95.

Cancer Research and Treatment 2016;48(1):37-44.

Treatment for IgG and IgA paraproteinaemic neuropathy.

Cochrane Database of Systematic Reviews 2015;3:CD005376.

Raw IF: 6.032 Normalized IF: 3

90

Raw IF: 4.069 Normalized IF: 3 Navarria P°, Ascolese AM, Tomatis S, Reggiori G, Clerici E, Villa E, Maggi G, Bello L, Pessina F, Cozzi L, Scorsetti M.

Raw IF: 3.318 Normalized IF: 4

Raw IF: 2.758 Normalized IF: 4

neurosurgery Beretta E, Nessi F, Ferrigno G, Di Meco F, Perin A, Bello L, Casaceli G, Raneri F, De Benedictis A, De Momi E.

Enhanced torque-based impedance control to assist brain targeting during open-skullneurosurgery: a feasibility study.

International Journal of Medical Robotics and Computer Assisted Surgery. Epub 2015 Jul 31.

Raw IF: 1.526 Normalized IF: 2 Castellano A, Donativi M, Rudà R, De Nunzio G, Riva M, Iadanza A, Bertero L, Rucco M, Bello L, Soffietti R, Falini A.

Evaluation of low-grade glioma structural changes after chemotherapy using DTIbased histogram analysis and functional diffusion maps.

European Radiology. Epub 2015 Aug 30.

Raw IF: 4.014 Normalized IF: 3

Raw IF: 2.758 Normalized IF: 2 Stork AC, Lunn MP, Nobile-Orazio E, Notermans NC.

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first generation somatostatin analogues: an immunohistochemical study.

Vanhoutte EK, P Draak TH, Gorson KC, van Nes SI, Hoeijmakers JG, Van der Pol WL, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS study group.

Raw IF: 2.758 Normalized IF: 4 Giannotta C°, Di Pietro D, Gallia F, Nobile-Orazio E.

Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L.

Costa F°, Dorelli G, Ortolina A, Cardia A, Attuati L, Tomei M, Milani D, Balzarini L, Galbusera F, Morenghi E, Fornari M.

Computed tomography-based imageguided system in spinal surgery: state of the art through 10 years of experience.

Neurosurgery 2015;11(s2):59-68.

Raw IF: 3.62 Normalized IF: 6

Navarria P, Pessina F, Cozzi L°, Clerici E, Villa E, Ascolese AM, De Rose F, Comito T, Franzese C, D’Agostino G, Lobefalo F, Fogliata A, Reggiori G, Fornari M, Tomatis S, Bello L, Scorsetti M.

Hypofractionated stereotactic radiation therapy in skull base meningiomas.

Journal of Neuro-Oncology 2015;124(2):283-9.

Raw IF: 3.07 Normalized IF: 4 Riva M, Fava E, Gallucci M, Comi A, Casarotti A, Alfiero T, Raneri FA, Pessina F, Bello L°.

Monopolar high-frequency language mapping: can it help in the surgical management of gliomas? A comparative clinical study.

Journal of Neurosurgery. Epub 2015 Sep 25.

Raw IF: 3.737 Normalized IF: 6 Riva M°, Rodriguez Y Baena R, Pessina F, Egesta L, Fernandes B, Galli C, Rossi M, Bello L.

The diffusion-weighted imaging and 11-C-methionine positron emission tomography depiction of an endodermal cyst at the cervico-medullary junction.

British Journal of Neurosurgery. Epub 2015 Mar 26.

Raw IF: 0.96 Normalized IF: 2 Scorsetti M, Navarria P, Pessina F, Ascolese AM, D’Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, Simonelli M, Clerici E, Soffietti R, Santoro A, Cozzi L°, Bello L.

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.

BMC Cancer 2015;15:486.

Raw IF: 3.362 Normalized IF: 4

Clinical Research

nuclear medicine Bombardieri E, Setti L, Kirienko M, Antunovic L, Guglielmo P, Ciocia G.

Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients?

An open discussion.

Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015;59(4):381-99.

Raw IF: 2.033 Normalized IF: 2 Carriò I, Chiti A.

Why new journals? The growth of the EJNMMI family.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(11):1625-6.

Raw IF: 5.383 Normalized IF: 6 Castagna L*°, Crocchiolo R*, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A.

High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.

Bone Marrow Transplantation 2015;50(4):499-504.

Raw IF: 3.57 Normalized IF: 4 Chiti A.

Imaging biomarkers in oncology: we can get more from what we see.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(4):535-6.

Raw IF: 5.383 Normalized IF: 6 Fahey FH, Bom HH, Chiti A, Choi YY, Huang G, Lassmann M, Laurin N, Mut F, Nuñez-Miller R, O’Keeffe D, Pradhan P, Scott AM, Song S, Soni N, Uchiyama M, Vargas L.

Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources.

Journal of Nuclear Medicine 2015;56(4):646-51.

Raw IF: 6.16 Normalized IF: 6

Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, Oyen W, Chiti A.

PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.

European Journal of Nuclear Medicine and Molecular Imaging 2016;43(1):55-69.

Raw IF: 5.383 Normalized IF: 6 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10 Kirienko M, Sollini M, Lopci E, Versari A, Chiti A°.

Applications of PET imaging with radiolabelled choline (11C/18F-choline).

Quarterly Journal of Nuclear medicine and Molecular Imaging 2015;59(1):83-94.

Raw IF: 2.033 Normalized IF: 4 Konert T, Vogel W, MacManus MP, Nestle U, Belderbos J, Grégoire V, Thorwarth D, Fidarova E, Paez D, Chiti A, Hanna GG.

PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014.

Radiotherapy and Oncology 2015;116(1):27-34.

Raw IF: 4.363 Normalized IF: 3 Liu Y, deSouza NM, Shankar LK, Kauczor HU, Trattnig S, Collette S, Chiti A.

A risk management approach for imaging biomarker-driven clinical trials in oncology.

Lopci E, Grassi I, Rubello D, Colletti PM, Cambioli S, Gamboni A, Salvi F, Cicoria G, Lodi F, Dazzi C, Mattioli S, Fanti S.

Prognostic evaluation of disease outcome in solid tumors investigated with 64CuATSM PET/CT. Clinical Nuclear Medicine. Epub 2015 Oct 8.

Raw IF: 3.931 Normalized IF: 6 Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6 Riva M°, Rodriguez Y Baena R, Pessina F, Egesta L, Fernandes B, Galli C, Rossi M, Bello L.

The diffusion-weighted imaging and 11-C-methionine positron emission tomography depiction of an endodermal cyst at the cervico-medullary junction.

British Journal of Neurosurgery. Epub 2015 Mar 26.

Raw IF: 0.96 Normalized IF: 2 Schinkelshoek M, Lopci E, Clerici E, Alongi F, Mancosu P, Rodari M, Navarria P, van der Hiel B, Scorsetti M, Chiti A°.

Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.

Tumori 2014;100(6):636-44.

Raw IF: 1.269 Normalized IF: 1 Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K.

SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach.

Clinical Nuclear Medicine 2015;40(5):e271-7.

Raw IF: 3.931 Normalized IF: 3

Lancet Oncology 2015;16(16):e622-8.

Raw IF: 24.69 Normalized IF: 15 Lopci E.

Neuroblastoma: from diagnosis to therapy.

Journal of Pediatric Oncology 2015;3(2):38-42.

Raw IF: 0 Normalized IF: 0

91

Papers published 2015

ophtalmology Asencio-Duran M, Manzano-Muñoz B, VallejoGarcía JL, García-Martínez J.

Complications of macular peeling.

Journal of Ophthalmology 2015;2015:467814.

Raw IF: 1.425 Normalized IF: 1 Di Maria A, Balia L, Poletti AM, Colombo G, Romano M.

Orbital exenteration: our experience.

Tumori. Epub 2015 Oct 7.

d’Agostino CM°, Craig K, Tibalt E, Respizzi S.

Shockwave as biological therapeutic tool: from mechanical stimulation to recovery and healing, through mechanotransduction.

Sala R, Malacarne M, Pagani M, Lucini D.

Association between aerobic fitness and indices of autonomic regulation: implications for cardiovascular risk.

Journal of Sports Medicine and Physical Fitness.

Epub 2015 Feb 13.

Raw IF: 0.972 Normalized IF: 2

International Journal of Surgery 2015;24(pt B):147-53.

Raw IF: 1.531 Normalized IF: 4

Sala R, Malacarne M, Pagani M, Lucini D°.

Donzelli S, Poma S, Balzarini L, Borboni A, Respizzi S, Villafane JH, Zaina F, Negrini S.

Evidence of increased cardiac parasympathetic drive in subjects meeting current physical activity recommendations.

State of the art of current 3-D scoliosis classifications: a systematic review from a clinical perspective.

Raw IF: 1.487 Normalized IF: 2

Romano MR, Vallejo Garcia J, Scotti F, Vinciguerra P.

Journal of Neuroengineering and Rehabilitation 2015;12(1):91.

Salvioli B°, Pellegatta G, Malacarne M, Pace F, Malesci A, Pagani M, Lucini D.

27-gauge vitrectomy for primary rhegmatogenous retinal detachment: is it feasible?

Raw IF: 2.74 Normalized IF: 3

Autonomic nervous system dysregulation in irritable bowel syndrome.

Leal C, d’Agostino C, Gomez-Garcia S, Fernandez A.

Neurogastroenterology and Motility 2015;27(3):423-30.

Current concepts of shockwave therapy in stress fractures.

Raw IF: 3.587 Normalized IF: 6

International Journal of Surgery. Epub 2015 Aug 25.

Sukubo NG, Tibalt E, Respizzi S, Locati M, d’Agostino MC°.

Raw IF: 1.269 Normalized IF: 1

Annals of the Academy of Medicine Singapore 2015;45(5):185-7.

Raw IF: 1.151 Normalized IF: 1 Shah S, Peris-Martinez C, Reinhard T, Vinciguerra P.

Visual outcomes after cataract surgery: multifocal versus monofocal intraocular lenses.

Journal of Refractive Surgery 2015;31(10):658-66.

Raw IF: 3.468 Normalized IF: 6 Vinciguerra P, Albé E°, Vinciguerra R, Romano M, Trazza S, Mastropasqua L, Epstein D.

Long-term resolution of immunological graft rejection after a dexamethasone intravitreal implant.

Cornea 2015;34(3):471-4.

Raw IF: 1.531 Normalized IF: 4 Lucini D, Cesana G, Vigo C, Malacarne M, Pagani M.

Reducing weight in an internal medicine outpatient clinic using a lifestyle medicine approach: A proof of concept.

European Journal of Internal Medicine 2015;26(9):680-4.

Raw IF: 2.891 Normalized IF: 6 Lucini D°, Zanuso S, Solaro N, Vigo C, Malacarne M, Pagani M.

Raw IF: 2.042 Normalized IF: 4

Reducing the risk of metabolic syndrome at the worksite: preliminary experience with an ecological approach.

Vinciguerra P, Azzolini C, Vinciguerra R.

Acta Diabetologica 2016;53(1):63-71.

Corneal curvature gradient determines corneal healing process and epithelial behavior.

Raw IF: 2.399 Normalized IF: 2

Journal of Refractive Surgery 2015;31(4):281-2.

Raw IF: 3.468 Normalized IF: 3 Vinciguerra P, Azzolini C, Vinciguerra R.

Reply: To PMID 24576651.

Journal of Refractive Surgery 2015;31(4):282-4.

Raw IF: 3.468 Normalized IF: 3

92

orthopaedic rehabilitation

Pagani M, Lucini D.

Cost-effectiveness of preparticipation screening of athletes with ECG in Europe and Algeria.

Internal and Emergency Medicine 2015;10(2):125-7.

Raw IF: 2.624 Normalized IF: 6

Clinical Autonomic Research 2015;25(5):285-91.

Effect of shock waves on macrophages: a possible role in tissue regeneration and remodeling.

International Journal of Surgery 2015;24(pt B):124-30.

Raw IF: 1.531 Normalized IF: 4 Vigo C, Gatzemeier W, Sala R, Malacarne M, Santoro A, Pagani M, Lucini D°.

Evidence of altered autonomic cardiac regulation in breast cancer survivors.

Journal of Cancer Survivorship: Research and Practice. Epub 2015 Apr 22.

Raw IF: 3.303 Normalized IF: 4

Otorhinolaryngology Di Maria A, Balia L, Poletti AM, Colombo G, Romano M.

Orbital exenteration: our experience.

Tumori. Epub 2015 Oct 7.

Raw IF: 1.269 Normalized IF: 1

Respizzi S°, Cavallin R.

Poletti AM°, Colombo G, Barucca F, Rognone E, Fiamengo B.

First patellar dislocation: from conservative treatment to return to sport.

Cerebellopontine angle mixed tumour in type 2 neurofibromatosis.

Joints 2014;2(3):141-5.

Otology & Neurotology 2016;37(3):e169-70.

Raw IF: 0 Normalized IF: 0

Raw IF: 1.787 Normalized IF: 4

Clinical Research

Poletti AM°, Miceli S, Rossi V, Di Pietro S, Tosi G, Colombo G.

Anderloni A°, Murino A, Jovani M, Battista S, Repici A.

The “one shot” diode laser stapedotomy.

Underwater endoscopic mucosal resection of a duodenal neuroendocrine tumor.

Photomedicine and Laser Surgery 2015;33(12):598-603.

Raw IF: 1.672 Normalized IF: 4

Paediatric and NeuroOrthopaedics Surgery Brambilla L, Pulici L, Carimati G, Quaglia A, Prospero E, Bait C, Morenghi E, Portinaro N, Denti M, Volpi P°.

Prevalence of associated lesions in anterior cruciate ligament reconstruction: correlation with surgical timing and with patient age, sex, and body mass index.

American Journal of Sports Medicine 2015;43(12):2966-73.

Gastrointestinal Endoscopy. Epub 2015 Aug 8.

Raw IF: 5.369 Normalized IF: 6 Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C°, Mantovani A°.

PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

Cell 2015;160(4):700-14.

Raw IF: 32.242 Normalized IF: 15

Raw IF: 4.362 Normalized IF: 6

Brambilla T, Fiamengo B, Tinterri C, Testori A, Grassi MM, Sciarra A, Abbate T, Gatzemeier W, Roncalli M, Di Tommaso L°.

Colombo G, Reggiani F, Podestà MA, Garavaglia ML, Portinaro NM, Milzani A, Badalamenti S, Dalle-Donne I.

One-step nucleic acid amplification in breast cancer sentinel lymph node: a single institutional experience and a short review.

Plasma protein thiolation index (PTI) as a biomarker of thiol-specific oxidative stress in haemodialyzed patients.

Free Radical Biology and Medicine 2015;89:443-51.

Raw IF: 5.736 Normalized IF: 6 Panou A°, Stanitski DF, Stanitski C, Peccati A, Portinaro NM.

Intra-observer and inter-observer errors in CT measurement of torsional profiles of lower limbs: a retrospective comparative study.

Journal of Orthopaedic Surgery and Research 2015;10(1):67.

Raw IF: 1.386 Normalized IF: 2

Frontiers in Medicine 2015;2:37.

Raw IF: 0 Normalized IF: 0 Carrara S°, Anderloni A, Jovani M, Di Tommaso L, Rahal D, Hassan C, Ridola L, Federico D, Loriga A, Repici A.

A prospective randomized study comparing 25-G and 22-G needles of a new platform for endoscopic ultrasoundguided fine needle aspiration of solid masses.

Digestive and Liver Disease 2016;48(1):49-54.

Raw IF: 2.963 Normalized IF: 4 Carrara S°, Rahal D, Repici A.

A case of gastric splenosis mimicking a stromal tumor.

pathology Anderloni A°, Genco C, Ballarè M, Carmagnola S, Battista S, Repici A.

A case of primary pancreatic non-Hodgkin B-cell lymphoma mimicking autoimmune pancreatitis.

Journal of Gastrointestinal and Liver Diseases 2015;24(2):245-8.

Raw IF: 2.202 Normalized IF: 2

Clinical Gastroenterology and Hepatology. Epub 2015 Oct 23.

Raw IF: 7.896 Normalized IF: 8 Colombo P°, Smith SC, Massa S, Renne SL, Brambilla S, Peschechera R, Graziotti P, Roncalli M, Amin MB.

De Mattos-Arruda L*, Bottai G*, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L°.

MicroRNA-21 links epithelialto-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

Oncotarget 2015;6(35):37269-80.

Raw IF: 6.359 Normalized IF: 6 Floreani A, Motta R, Cazzagon N, Franceschet I, Roncalli M, Del Ross T, Rosina F, Lleo A, Mescoli C, Colloredo G, Invernizzi P.

The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis.

Digestive and Liver Disease 2015;47(5):432-5.

Raw IF: 2.963 Normalized IF: 4 Infante M°, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M.

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.

International Journal of Cancer 2016;138(4):983-91.

Raw IF: 5.085 Normalized IF: 6 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10

Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait.

Urology Case Reports 2015;3(6):215-8.

Raw IF: 0 Normalized IF: 0

93

Papers published 2015

Masci G°, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series.

Oncologist 2015;20(6):586-92.

Raw IF: 4.865 Normalized IF: 6 Mazzieri R, Pietrogrande G, Gerasi L, Gandelli A, Colombo P, Moi D, Brombin C, Ambrosi A, Danese S, Mignatti P, Blasi F, D’Alessio S°.

Sciarra A, Ronot M, Di Tommaso L, Raschioni C, Castera L, Belghiti J, Bedossa P, Vilgrain V, Roncalli M, Paradis V.

TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma.

Liver International 2015;35(11):2466-73.

Raw IF: 4.85 Normalized IF: 6 Sclafani F°, Rimassa L, Colombo P, Destro A, Stinco S, Lutman FR, Carnaghi C, Giordano Beretta G, Zanello A, Roncalli M, Giordano M, Santoro A.

Viganò L°, Conci S, Cescon M, Fava C, Capelli P, D’Errico A, Torzilli G, Tommaso LD, Giuliante F, Vecchio FM, Salizzoni M, David E, Pinna AD, Guglielmi A, Capussotti L.

Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC. Journal of Hepatology 2015;63(1):93-101.

Raw IF: 11.336 Normalized IF: 8

plastic surgery

An exploratory biomarker study in metastatic tumours from colorectal cancer patients treated with bevacizumab.

Klinger M°, Lisa A, Caviggioli F, Maione L, Murolo M, Vinci V, Klinger FM.

Cancer Research 2015;75(22):4895-909.

International Journal of Biological Markers 2015;30(1):e73-80.

Autologous fat grafting improves facial nerve function.

Raw IF: 9.329 Normalized IF: 8

Raw IF: 1.371 Normalized IF: 2

Case Reports in Surgery 2015;2015:520746.

Personeni N°, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A.

Taverna G°, Grizzi F, Colombo P, Seveso M, Giusti G, Proietti S, Fiorini G, Lughezzani G, Casale P, Buffi N, Lazzeri M, Guazzoni G.

Urokinase receptor promotes skin tumor formation by preventing epithelial cell activation of Notch1.

Raw IF: 0 Normalized IF: 0

FOLFIRI and cetuximab every second week for first-line treatment of KRAS wild-type metastatic colorectal cancer according to PTEN expression: a phase II study.

Clinical Colorectal Cancer. Epub 2015 Mar 6.

Raw IF: 2.813 Normalized IF: 4 Poletti AM°, Colombo G, Barucca F, Rognone E, Fiamengo B.

Cerebellopontine angle mixed tumour in type 2 neurofibromatosis.

Otology & Neurotology 2016;37(3):e169-70.

Raw IF: 1.787 Normalized IF: 4 Riva M°, Rodriguez Y Baena R, Pessina F, Egesta L, Fernandes B, Galli C, Rossi M, Bello L.

The diffusion-weighted imaging and 11-C-methionine positron emission tomography depiction of an endodermal cyst at the cervico-medullary junction.

British Journal of Neurosurgery. Epub 2015 Mar 26.

Raw IF: 0.96 Normalized IF: 2 Sciarra A, Di Tommaso L, Nakano M, Destro A, Torzilli G, Donadon M, Maggioni M, Bosari S, Bulfamante G, Matsuda M, Fujii H, Ichikawa T, Morisaka H, Sano K, Ichikawa S, Roncalli M°.

Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications.

Journal of Hepatology 2016;64(1):87-93.

Raw IF: 11.336 Normalized IF: 8

94

Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.

Korean Journal of Urology 2015;56(6):435-442.

Raw IF: 0 Normalized IF: 0 Testori A°, Meroni S, Colombo P, Fiori S, Voulaz E, Alloisio M.

Follicular dendritic cell sarcoma with atypical features surrounding undescended testis: description of a rare case.

World Journal of Surgical Oncology 2015;13:69.

Raw IF: 1.408 Normalized IF: 4 Tozzi A°, Iftode C, Cozzi L, Ascolese AM, Battista S, Cavina R, Clerici E, Comito T, D’Agostino GR, DE Rose F, Franzese C, Garassino I, Fumagalli Romario U, Navarria P, Rosati R, Spaggiari P, Tomatis S, Scorsetti M.

Neoadjuvant chemoradiotherapy with volumetric-modulated arc therapy for medium-distal oesophageal and gastrooesophageal junction carcinoma.

Anticancer Research 2015;35(7):4109-16.

Raw IF: 1.826 Normalized IF: 2

Klinger M°, Lisa A, Klinger F, Giannasi S, Veronesi A, Banzatti B, Bandi V, Catania B, Forcellini D, Maione L, Vinci V, Caviggioli F.

Regenerative approach to scars, ulcers and related problems with fat grafting.

Clinics in Plastic Surgery 2015;42(3):345-52.

Raw IF: 0.906 Normalized IF: 2 Klinger M, Vinci V, Klinger F, Lisa A, Maione L°.

Fat grafting for thermal injury: current state and future directions.

Journal of Burn Care and Research 2015;36(3):e228.

Raw IF:1.425 Normalized IF: 2 Lisa A, Caviggioli F, Maione L, Forcellini D, Vinci V, Klinger F, Klinger ME°.

Outcomes of immediate tissue expander breast reconstruction followed by reconstruction of choice in the setting of postmastectomy radiation therapy.

Annals of Plastic Surgery 2015;74(2):270-1.

Raw IF: 1.494 Normalized IF: 2 Lisa A, Klinger F, Caviggioli F, Maione L, Murolo M, Klinger M°.

Response to “autologous fat grafting: in search of the optimal technique”.

Surgical Innovation 2015;22(3):320-1.

Raw IF: 1.458 Normalized IF: 2

Clinical Research

Lisa A, Klinger F, Caviggioli F, Maione L, Murolo M, Klinger ME°.

Comparison of delayed and immediate tissue expander breast reconstruction in the setting of postmastectomy radiation therapy.

Annals of Plastic Surgery 2015;75(2):246.

Raw IF: 1.494 Normalized IF: 2 Lisa A, Murolo M, Vinci V, Maione L, Klinger F, Klinger M°.

Alleviation of neuropathic scar pain using autologous fat grafting: letter to the Editor.

Annals of Plastic Surgery. Epub 2015 Jun 20.

Raw IF: 1.494 Normalized IF: 2 Lisa A, Summo V, Bandi V, Maione L, Murolo M, Klinger F, Klinger M°.

Autologous fat grafting in the treatment of painful postsurgical scar of the oral mucosa.

Case Reports in Medicine 2015;2015:842854.

Raw IF: 0 Normalized IF: 0 Maione L°, Forcellini D, Vinci V, Lisa A, Caviggioli F, Klinger F.

Reply: The effects of postmastectomy adjuvant radiotherapy on immediate twostage prosthetic breast reconstruction: a systematic review.

Plastic and Reconstructive Surgery 2015;135(2):446e.

Raw IF: 2.993 Normalized IF:3

Comito T°, Clerici E, Tozzi A, D’Agostino G.

Liver metastases and SBRT: A new paradigm?

Reports of Practical Oncology and Radiotherapy 2015;20(6):464-71.

Raw IF: 0 Normalized IF: 0 De Rose F°, Cozzi L, Navarria P, Ascolese AM, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M.

Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 3.398 Normalized IF: 4

Raw IF: 12.996 Normalized IF: 10

Esposito M, Maggi G, Marino C, Bottalico L, Cagni E, Carbonini C, Casale M, Clemente S, D’Alesio V, Fedele D, Giglioli FR, Landoni V, Martinotti A, Nigro R, Strigari L, Villaggi E, Mancosu P.

Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P, Barsacchi L, Bedini N, Bracelli S, Buffoli A, Cagna E, Catalano G, Gottardo S, Italia C, Ivaldi GB, Masciullo S, Merlotti A, Sarti E, Scorsetti M, Serafini F, Toninelli M, Vitali E, Valdagni R, Villa E, Zerini D, Cobelli O, Orecchia R.

Multicentre treatment planning intercomparison in a national context: the liver stereotactic ablative radiotherapy case.

Physica Medica 2016;32(1):277-83.

Raw IF: 2.403 Normalized IF: 4

Role of the technical aspects of hypofractionated radiation therapy treatment of prostate cancer: a review.

International Journal of Radiation Oncology, Biology, Physics 2015;91(1):182-95.

Raw IF: 4.258 Normalized IF: 3

Performance of a knowledge-based model for optimization of volumetric modulated arc therapy plans for single and bilateral breast irradiation.

Fogliata A, Nicolini G, Clivio A, Vanetti E, Laksar S, Tozzi A, Scorsetti M, Cozzi L°.

A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers.

Radiation Oncology 2015;10(1):220.

Raw IF: 2.546 Normalized IF: 4 Franzese C, Fogliata A°, Clerici E, Franceschini D, Villa E, D’Agostino G, Navarria P, Mancosu P, Tomatis S, Cozzi L, Scorsetti M.

Evaluation of the Machine Performance Check application for TrueBeam Linac.

Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy.

Radiation Oncology 2015;10(1):87.

Radiation Oncology 2015;10(1):224.

Raw IF: 2.546 Normalized IF: 4

Raw IF: 2.546 Normalized IF: 4

Clivio A, Vanetti E, Rose S, Nicolini G, Belosi MF, Cozzi L, Baltes C, Fogliata A°.

Urinary bladder preservation for muscleinvasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy.

Tumori 2015;101(2):174-8.

Fogliata A°, Nicolini G, Bourgier C, Clivio A, De Rose F, Fenoglietto P, Lobefalo F, Mancosu P, Tomatis S, Vanetti E, Scorsetti M, Cozzi L.

Raw IF: 3.234 Normalized IF: 6

Clemente S, Nigro R, Oliviero C, Marchioni C, Esposito M, Giglioli FR, Mancosu P, Marino C, Russo S, Stasi M, Strigari L, Veronese I, Landoni V.

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

Clinical Oncology 2016; 28(1):13-20.

PLoS One 2015;10(12):e0145137.

Radiotherapy and Radiosurgery

Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Raw IF: 1.269 Normalized IF: 1 Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6 Mancosu P°, Navarria P, Castagna L, Reggiori G, Stravato A, Gaudino A, Sarina B, Tomatis S, Scorsetti M.

Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. Physica Medica 2015;31(7):677-82.

Raw IF: 2.403 Normalized IF: 4 Mancosu P°, Navarria P, Reggiori G, Cozzi L, Fogliata A, Gaudino A, Lobefalo F, Paganini L, Palumbo V, Sarina B, Stravato A, Castagna L, Tomatis S, Scorsetti M.

In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study.

Radiation Oncology 2015;10(1):86.

Raw IF: 2.546 Normalized IF: 4

95

Papers published 2015

Mancosu P, Reggiori G°, Gaudino A, Lobefalo F, Paganini L, Palumbo V, Stravato A, Tomatis S, Scorsetti M.

Navarria P°, Ascolese AM, Tomatis S, Reggiori G, Clerici E, Villa E, Maggi G, Bello L, Pessina F, Cozzi L, Scorsetti M.

Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions.

Hypofractionated stereotactic radiation therapy in recurrent high-grade glioma: a new challenge.

British Journal of Radiology 2015;88(1055):20150468.

Cancer Research and Treatment 2016;48(1):37-44.

Raw IF: 2.026 Normalized IF: 4 Mancosu P, Reggiori G°, Stravato A, Gaudino A, Lobefalo F, Palumbo V, Navarria P, Ascolese A, Picozzi P, Marinelli M, Verona-Rinati G, Tomatis S, Scorsetti M.

Evaluation of a synthetic single-crystal diamond detector for relative dosimetry on the Leksell Gamma Knife Perfexion radiosurgery system.

Medical Physics 2015;42(9):5035.

Raw IF: 2.635 Normalized IF: 4 Marino C, Villaggi E, Maggi G, Esposito M, Strigari L, Bonanno E, Borzì GR, Carbonini C, Consorti R, Fedele D, Fiandra C, Ielo I, Malatesta T, Malisan MR, Martinotti A, Moretti R, Nardiello B, Oliviero C, Clemente S, Mancosu P.

A feasibility dosimetric study on prostate cancer: are we ready for a multicenter clinical trial on SBRT?

Raw IF: 3.318 Normalized IF: 4 Navarria P, De Rose F°, Ascolese AM.

SBRT for lung oligometastases: who is the perfect candidate?

Reports of Practical Oncology and Radiotherapy 2015;20(6):446-53.

Raw IF: 0 Normalized IF: 0 Navarria P, Pessina F, Cozzi L°, Clerici E, Villa E, Ascolese AM, De Rose F, Comito T, Franzese C, D’Agostino G, Lobefalo F, Fogliata A, Reggiori G, Fornari M, Tomatis S, Bello L, Scorsetti M.

Hypofractionated stereotactic radiation therapy in skull base meningiomas.

Journal of Neuro-Oncology 2015;124(2):283-9.

Raw IF: 3.07 Normalized IF: 4

Stereotactic Body Radiation Therapy: a useful weapon in anticancer treatment.

Reports of Practical Oncology and Radiotherapy 2015;20(6):ix-x.

Raw IF: 0 Normalized IF: 0 Scorsetti M, Clerici E°, Navarria P, D’Agostino G, Piergallini L, De Rose F, Ascolese A, Tozzi A, Iftode C, Villa E, Comito T, Franzese C, Mancosu P, Tomatis S, Cozzi L.

The role of Stereotactic Body Radiation Therapy (SBRT) in the treatment of oligometastatic disease in the elderly.

British Journal of Radiology 2015;88(1053):20150111.

Raw IF: 2.026 Normalized IF: 4 Scorsetti M°, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D’Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G.

The challenge of inoperable hepatocellular carcinoma (HCC): results of a singleinstitutional experience on stereotactic body radiation therapy (SBRT).

Otter S, Schick U, Gulliford S, Lal P, Franceschini D, Newbold K, Nutting C, Harrington K, Bhide S.

Journal of Cancer Research and Clinical Oncology 2015;141(7):1301-9.

Raw IF: 3.081 Normalized IF: 4

Raw IF: 2.914 Normalized IF: 6

Evaluation of the risk of grade 3 oral and pharyngeal dysphagia using atlas-based method and multivariate analyses of individual patient dose distributions.

Marnitz S, Wlodarczyk W, Neumann O, Koehler C, Weihrauch M, Budach V, Cozzi L°.

International Journal of Radiation Oncology, Biology, Physics 2015;93(3):507-15.

Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation - an intraindividual comparison.

Raw IF: 4.258 Normalized IF: 3

Strahlentherapie und Onkologie 2015;191(7):573-81.

Radiation Oncology 2015;10(1):91.

Raw IF: 2.546 Normalized IF: 4 Navarria P, Ascolese AM, Cozzi L°, Tomatis S, D’Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M.

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.

European Journal of Cancer 2015;51(5):668-74.

Raw IF: 5.417 Normalized IF: 6

Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F.

Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased nearmaximum target dose and of a rectal spacer.

British Journal of Radiology 2015;88(1054):20140736.

Raw IF: 2.026 Normalized IF: 2 Schinkelshoek M, Lopci E, Clerici E, Alongi F, Mancosu P, Rodari M, Navarria P, van der Hiel B, Scorsetti M, Chiti A°.

Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.

Tumori 2014;100(6):636-44.

Raw IF: 1.269 Normalized IF: 1

96

Scorsetti M.

Scorsetti M, Navarria P, Pessina F, Ascolese AM, D’Agostino G, Tomatis S, De Rose F, Villa E, Maggi G, Simonelli M, Clerici E, Soffietti R, Santoro A, Cozzi L°, Bello L.

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.

BMC Cancer 2015;15:486.

Raw IF: 3.362 Normalized IF: 4 Tozzi A°, Iftode C, Cozzi L, Ascolese AM, Battista S, Cavina R, Clerici E, Comito T, D’Agostino GR, DE Rose F, Franzese C, Garassino I, Fumagalli Romario U, Navarria P, Rosati R, Spaggiari P, Tomatis S, Scorsetti M.

Neoadjuvant chemoradiotherapy with volumetric-modulated arc therapy for medium-distal oesophageal and gastrooesophageal junction carcinoma.

Anticancer Research 2015;35(7):4109-16.

Raw IF: 1.826 Normalized IF: 2

Clinical Research

Vavassori V, Alongi F, D’Agostino G, Della Bosca E, Scorsetti M.

Lymph-node relapsed prostate cancer management and PET-driven external beam radiotherapy: salvage or palliative treatment?

Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015;59(4):411-9.

Raw IF: 2.033 Normalized IF: 4 Veronese I, De Martin E, Martinotti AS, Fumagalli ML, Vite C, Redaelli I, Malatesta T, Mancosu P, Beltramo G, Fariselli L, Cantone MC.

Multi-institutional application of Failure Mode and Effects Analysis (FMEA) to CyberKnife Stereotactic Body Radiation Therapy (SBRT).

shoulder and elbow surgery

Arrigoni P, Rose GD, D'Ambrosi R, Rotundo G, Campagna V, Pirani P, Panascì M, Petriccioli D, Bertone C, Grasso A, Latte C, Costa A, Viola G, DE Giorgi S, Panella A, Padua R, Beccarini A, Salcher B, Olivieri M, Mugnaini M, Pannone A, Ceoldo C, Longo UG, Denaro V, Cerciello S, Panni AS, Avanzi P, Zorzi C, Ragone V, Castagna A, Randelli P.

Reliability of forced internal rotation and active internal rotation to assess lateral instability of the biceps pulley.

Joints 2015;3(1):20-4.

Raw IF: 0 Normalized IF: 0

Raw IF: 2.546 Normalized IF: 2

Chillemi C, Petrozza V, Franceschini V, Garro L, Pacchiarotti A, Porta N, Cirenza M, Salate Santone F, Castagna A.

Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M.

The role of tendon and subacromial bursa in rotator cuff tear pain: a clinical and histopathological study.

Radiation Oncology 2015;10(1):132.

Stereotactic body radiation therapy in hepatocellular carcinoma: optimal treatment strategies based on liver segmentation and functional hepatic reserve.

Reports of Practical Oncology and Radiotherapy 2015;20(6):417-24.

Raw IF: 0 Normalized IF: 0

Knee Surgery, Sports Traumatology, Arthroscopy.

Epub 2015 May 24.

Raw IF: 3.053 Normalized IF: 6

Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.

Lupus 2015;24(4-5):442-7.

Raw IF: 2.197 Normalized IF: 2 Generali E, Ceribelli A, Massarotti MS, Cantarini L, Selmi C°.

Seronegative reactive spondyloarthritis and the skin.

Clinics in Dermatology 2015;33(5):531-7.

Raw IF: 2.47 Normalized IF: 6

Journal of Orthopaedic Surgery and Research 2015;10:129.

Raw IF: 1.386 Normalized IF: 2 Garofalo R, Flanagin B, Castagna A, Lo EY, Krishnan SG.

Long stem reverse shoulder arthroplasty and cerclage for treatment of complex long segment proximal humeral fractures with diaphyseal extension in patients more than 65 years old.

Injury 2015;46(12):2379-83.

Raw IF: 2.137 Normalized IF: 3 Imberti D, Dentali F, Ivaldo N, Murena L, Paladini P, Castagna A, Barillari G, Guerra E, Tonello C, Castoldi F, Lazzaro F, Benedetti R, Camporese G, Porcellini G; RECOS Investigators.

(Collaborator: Castagna A).

Conti M, Garofalo R, Castagna A.

Does a brace influence clinical outcomes after arthroscopic rotator cuff repair?

Clinical and Applied Thrombosis – Hemostasis 2015;21(5):486-8.

Raw IF: 0 Normalized IF: 0

De Santis M, Cavaciocchi F, Ceribelli A, Crotti C, Generali E, Fabbriciani G, Selmi C°, Massarotti M.

Reverse shoulder arthroplasty for proximal humerus fracture using a dedicated stem: radiological outcomes at a minimum 2 years of follow-up-case series.

Venous thromboembolism in patients undergoing shoulder arthroscopy: findings from the RECOS Registry.

Musculoskeletal Surgery 2015;99(s1):S31-5.

Rheumatology and Clinical Immunology

Garofalo R, Flanagin B, Castagna A, Lo EY, Krishnan SG.

De Filippo M, Saba L, Negrini G, Silva M, Pedrazzi G, Pogliacomi F, Castagna A.

Inter-observer agreement of CT measurement of the glenoid bone surface by the CT Pico method: comparison with laser in a cadaveric model.

Skeletal Radiology. Epub 2015 Jul 1.

Raw IF: 2.392 Normalized IF: 0.8 Krishnan SG, Garofalo R, Flanagin B, Castagna A.

Intramedullary clavicle fixation with single large fragmentary screw.

Musculoskeletal Surgery 2015;99(s1):s25-30.

Raw IF: 0 Normalized IF: 0 Zappia M, Carfora M, Romano A.M, Reginelli A, Brunese L, Rotondo A, Castagna A.

Raw IF: 1.51 Normalized IF: 2

Sonography of chondral print on humeral head.

De Giorgi S, Saracino M, Castagna A.

Skeletal Radiology 2016;45(1):35-40.

Degenerative disease in rotator cuff tears: what are the biochemical and histological changes?

Raw IF: 1.51 Normalized IF: 2

Joints 2014;2(1):26-8.

Raw IF: 0 Normalized IF: 0 DeCarli A, Pulcinelli F, Rose GD, Pitino D, Ferretti A.

Calcific tendinitis of the shoulder.

Joints 2014;2(3):130-6.

Raw IF: 0 Normalized IF: 0

thoracic surgery Bettio D°, Venci A, Achille V, Alloisio M, Santoro A.

Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: A case report.

Experimental and Therapeutic Medicine 2016;11(1):98-100.

Raw IF: 1.269 Normalized IF: 1

97

Papers published 2015

Brambilla T, Fiamengo B, Tinterri C, Testori A, Grassi MM, Sciarra A, Abbate T, Gatzemeier W, Roncalli M, Di Tommaso L°.

One-step nucleic acid amplification in breast cancer sentinel lymph node: a single institutional experience and a short review.

Frontiers in Medicine 2015;2:37.

Raw IF: 0 Normalized IF: 0 Cariboni U, Stella GM.

Surgical options to early-stage lung cancer: can “the less” mean “the safe”?

Minerva Medica 2015;106(s2):17-21.

Raw IF: 0.913 Normalized IF: 2 De Rose F°, Cozzi L, Navarria P, Ascolese AM, Clerici E, Infante M, Alloisio M, Testori A, Toschi L, Finocchiaro G, Santoro A, Scorsetti M.

Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients.

Clinical Oncology 2016;28(1):13-20.

Raw IF: 3.398 Normalized IF: 4 Galvan A, Colombo F, Frullanti E, Dassano A, Noci S, Wang Y, Eisen T, Matakidou A, Tomasello L, Vezzalini M, Sorio C, Dugo M, Ambrogi F, Iacobucci I, Martinelli G, Incarbone M, Alloisio M, Nosotti M, Tosi D, Santambrogio L, Pelosi G, Pastorino U, Houlston RS, Dragani TA.

Germline polymorphisms and survival of lung adenocarcinoma patients: a genomewide study in two European patient series.

International Journal of Cancer 2015;136(5):E26271.

Raw IF: 5.085 Normalized IF: 6 Ghidini M°, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L.

KRAS mutation in lung metastases from colorectal cancer: prognostic implications.

Cancer Medicine 2016;5(2):256-64.

Raw IF: 2.5 Normalized IF: 2 Infante M.

A conservative approach for subsolid lung nodules – safe enough?

European Respiratory Journal 2015;45(3):592-5.

Raw IF: 7.636 Normalized IF: 8

98

Infante M°, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, Roncalli M, Cavuto S, Pesce S, Monari M, Valaperta S, Montanelli A, Solomon D, Bottoni E, Errico V, Voulaz E, Bossi M, Chiesa G, Passera E, Mantovani A, Alloisio M.

Masci G°, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients.

Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series.

International Journal of Cancer 2016;138(4):983-91.

Raw IF: 5.085 Normalized IF: 6 Infante M, Cavuto S.

Reply: Mortality reduction, overdiagnosis, and the benefit-to-harm ratio of computed tomography screening.

American Journal of Respiratory and Critical Care Medicine 2015;192(3):399-400.

Raw IF: 12.996 Normalized IF: 5 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Raw IF: 12.996 Normalized IF: 10 Leuzzi G, Rea F, Spaggiari L, Marulli G, Sperduti I, Alessandrini G, Casiraghi M, Bovolato P, Pariscenti G, Alloisio M, Infante M, Pagan V, Fontana P, Oliaro A, Ruffini E, Ratto GB, Leoncini G, Sacco R, Mucilli F, Facciolo F.

Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a multicenter analysis.

Annals of Thoracic Surgery 2015;100(3):890-7.

Raw IF: 3.849 Normalized IF: 3

Oncologist 2015;20(6):586-92.

Raw IF: 4.865 Normalized IF: 6 Navarria P, Ascolese AM, Cozzi L°, Tomatis S, D'Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M.

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.

European Journal of Cancer 2015;51(5):668-74.

Raw IF: 5.417 Normalized IF: 6 Simonelli M°, Zucali PA, Suter MB, Lorenzi E, Rubino L, Fatuzzo G, Alloisio M, Santoro A.

Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases of heavilypretreated metastatic thymoma with striking responses to sorafenib in combination with lapatinib.

Future Oncology 2015;11(8):1223-32.

Raw IF: 2.477 Normalized IF: 2 Spaggiari L, Marulli G, Pariscenti GL, Alloisio M, Fontana P, Oliaro A, Ratto GB, Facciolo F, Mucilli F, Casiraghi M, Rea F.

Reply. To PMID 24726598.

Annals of Thoracic Surgery 2015;100(2):770-1.

Raw IF: 3.849 Normalized IF: 3 Testori A°, Cioffi U, De Simone M, Bini F, Vaghi A, Lemos AA, Ciulla MM, Alloisio M°.

Multiple primary synchronous malignant tumors.

Biomed Central Research Notes 2015;8:730.

Raw IF: 0 Normalized IF: 0

Maisonneuve P, Shivappa N, Hébert JR, Bellomi M, Rampinelli C, Bertolotti R, Spaggiari L, Palli D, Veronesi G, Gnagnarella P.

Testori A°, Meroni S, Colombo P, Fiori S, Voulaz E, Alloisio M.

Dietary inflammatory index and risk of lung cancer and other respiratory conditions among heavy smokers in the COSMOS screening study.

Follicular dendritic cell sarcoma with atypical features surrounding undescended testis: description of a rare case.

European Journal of Nutrition. Epub 2015 May 8.

World Journal of Surgical Oncology 2015;13:69.

Raw IF: 3.467 Normalized IF: 3

Raw IF: 1.408 Normalized IF: 4

Clinical Research

Testori A, Meroni S, Errico V, Travaglini R, Voulaz E, Alloisio M.

Huge malignant phyllodes breast tumor: a real entity in a new era of early breast cancer.

World Journal of Surgical Oncology 2015;13:81.

Raw IF: 1.408 Normalized IF: 4 Veronesi G.

Robotic lobectomy and segmentectomy for lung cancer: results and operating technique.

Journal of Thoracic Disease 2015;7(suppl2):S122-30.

Raw IF: 1.783 Normalized IF: 2 Veronesi G°, Bottoni E, Finocchiaro G, Alloisio M.

When is surgery indicated for small-cell lung cancer?

Lung Cancer 2015;90(3):582-9.

Raw IF: 3.958 Normalized IF: 6 Veronesi G, Guerrieri-Gonzaga A, Infante M, Bonanni B.

Chemoprevention studies within lung cancer screening programmes.

Ecancermedicalscience 2015;9:957.

Raw IF: 0 Normalized IF:0

traumatology di Mento L°, Staletti L, Cavanna M, Mocchi M, Berlusconi M.

Posterior sternoclavicular joint dislocation with brachiocephalic vein injury: a case report.

Injury 2015;46(suppl7):s8-10.

Raw IF: 2.137 Normalized IF: 6

Blanco-Molina A, Enea I, Gadelha T, Tufano A, Bura-Riviere A, Di Micco P, Bounameaux H, González J, Villalta J, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.

Medicine 2014;93(17):309-17.

Raw IF: 5.723 Normalized IF: 1.2 Cote LP, Greenberg S, Caprini JA, Stone J, Arcelus JI, López-Jiménez L, Rosa V, Schellong S, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

Outcomes in neurosurgical patients who develop venous thromboembolism: a review of the RIETE registry.

Clinical and Applied Thrombosis Hemostasis 2014;20(8):772-8.

Raw IF: 2.392 Normalized IF: 0.8 Dentali F, Di Micco G, Giorgi Pierfranceschi M, Gussoni G, Barillari G, Amitrano M, Fontanella A, Lodigiani C, Guida A, Visonà A, Monreal M, Di Micco P.

Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice.

Annals of Medicine 2015;47(7):546-54.

Raw IF: 3.886 Normalized IF: 6 Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators.

(Collaborator: Lodigiani C).

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.

Circulation. Cardiovascular Quality and Outcomes 2015;8(2 suppl1):S12-20.

thrombosis center Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M; RIETE investigators.

(Collaborator: Rota LL).

Duration of anticoagulation after venous thromboembolism in real world clinical practice.

Raw IF: 5.656 Normalized IF: 1.2 Lopez-Reyes R, Nauffal D, Ballester M, MartinAntoran JM, Sarai de Sousa M, Riera-Mestre A, Ruiz-Ruiz J, Fernandez- Capitan C, Uresandi F, Monreal M, RIETE investigators.

(Collaborators: Ferrazzi P, Rota LL).

Lozano F, Trujillo-Santos J, Barrón M, Gallego P, Babalis D, Santos M, Falgá C, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs.

Journal of Vascular Surgery 2014;59(5):1362-7.e1.

Raw IF: 3.021 Normalized IF: 1.2 Madridano O, del Toro J, Lorenzo A, Martín M, Gómez Cerezo J, Hernández L, Prandoni P, Monreal M, on behalf of the RIETE Investigators.

(Collaborator: Rota LL).

Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism.

Journal of Vascular Surgery. Venous and Lymphatic Disorders 2015;3(2):135-41.

Raw IF: 0 Normalized IF: 0 Maestre A, Trujillo-Santos J, Visoná A, Lobo JL, Grau E, Malý R, Duce R, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer.

Thrombosis Research 2014;133(3):384-9.

Raw IF: 2.447 Normalized IF: 0.4 Mahé I, Sterpu R, Bertoletti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, Ballaz A, Hernández Blasco LM, Marchena PJ, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

Long-term anticoagulant therapy of patients with venous thromboembolism.

What are the practices?

PLoS One 2015;10(6):e0128741.

Raw IF: 3.234 Normalized IF: 1.2 Martín-Martos F, Trujillo-Santos J, Barrón M, Vela J, Javier Marchena P, Braester A, Hij A, Hernández-Blasco L, Verhamme P, Manuel M; RIETE Investigators.

(Collaborator: Rota LL).

Gender differences in cancer patients with acute venous thromboembolism.

Thrombosis Research 2015;135(suppl1):S12-5.

Raw IF: 2.447 Normalized IF: 0.4

Venous thromboembolism in patients immobilized at home.

Thrombosis Research 2015;135(4):666-72.

European Respiratory Journal 2015;45(6):1728-31.

Raw IF: 2.447 Normalized IF: 0.4

Raw IF: 7.636 Normalized IF: 1.6

99

Papers published 2015

Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, López-Jiménez L, Falgá C, García-Bragado F, Piovella C, Prandoni P, Monreal M; RIETE Investigators.

(Collaborator: Rota LL).

Fondaparinux in the initial and long-term treatment of venous thromboembolism.

Thrombosis Research 2015;35(2):311-7.

Raw IF: 2.447 Normalized IF: 0.4 Piovella C, Dalla Valle F, Trujillo-Santos J, Pesavento R, López L, Font L, Valle R, Nauffal D, Monreal M, Prandoni P; RIETE Investigators.

(Collaborator: Rota LL).

Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry.

Internal and Emergency Medicine 2014;9(8):847-52.

Raw IF: 2.624 Normalized IF: 1.2 Rosa-Salazar V, Trujillo-Santos J, Díaz Peromingo JA, Apollonio A, Sanz O, Malý R, Muñoz-Rodriguez FJ, Serrano JC, Soler S, Monreal M; RIETE Investigators.

(Collaborators: Ferrazzi P, Rota LL).

A prognostic score to identify lowrisk outpatients with acute deep vein thrombosis in the upper extremity.

Journal of Thrombosis and Haemostasis 2015;31(7):1274-8.

Raw IF: 5.72 Normalized IF: 1.2 Ruggeri ZM, Mendolicchio GL.

Interaction of von Willebrand factor with platelets and the vessel wall.

Hamostaseologie 2015;35(3):211-24.

Raw IF: 1.602 Normalized IF: 1 Suppiej A, Gentilomo C, Saracco P, Sartori S, Agostini M, Bagna R, Bassi B, Giordano P, Grassi M, Guzzetta A, Lasagni D, Luciani M, Molinari AC, Palmieri A, Putti MC, Ramenghi LA, Rota LL, Sperlì D, Laverda AM, Simioni P; Stroke working group of the R. I. T. I. (Registro Italiano Trombosi Infantili).

Paediatric arterial ischaemic stroke and cerebral sinovenous thrombosis. First report from the Italian Registry of Pediatric Thrombosis (R. I. T. I., Registro Italiano Trombosi Infantili).

Thrombosis and Haemostasis 2015;113(6):1270-7.

Raw IF: 4.984 Normalized IF: 6

Tzoran I, Brenner B, Sakharov G, Trujillo-Santos J, Lorenzo A, Madridano O, López-Sáez JB, Monreal M; RIETE investigators.

(Collaborator: Rota LL).

Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy.

European Journal of Internal Medicine 2014;25(9):821-5.

Raw IF: 2.891 Normalized IF: 1.2

urology Alfano M, Cinque P, Giusti G, Proietti S, Nebuloni M, Danese S, D'Alessio S, Genua M, Portale F, Lo Porto M, Singhal PC, Rastaldi MP, Saleem MA, Mavilio D°, Mikulak J°.

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Scientific Reports 2015;5:13647.

Editorial comment to: Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.

International Journal of Urology 2015;22(3):270.

Raw IF: 2.409 Normalized IF: 4 Colombo P°, Smith SC, Massa S, Renne SL, Brambilla S, Peschechera R, Graziotti P, Roncalli M, Amin MB.

Unclassified renal cell carcinoma with medullary phenotype versus renal medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait.

Urology Case Reports 2015;3(6):215-8.

Raw IF: 0 Normalized IF: 0 Costantini E, Lazzeri M.

Raw IF: 5.578 Normalized IF: 6

What part does mesh play in urogenital prolapse management today?

Barbagli G, Lazzeri M.

Current Opinion in Urology 2015;25(4):300-4.

Clinical experience with urethral reconstruction using tissue-engineered oral mucosa: a quiet revolution.

European Urology 2015;68(6):917-8.

Raw IF: 13.938 Normalized IF: 10 Barbagli G, Lazzeri M.

Reply to Nadir I. Osman, Christopher R. Chapple, Sheila MacNeil's Letter to the Editor re: Guido Barbagli, Massimo Lazzeri. Clinical experience with urethral reconstruction using tissue-engineered oral mucosa: a quiet revolution.

European Urology. In press. http://dx.doi. org/10.1016/j.eururo.2015.05.043.

Raw IF: 2.333 Normalized IF: 4 Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditonno P, Perdonà S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D.

Modified Glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience.

Medicine 2015;94(42):e1861.

Raw IF: 5.723 Normalized IF: 6

European Urology. Epub 2015 Aug 7.

Raw IF: 13.938 Normalized IF: 5 Buffi NM, Lughezzani G, Lazzeri M, Casale P, Fiorini G, Hurle R, Taverna GL, Guazzoni G°.

Fossati N, Barbagli G, Larcher A, Dell’Oglio P, Sansalone S, Lughezzani G, Guazzoni G, Montorsi F, Lazzeri M.

The added value of robotic surgery.

The surgical learning curve for one-stage anterior urethroplasty: a prospective single-surgeon study.

Urologia 2015;82(1):11-13.

European Urology. Epub 2015 Sep 28.

Raw IF: 0 Normalized IF: 0 Cindolo L, Castellan P, Scoffone CM, Cracco CM, Celia A, Paccaduscio A, Schips L, Proietti S, Breda A, Giusti G.

Mortality and flexible ureteroscopy: analysis of six cases.

World Journal of Urology 2016;34(3):305-10.

100

Cindolo L, Giusti G, Castellan P, Antonelli A, Schips L.

Raw IF: 2.666 Normalized IF: 6

Raw IF: 13.938 Normalized IF: 10

Clinical Research

Fossati N, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, Lughezzani G, Gadda GM, Lista G, Larcher A, Abrate A, Mistretta F, Bini V, Redorta JP, Graefen M, Guazzoni G.

Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study.

BJU International 2015;115(6):913-20.

Raw IF: 3.533 Normalized IF: 6 Fossati N, Nguyen DP, Trinh QD, Sammon J, Sood A, Larcher A, Guazzoni G, Montorsi F, Briganti A, Menon M, Abdollah F.

The impact of insurance status on tumor characteristics and treatment selection in contemporary patients with prostate cancer.

Journal of the National Comprehensive Cancer Network 2015;13(11):1351-8.

Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuardi L, Janetschek G, Hurle R, Wolters M, Abbas M, von Klot CA, Leitenberger A, Riedl M, Nagele U, Merseburger AS, Kuczyk MA, Babjuk M, Herrmann TR.

En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor.

World Journal of Urology 2015;33(12):1937-43.

Raw IF: 2.666 Normalized IF: 3 Larcher A, Fossati N, Tian Z, Boehm K, Meskawi M, Valdivieso R, Trudeau V, Dell’Oglio P, Buffi N, Montorsi F, Guazzoni G, Sun M, Karakiewicz PI.

Lughezzani G°, Lazzeri M, Buffi NM, Abrate A, Mistretta FA, Hurle R, Pasini L, Castaldo L, Zandegiacomo De Zorzi S, Peschechera R, Fiorini G, Taverna G, Casale P, Guazzoni G.

Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study.

Urologic Oncology 2015;33(8):337.e7-14.

Raw IF: 2.768 Normalized IF: 6 Novara G, La Falce S, Abaza R, Adshead J, Ahlawat R, Buffi NM, Challacombe B, Dasgupta P, Moon DA, Parekh D, Porpiglia F, Rawal S, Rogers C, Volpe A, Bhandari M, Mottrie A.

Prediction of complications following partial nephrectomy: implications for ablative techniques candidates.

Robot-assisted partial nephrectomy in cystic tumors: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database.

European Urology. Epub 2015 Jul 20.

BJU International. Epub 2015 Aug 25.

Raw IF: 4.178 Normalized IF: 3

Raw IF: 13.938 Normalized IF: 5

Raw IF: 3.533 Normalized IF: 6

Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, Vickers AJ, Montorsi F, Briganti A.

Lazzeri M.

Proietti S°, Sofer M, Giannantoni A, Luciani L, Taverna G, Giusti G.

Impact of stage migration and practice changes on high risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.

BJU International. Epub 2015 Mar 17.

New horizons for GAG therapy in the management of urothelial damage.

Urologia 2015;82(3):10-14.

Raw IF: 0 Normalized IF: 0 Lazzeri M.

Raw IF: 3.533 Normalized IF: 3

Prostate cancer claims for a personalized medicine.

Giannantoni A, Proietti S.

North American Journal of Medical Sciences 2015;7:436-7.

Chronic prostatitis: how to give our best without apposite vagueness.

BJU International 2015;116(4):499-500.

Raw IF: 3.533 Normalized IF: 6 Giannantoni A, Proietti S, Giusti G, Gubbiotti M, Millefiorini E, Costantini E, Berardelli A, Conte A.

OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results.

Raw IF: 0 Normalized IF: 0 Lazzeri M°, Lughezzani G, Guazzoni G.

Re: Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.

European Urology 2015;68(3):535-6.

Raw IF: 13.938 Normalized IF: 5

World Journal of Urology. Epub 2015 May 13.

Lughezzani G°, Buffi NM.

Raw IF: 2.666 Normalized IF: 6 Giusti G.

Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?

Editorial comment.

Asian Journal of Andrology 2015;17(5):769-70.

Journal of Urology. Epub 2015 Aug 17.

Raw IF: 2.596 Normalized IF:4

Raw IF: 4.471 Normalized IF: 6

Resonance® metallic stent in patients with ureterocutaneostomies.

International Urology and Nephrology 2016;48(2):207-12.

Raw IF: 1.519 Normalized IF: 2 Proietti S, Sortino G, Giannantoni A, Sofer M, Peschechera R, Luciani LG, Morgia G, Giusti G°.

Single-session supine bilateral percutaneous nephrolithotomy.

Urology 2015;85(2):304-10.

Raw IF: 2.188 Normalized IF: 4 Sofer M, Giusti G, Proietti S, Mintz I, Kabha M, Matzkin H, Aviram G.

Upper calyx approachability through a lower calyx access: comparison between prone and supine PCNL and assessment of anatomical factors that may influence it using three-dimensional CT reconstructions.

Journal of Urology 2016;195(2):377-82.

Raw IF: 4.471 Normalized IF: 6 Suardi N, Dell’Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, Shariat SF, Guazzoni G, Gaboardi F, Montorsi F, Briganti A.

Reply: To PMID 25623671.

Predicting cancer-specific mortality after radical prostatectomy: still a long way to go.

Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups.

Urology 2015;85(2):309-10.

European Urology. Epub 2015 Aug 27.

Urologic Oncology. Epub 2015 Sep 28.

Raw IF: 2.188 Normalized IF: 2

Raw IF: 13.938 Normalized IF: 10

Raw IF: 2.768 Normalized IF: 6

Lughezzani G°, Buffi NM, Guazzoni G. Giusti G, Proietti S.

101

Papers published 2015

Taverna G, Bozzini G, Grizzi F, Seveso M, Mandressi A, Balzarini L, Mrakic F, Bono P, De Franceco O, Buffi N, Lughezzani G, Lazzeri M, Casale P, Guazzoni GF.

Endorectal multiparametric 3-tesla magnetic resonance imaging associated with systematic cognitive biopsies does not increase prostate cancer detection rate: a randomized prospective trial.

World Journal of Urology. Epub 2015 Oct 19.

Raw IF: 2.666 Normalized IF: 6 Taverna G°, Cote RJ, Grizzi F.

Editorial: prostate cancer. What we know and what we would like to know.

Frontiers in Oncology 2015;5:114.

Raw IF: 0 Normalized IF: 0 Taverna G°, Grizzi F, Colombo P, Seveso M, Giusti G, Proietti S, Fiorini G, Lughezzani G, Casale P, Buffi N, Lazzeri M, Guazzoni G.

Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.

Korean Journal of Urology 2015;56(6):435-42.

Raw IF: 0 Normalized IF: 0

Vascular and Interventional Radiology Cazzato RL, Palussière J, Buy X, Denaro V, Santini D, Tonini G, Grasso RF, Zobel BB, Poretti D, Pedicini V, Balzarini L, Lanza E.

Percutaneous long bone cementoplasty for palliation of malignant lesions of the limbs: a systematic review.

Cardiovascular and Interventional Radiology 2015;38(6):1563-72.

Raw IF: 2.071 Normalized IF: 4 Infante M°, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, Brambilla G, Angeli E, Aranzulla G, Chiti A, Scorsetti M, Navarria P, Cavina R, Ciccarelli M, Roncalli M, Destro A, Bottoni E, Voulaz E, Errico V, Ferraroli G, Finocchiaro G, Toschi L, Santoro A, Alloisio M; DANTE Study Group.

(Collaborators: Cariboni U, Testori A,Balzarini L, Imparato S, Pedicini V, Poretti S, Ragucci P, Profili M, Bianchi P, Rodari M, Ciccarelli M, Puggioni F, Tedeschi M, Morenghi E).

Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography.

American Journal of Respiratory and Critical Care Medicine 2015;191(10):1166-75.

Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F°.

Raw IF: 12.996 Normalized IF: 10

Inflammation and prostate cancer: friends or foe?

Lanza E°, Palussiere J, Buy X, Grasso RF, Beomonte Zobel B, Poretti D, Pedicini V, Balzarini L, Cazzato LR.

Inflammation Research 2015;64(5):275-86.

Raw IF: 2.347 Normalized IF: 2

Percutaneous image-guided cryoablation of breast cancer: a systematic review.

Taverna G°, Tidu L, Grizzi F.

Journal of Vascular and Interventional Radiology 2015;26(11):1652-7.e1.

Sniffing out prostate cancer: a new clinical opportunity.

Central European Journal of Urology 2015;68(39):308-10.

Raw IF: 0 Normalized IF: 0

Raw IF: 2.409 Normalized IF: 4 Lopci E°, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A.

Diagnostic accuracy of 11C-choline PET/ CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

European Journal of Nuclear Medicine and Molecular Imaging 2015;42(9):1399-407.

Raw IF: 5.383 Normalized IF: 6

102

Scientific Report Š Humanitas IRCCS Istituto Clinico Humanitas June 2016 via Manzoni 56 20089 Rozzano (Milano, Italy) Scientific Direction: Phone +39 02 8224 2445 Alberto Mantovani Fax +39 02 8224 5101 www.humanitas.it Communication Manager:

Walter Bruno Editorial Coordination: Humanitas: Monica Florianello in collaboration with: Michele Tedeschi (Clinical Trials Office) Silvia Marra (Library) Danilo Petroni (Grant Office) Elena Pisano and Vito De Giorgi (Human Resources Office) Zadig, Milano: Giulia Candiani in collaboration with: Maria Rosa Valetto and Laura Ferroglio Graphic design: Luisa Goglio www.gogliodesign.com Photographs: Marco Capovilla, Milano Paolo Carlini, Milano Renzo Chiesa, Milano Humanitas Press Office

Printed in July 2016

by Tipografia F.lli Verderio, Milano